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SUMMARY
14Following oral administration of [ C]-dl-fenfluramine 
(60mg) to human volunteers greater than 90% of the dose was 
recovered in urine within three days after dosing. 
Metabolism was extensive. The identified metabolites were 
the products of N-deethylation (norfenfluramine) and 
deamination with subsequent side chain oxidation. The parent 
drug was also present. The stereoselective pharmacology of 
fenfluramine led to studies on the individual enantiomers 
(30mg of each). There was a longer plasma half-life for 
both total radioactivity and parent drug with 
[■^C]-1-fenfluramine. The areas under the plasma time curve 
for 1-fenfluramine and 1-norfenfluramine were greater than 
for the d-isomers. There was no apparent enantiomeric 
interaction, that is, the isomers behaved as individual 
compounds when administered together as a racemate. 
Investigation of the urinary metabolites of d-fenfluramine 
showed a greater abundance of deaminated products and less
parent compound compared with 1-fenfluramine. However, 
ratios of fenfluramine to norfenfluramine were the same and
thus the stereoselectivity seemed to reside in the
deamination stage. A definitive pharmacokinetic study with 
d-fenfluramine showed slight first pass metabolism, the 
product of which appeared not to be norfenfluramine. This 
observation together with the urinary metabolite ratios, 
indicated that d-fenfluramine could be deaminated directly 
without being first N-deethylated.
14[ C]-Benfluorex was administered orally to man, rhesus 
monkey, baboon, beagle dog and Wistar rat. Urinary 
metabolic profiles were compared and the rhesus monkey was 
found to bear the closest resemblence to man in this
respect. The parent drug appeared to undergo total first 
pass hydrolysis as it could not be detected in the plasma of 
a human volunteer following an oral dose. In man, further 
metabolism mainly involved oxidation of the N-2-hydroxyethyl 
side chain. Norfenfluramine and a single deamination
product were minor urinary metabolites, although the 
deamination product was quantitatively important in plasma. 
The plasma metabolite profile, however, suggests that the 
deamination product was a product of first pass metabolism. 
The deaminated metabolite of benfluorex was not found as a 
metabolite of fenfluramine indicating that the 
N-ethyl-substitution had influenced the deamination route as 
well as the overall metabolic fate of the 1- (m-tr if luoro­
methylphenyl) -2-aminopropane nucleus.
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CHAPTER 1 
INTRODUCTION
Fenfluramine and benfluorex are two substituted amphetamines 
which exhibit anti-obesity qualities without the side 
effects normally attributed to this class of compound. This 
chapter attempts to review briefly the pharmacological and 
pharmacokinetic background to these compounds, in 
particular, and to discuss the amphetamines in general. The 
structure of the chapter is as follows
1.1 The Treatment of Obesity
1.2 Amphetamine History and Pharmacology
1.3 Fenfluramine History and Pharmacology
1.4 Benfluorex (780SE) History and Pharmacology
1.5 The Metabolism and Kinetics of Amphetamine and its 
Derivatives
1.6 The Metabolism and Kinetics of Fenfluramine and 
Benfluorex in Man
1.7 Aims and Objectives of the Present Work.
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1.1 The Treatment of Obesity
1.1.1 Obesity - the disease
For many centuries the fat person has been seen 
to personify the ideal and to portray a picture 
of happiness and contentment. Only recently, 
both on aesthetic and health grounds has the 
slim person gained credit. Obesity is considered 
to be a first-order public health hazard in 
industrialised societies. With the general 
assumption that decreased obesity will 
consequently decrease the population's mortality 
and morbidity, costly and sometimes hazardous 
programmes have been developed to treat the 
disease and it is apparent that these efforts
are not always the result of scientific or 
medical findings (Mann, 1974).
Obesity has been defined as an excessive
accumulation of fat in the storage areas of the 
body. The problem here is to measure this 
accumulation and to decide, on an individual 
basis, the point at which it becomes excessive. 
The most common method is to relate an 
individual's weight to one of many average
weight tables. However, many clinicians have 
argued that the definition of obesity must
remain subjective (McMullan, 1959; Yudkin, 
1971) . The medical community has more and more 
concentrated on operational definitions of 
obesity based on its associations with 
mortality, morbidity and performance capacity 
and an increasing number of epidemiological 
studies have been carried out to assess these 
associations.
Numerous factors may be involved in the 
development of obesity. Simple over-eating,
14
particularly of high caloric foods, is a major 
cause and as well as this positive aspect, the 
negative cause of not taking enough exercise can 
also contribute. Another factor is the very 
real psychological involvement which we all have 
with food (McKenzie, 1967). Although very few
obese patients have marked psychiatric 
abnormalities, many are of an anxious
disposition and over-eat when upset or worried 
(Silverstone and Solomon, 1965). The 
hypothalamus is thought to contain most of the 
regions regulating appetite, although the 
multiplicity of central neurotransmitters
involved in the central regulation of appetite 
has been outlined and the complexity of the 
system emphasised (Morley and Levine, 1983).
Obesity is only rarely designated as the 
specific cause of death but is often regarded as 
being a significant factor in other diseases.
There are mechanical effects of obesity on 
joints and ligaments. Metabolic effects of 
maturity-onset diabetes and chronic lipaemia are 
often associated with obesity. There are many 
cardiovascular effects of obesity and the obese 
hypertensive is at a particularly high risk of 
congestive heart failure (Messerli, 1982). It 
has also been demonstrated that women who start 
their pregnancy with a high initial weight are 
more likely to develop toxaemia of pregnancy, 
hypertension and a number of other complications 
(Emerson, 1962).
1.1.2 Obesity - the treatment
There are two phases in the treatment of 
obesity. The first is to reduce weight to within 
normal limits, and the second to maintain body
15
weight at this level. Given that obesity is 
caused by the ingestion of more calories than is 
required, then the obvious cure would seem to be 
to reduce the level of caloric intake. Various 
theories have been put forward as to what food 
should be consumed and indeed the way in which 
it should be consumed (Kekwick and Pawan,1956; 
Fabrey et al. , 1964; Munro et al. , 1966) .
However, one of the main problems in controlling 
obesity by means of diet depends on the ability 
of the individual to keep to a particular diet. 
Although attempts to reduce weight by
restriction of food intake is favoured by most 
clinicians, a study of general practitioners, 
indicated that 50% of doctors were prescribing
medicines as well as recommending dietary 
changes to deal with obesity (Yudkin, 1968). It 
is much easier for a doctor to prescribe a low 
calorie diet than it is for a patient to stick 
to it. Because it is so difficult to refrain 
from what are, after all, among the good things 
in life, many attempts have been made to reduce 
patients desires to eat and thereby enabling 
them to keep more strictly to their diets 
(Silverstone, 1967). In consequence, medicine 
may be used to help the patient adhere to a 
particular diet. This may partly imply creating 
a state of mind in which an individual becomes 
more determined to stick to the diet, and can 
therefore overcome the difficulties involved
with it. It may also involve physically reducing 
appetite, or increasing metabolic rate.
The report of the British Medical Association
Working Party on Amphetamine Preparations (1968) 
defines the ideal anorectic drug. 'it should be 
effective, and help patients to eat considerably
16
less food than previously, should retain this 
effect for as long as it is taken, should have 
no undesirable side effects and should not lead 
to dependence.'
1.2 Amphetamine History and Pharmacology
In the early sixties, amphetamine (l-phenyl-2- 
propylamine) was the medicine most widely used to deal 
with obesity. It was first synthesised by Edeleano 
(1887). However pharmacological studies were carried 
out much later (Allés, 1927), after the realisation of 
its sympathomimetic activity (Barger and Dale, 1910). 
Experiments in both animals and man, which compared the 
central excitatory and analeptic properties with those 
of other drugs, showed that amphetamine could stimulate 
the medullary and respiratory centre and cerebrospinal 
axis as well as opposing the effects brought about by 
central nervous system depressant drugs. These actions 
were a result of stimulation of both the cortex and 
reticular activating system (Goodman and Gilman, 1968). 
Amphetamine also exerts a peripheral stimulation 
indirectly by releasing catecholamines from the storage 
pool contained in the post-ganglionic sympathetic nerve 
endings (Trendelenburg, 1961; Grout, Muskus and 
Trendelenburg, 1962).
N-Methylamphetamine was also used as an anoretic agent. 
It was first synthesised by Ogata (1919) and its 
pharmacology investigated by Flügel . (1938). This and 
other studies described its pressor action, euphoric 
properties and waking effects.
The two compounds so far described, produce desirable 
anorectic effects but with some undesirable 
side-effects related to central nervous stimulation 
such as insomnia, nervousness and hyperactivity. The 
subjective effects in man are an increase in energy and
17.
self-confidence together with an unawareness of the 
sense of fatigue and exhaustion. This aspect has led 
to indiscriminate use of the drug by combat and assault 
troops in the Second World War and later by lorry 
drivers and athletes (Beckett, Tucker and Moffat, 
1967) . The abuse and indiscriminate application of 
these compounds for the stimulant effect has given rise 
to many social problems and can lead to profound 
physiological (Oswald and Thacore, 1963) and 
psychological (Connell, 1958) changes.
Consideration of these problems has led to attempts to 
synthesise other sympathomimetic amines possessing the 
anorectic activity of amphetamine but devoid of the 
central nervous stimulation. Amphetamine has a simple 
chemical structure showing a multiplicity in its 
biological effects which has made the molecule a target 
for extensive molecular modification (Biel, 1970) . All 
of the structural elements of amphetamine are critical 
to its pharmacological and biochemical activity. Any 
type of substitution on the phenyl ring will abolish or 
radically alter the nature of its central effects as 
demonstrated by fenfluramine.
1.3 Fenfluramine History and Pharmacology
Although structurally related to amphetamine (Figure 
1.1), it is well established that fenfluramine is quite 
different, both pharmacologically and clinically. 
Fenfluramine was the first amphetamine-like structure 
which was shown to possess appetite suppressant 
activity without stimulant and addictive properties 
(Beregi et al., 1970).
The pharmacology of fenfluramine has been discussed by 
Garattini et al. (1979). Since its discovery it was 
noted that fenfluramine differed from amphetamine in 
that it had no stimulant activity. If anything, at
18
FIGURE 1.1 : The S tructura l Formulae of Amphetamine, 
Fenfluramine and Benfluorex
NH.
CH2— C H — CH3
AMPHETAMINE
CF
N H — CH
t H  — CH — CH.
FENFLURAMINE
N H — C H — CH2— O — C 
I
C H — CH — C H ,
BENFLUOREX
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moderate doses, the drug had sedative action and it can 
even counteract the hyperactivity and stereotypy 
induced by several compounds, including amphetamine. 
Amphetamine toxicity in grouped mice was reduced by 
fenfluramine treatment.
The neurochemical effects of amphetamine and 
fenfluramine also differ, since the former interacts 
mainly with brain catecholamines while the latter has a 
marked effect on the serotoninergic system. Thus, even 
when the two drugs produce the same biochemical effect, 
the mechanisms involved may be different. For
instance, when used at relatively high doses, both 
compounds induce a marked increase in striatal 
homovanillic acid but the effect of amphetamine is the 
outcome of increased dopamine release, while 
fenfluramine probably achieves the same results through 
blockade of post-synaptic dopamine receptors. The 
increase in striatal acetylcholine induced by both 
amphetamine and fenfluramine also appears to depend on 
their effects on catecholamines and serotonin, 
respectively. The neurochemical effects of amphetamine 
and fenfluramine, particularly on catecholamines and 
serotonin, appear significant in explaining how they 
inhibit food intake.
The activity of amphetamine appears to be mediated by 
central catecholaminergic neurones, noradrenaline being 
more important than dopamine in explaining the 
anorectic effect of low doses of amphetamine, whereas 
the integrity of the central serotoninergic system is 
important if fenfluramine is to exert full anorectic 
activity. The reduction in serotonin levels caused by 
fenfluramine may have significance in the treatment of 
infantile autism (Ciaranello, 1982; Geller, E. 1982; 
Ruttenberg, 1982).
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There are many studies discussed by Turner (1979) which 
suggest that the changes in blood glucose 
concentrations, glucose tolerance, serum triglycerides 
and plasma lipids that have been described in man 
during long-term treatment with fenfluramine may not 
only be due to associated weight loss, but may be due, 
at least in part, to a direct pharmacological effect of 
fenfluramine. Consistent with this is the demonstration 
by Innés et al. (1977) that maximum weight loss during 
fenfluramine treatment was associated with plasma 
fenfluramine concentrations of 200ng.ml_1 and above, 
which is of the same order as that producing a maximum 
effect on isolated human skeletal muscle glucose 
uptake. It is of interest that Durnin and Womersley 
(1973) found that fenfluramine produced weight loss 
even when patients were not instructed to reduce their 
food intake, and that there was a significant 
difference in the proportion of tissue fat lost,
between fenfluramine-treated and diet-treated women. It 
appears that 5-hydroxytryptaminergic mechanisms may be 
involved in both the peripheral and central actions of 
fenfluramine. Turner (1979) proposed a mechanism of 
action for fenfluramine whereby it causes weight loss 
not only by changing brain amines which results in a 
reduced appetite and reduced food intake but also by 
increased peripheral uptake and metabolism. More 
recently, in an isolated hepatocyte system,
fenfluramine has been shown to inhibit the formation of 
glucose from lactate plus pyruvate and from alanine as 
well as the production of ketone bodies from added 
oleate (Geelen, 1983). Fatty acid synthesis was also 
slightly stimulated.
When racemic fenfluramine is administered in vivo, it 
results in at least four compounds with pharmacological 
activity, d- and 1-f enf luramine and d- and
1-norfenfluramine, the de-ethylated metabolites. The 
d- isomers have been shown to possess the greater
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anorectic activity as well as the greater effect on 
uptake and release of 5-HT and in increasing striatal 
acetylcholine. These and other findings led Garattini 
et al. (1979) to conclude that the acute anorectic 
effect of fenfluramine was probably due to the action 
of d-fenfluramine with d-norfenfluramine playing a 
minor role, if any.
1.4 Benfluorex (780SE) History and Pharmacology
During the pharmacological screening of many 
trifluoromethyl-substituted amphetamine analogues, 
780SE (1-(m-trifluoromethylphenyl)-N-benzoyloxyethyl
isopropylamine ; Figure 1.1) was found to possess a 
relatively high anorectic activity with low toxicity 
(Beregi et al., 1970). The central nervous effects of 
Benfluorex appear qualitatively similar to those of 
fenfluramine with changes in brain amines, anorexia, 
behaviour and sleep (Jori and Bernard!, 1969; Duce and 
Gessa, 1967; Offermeier and Potgieter, 1971; Taylor et 
al., 1973; Weischer, 1972; Jesperson and Scheel-Kruger,
1970). Benfluorex has been shown to reduce 
hyperlipidaemia and hypercholesterolaemia in man and to 
reduce fat absorption. It has also been shown to have 
a peripheral effect (Turner et al., 1982).
1.5 The Metabolism and Kinetics of Amphetamine and its 
Derivatives
This section briefly reviews the in vivo metabolic 
products of amphetamine, the biochemical mechanisms 
involved in their formation and the effect of chain and 
ring substitution on the metabolism and kinetics of the 
amphetamines.
1.5.1 The kinetics of amphetamine
A knowledge of the pharmacokinetics of a
22
compound is necessary to establish optimum dose
regimens and to enable the study of the 
absorption and availability of the drug. 
Kinetic considerations are thus very pertinent 
to the clinical situation and this section is 
limited to kinetic considerations in man. 
Urinary measurement of amphetamine was 
originally used to study its kinetics, however, 
the drug's elimination is profoundly influenced 
by urinary pH (Beckett and Rowland, 1965) and a 
constant (acidic) urinary pH has to be
maintained for excretion studies to be
meaningful; whole blood or plasma studies are 
preferable.
Dring et al. (1966) adminstered radiolabelled 
dl-amphetamine to various species and found that 
all of the administered radioactivity was 
eliminated in the urine but the recovered 
radioactivity was composed not only of unchanged 
amphetamine but also considerable quantities 
(>50%) of metabolites. Measurement of total 
radioactivity in blood was therefore not 
acceptable for kinetic determinations as the
composition of the radioactive material was
unknown. The development of a specific method 
for the determination of amphetamine in whole 
blood enabled preliminary kinetic parameters to 
be determined (Rowland, 1969). Meaned data from 
three subjects given lOmg dl-amphetamine 
sulphate showed a urinary recovery of unchanged 
drug of 45%, a renal clearance estimate of 
120ml.min and a high volume of distribution 
(270 litres). Peak blood concentrations occurred 
2 hours after dosing and declined 
exponentially with a half-life around 12 hours.
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Much later, Wan et al. (1978) used a refined 
analytical procedure to measure the separated 
optical isomers and found that the d-isomer was 
eliminated more rapidly than the 1 form. The 
peak plasma concentration of amphetamine 
following d-amphetamine (lOmg) was in the order 
of SOng.ml”1 (Campbell, 1969).
1.5.1.1 Kinetics of chain- and ring- substituted 
amphetamines
Most amphetamines and related compounds are 
weak to moderately strong organic bases. The 
pKa of amphetamine itself is about 10 (Leffler 
et al., 1951) and thus at physiological pH 
only a small fraction exists in the unionised 
form which is subject to tubular resorption 
which, in turn, is influenced by the
lipid solubility of the neutral form (true 
partition coefficient) . Thus both the pKa and 
partition coefficient of the compound are 
important when considering the renal clearance 
of the compound.
Using controlled (acidic) urinary pH, Beckett 
and Brookes (1970) administered to volunteers, 
various amphetamines (Figure 1.3) with 
substitutions in the side chain (norpseudo- 
ephedrine, ephedrine, phentermine), the 
nitrogen (methylamphetamine e thylamphe tamine) 
and the ring (chlorphentermine, fenfluramine). 
The amount of unchanged drug (and 
N-dealkylated drug where appropriate) excreted 
into urine was determined in each case. The 
total amount of parent drug and amphetamine 
excreted into urine was decreased with 
increasing N-alkyl chain length. The 
introduction of the lipophilic
m-trifluoromethyl group into the ring of
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N-ethylamphetamine did not significantly alter 
its abundance in urine. However, 
norfenfluramine (m-trifluoromethyl substituted 
amphetamine) showed a much reduced urinary 
excretion. Similarly, urinary elimination of 
chlorphentermine was much less than that of 
phentermine which, in turn, was rather more 
abundant than the parent amphetamine. The 
1-hydroxy substituted amphetamines, norpseudo- 
ephedrine and ephedrine both showed an 
increased urinary recovery over the parent 
molecules.
Vree and van Rossum (1970) also administered 
various amphetamine analogues to volunteers 
and frequently measured parent drug and 
amphetamine or other N-dealkylated metabolites 
enabling some kinetic determinations. They 
found that the biological half-life of 
d-amphetamine derivatives increased with 
increasing N-alkyl chain length up to 
N-ethylamphetamine (half-life around 15 
hours). N-isopropylamphetamine, however, is 
rapidly eliminated (half-life of the d-isomer 
around 3 hours) and the fraction excreted 
unchanged is small. Chlorphentermine showed a 
longer biological half-life than phentermine. 
Similarly, norfenfluramine has been shown to 
have a longer half-life than amphetamine 
whereas fenfluramine and ethylamphetamine do 
not show such a marked difference (Beckett and 
Brookes, 1967). Attempts have been made to 
relate kinetic parameters and physicochemical 
properties of series of compounds (Jenner and 
Testa 1976) but as substitutent groups become 
large, steric effects complicate any direct 
relationships.
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1.5.1.2 Enantiomeric differences in the kinetics of 
the amphetamines
The greater pharmacological activity of
d-amphetamine over the 1-isomer could be
explained in terms of stereoselective 
metabolism and thus many studies have been 
carried out on the comparative metabolism and 
kinetics of the isomers. The metabolic 
considerations are discussed later (section 
1.5.2). Early studies, reviewed by Wan et al. 
(1978) and Jenner and Testa (1973) and based 
on urinary excretion data, indicated that 
1-amphetamine had a longer biological
half-life and showed a higher percentage 
excreted unchanged than the d-isomer. Using a 
mass spectrometric method capable of resolving 
and quantitating the enantiomers in plasma as 
well as urine. Wan et al. (1978) showed a 
longer half-life for the 1-isomer in man with 
the difference being maximal under basic 
urinary pH conditions. There were no
significant differences between rates of 
absorption, plasma protein binding or volumes 
of distribution (oral dosing).
The length of the N-alkyl side-chain in 
^-substituted amphetamines was shown to 
influence the isomeric difference in the 
urinary recoveries of unchanged drug (Shenoy,
1971). Amphetamine, N-methylamphetamine, 
N-ethylamphetamine and N-n-propylamphetamine 
showed an increasing isomeric difference with 
increasing chain length, the d-isomers having 
a progressively lower urinary recovery. 
d-N-n-Butylamphetamine followed the pattern of 
decreasing urinary excretion but with this 
analogue there was no difference between the 
two isomers. Introduction of the
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m-trifluoromethyl group into ethylamphetamine 
(fenfluramine) decreased the stereoselective 
difference in the urinary recoveries with a 
considerable reduction seen for the 1-isomer 
(Beckett and Brookes, 1970). Using a gas 
chromatographic method to resolve and 
quantitate the enantiomers of fenfluramine 
(and norfenfluramine), Caccia et al. (1979) 
demonstrated that plasma concentrations and 
biological half-lives were similar for both 
enantiomers of fenfluramine after single oral 
doses. After 10 days chronic dosing, however, 
the half-life of d-fenfluramine became shorter 
with a smaller area under the plasma/time 
curve.
1.5.2 The metabolism of amphetamine
Amphetamine is excreted into the urine of man 
predominantly unchanged (Beckett and Rowland, 
1965). The major route of metabolism is 
oxidative deamination through to benzoic acid 
which is excreted predominantly as its glycine 
conjugate (Caldwell et al., 1972). Other 
metabolites are norephedrine, p-hydroxy 
amphetamine and p-hydroxynorephedrine. Studies 
using other species and in vitro systems 
designed to investigate specific reactions have 
demonstrated the complexity of metabolism of the 
amphetamine molecule which has been the subject 
of several reviews (Caldwell, 1976; Cho and 
Wright, 1978; Bring and Millburn, 1979). 
Essentially, four phase I metabolic routes are 
involved:
a) Deamination with subsequent side chain 
oxidation
b) Ring hydroxylation
c) Beta-hydroxylation
d) N-oxidation (without deamination)
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The various routes of metabolism which have been 
proposed and, sometimes, proved are shown in 
Figure 1.2. The complexity is apparent, but 
each pathway is described under the headings 
above and with reference to the biochemical 
mechanisms involved. The structures have been 
numbered for ease of identification.
1.5.2.1 Deamination of amphetamine with subsequent 
side-chain oxidation
The biochemical mechanism of amphetamine (1) 
deamination has been a source of much debate 
for many years. Brodie et al. (1958) 
originally proposed an =-C oxidation to give 
the carbinolamine intermediate (2) which has 
never been isolated. More recently N-oxidation 
to N-hydroxy amphetamine (6) has been favoured 
(Beckett and Al-Sarraj, 1972). Reduction of 
(6) to amphetamine has been demonstrated 
(Danielson et al., 1977). Hucker et al. (1970 
and 1971) showed that phenylacetone oxime (4) 
was a major intermediate in the formation of 
the deamination product, phenylacetone (5), 
and discussed three possible routes of 
formation of the oxime from amphetamine. Two 
of these proposed the N-oxidised precursors, 
N-hydroxy amphetamine (6) and =-hydroxy-N- 
hydroxy amphetamine (13) and the other 
precursor was an imine (3) previously proposed 
by Dring et al. (1966). This was discussed 
later by Wright et al. (1977) who described 
how the oxime (4) might arise from 
hydroxylation of the imine (3) formed by 
dehydration of the carbinolamine (2). Wright 
et al. (1977) described their own experiments 
which indicated that although the ketone (5) 
can form from N-hydroxyamphetamine (6), it is 
not an obligatory intermediate. Cho and
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Wright (1978), in a mini-review of amphetamine 
metabolism, described the results of Parli et 
al. (1971) which suggested that most 
phenylacetone (5) arose from a hydrolytic 
pathway through the oxime rather than direct 
elimination of ammonia from the carbinolamine 
(2). Different workers have reported different 
theories and evidence for the mechanisms 
involved in the deamination process and the 
controversy is complicated by the variations 
seen in different in vitro preparations. 
Benzyl alcohol (9) has been identified as an 
in vitro metabolic product of phenylacetone 
oxime (4) by Coutts, Dawe et al. (1976) 
although the mechanism of formation of this 
product is not discussed. l-Phenylpropan-2-ol 
(11) and benzoic acid (10) were identified in
vivo as metabolites of amphetamine (Dring et 
al., 1970). The alcohol (11) formation from 
the ketone (5) was discussed by Wright et al.
(1977) and the reaction was found to be
reversible in the liver microsomal system
(Axelrod, 1955).
Phenylacetone (5) has been considered to be 
the key intermediate in the formation of
benzoic acid (10) in a number of reviews 
(Smith and Dring, 1970; Caldwell, 1976) but 
the mechanism is unknown. Lindeke et al.
(1978) discussed in vivo and in vitro studies 
indicating that phenylacetone (5) only formed 
minor quantities of benzoic acid (10). Also a 
correlation was shown between the ability of a 
species to N-hydroxylate and the excretion 
benzoic acid (Caldwell, 1978) . Lindeke (1978) 
went on to discuss the chemical stability of 
@-hydroxyphenylalkylhydroxylamines (e.g. 
compound 7) which undergo rapid oxidative
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decomposition to benzaldehyde (8) and an oxime 
in the presence of cupric ions. Thus a 
pathway was proposed involving N-oxidation and 
B-hydroxylation (section 1.6.2.3) to form 
8-hydroxy-N-hydroxyamphetamine (7) which 
decomposed to benzaldehyde (8), the precursor 
of benzoic acid (10). Thus benzoic acid could 
result from N-oxidation rather than 
C-oxidation. Benzoic acid is excreted in vivo 
as a glucuronide (Bridges et al.,, 1970) and as 
its glycine conjugate, hippuric acid (Caldwell 
et al., 1976 and 1979).
1.5.2.2 Ring hydroxylation
Rats were shown to convert about 60% of an 
administered dose of amphetamine to 
p-hydroxyamphetamine (20) by Axelrod (1954). 
Although the rats appear to be the most active 
in forming p-hydroxyamphetamine and its 
glucuronide conjugate, the metabolites have 
been identified in the urine of several 
species including man, monkey, dog, rabbit, 
rat and mouse but not guinea pig (Dring et 
al., 1970; Caldwell et al., 1979). Rat liver 
microsomes in the presence of NADPH were found 
to catalyse the reaction in vitro (Cho et al.,
1975) and there are a number of unusual 
features which distinguish it from other 
aromatic hydroxylations (Caldwell, 1976). 
p-Hydroxyamphetamine is eliminated in vivo 
either unchanged or as a glucuronide or 
sulphate conjugate (Sever et al., 1976). It 
can also undergo further oxidation by both 
dopamine-B-hydroxylase to form p-hydroxy- 
norephedrine (18) as shown in rat brain tissue 
(Kuhn et al., 1978) and also ring 
hydroxylation to yield =-methyldopamine (21) 
which can subsequently be 0-methylated to
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3-methoxy-4-hydroxyamphetamine (22) although 
this metabolite has never been reported in
vivo (Caldwell, 1976). Amphetamine can also 
form m-hydroxyamphetamine (19) although the 
mechanism for this and p-hydroxylation is not 
yet known (Jonsson, 1977).
1.5.2.3 fl-Hydroxylation
Hydroxylation of p-hydroxyamphetamine (20) on 
the 3 -carbon to the nitrogen has already been 
described (section 1.5.2.2). Amphetamine
itself can undergo 3-hydroxylation to form 
norephedrine (17), a quantitatively minor but 
pharmacologically important reaction as the 
product can contribute to the drug's actions 
and be involved in the development of 
tolerance (Sever et al., 1976). Unlike the
other reactions discussed so far, 
3-hydroxylation is carried out in the
noradrenergic nerves of the central and 
peripheral nervous system by the enzyme
dopamine-3-hydroxylase which converts many
phenylethylamines and amphetamines to their
3-hydroxylated metabolites (Creveling et al., 
1962). The importance of 3-hydroxylation in 
the deamination process has been discussed
(section 1.5.1.1). Oxidation of the nitrogen
of norephedrine (17) has been demonstrated in 
vitro (Beckett et al., 1974) to norephedrine
hydroxylamine (7) and l-hydroxy-2-oxo-l- 
phenylpropane oxime (25) with subsequent 
deamination to 1, 2-dihydroxy-l-phenylpropane 
(23), l-hydroxy-2-oxo-l-phenylpropane (24). 
Thus the presence of the 3-hydroxyl group in 
an aralkylamine does not block the N-oxidation 
metabolic route.
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1.5.2.4 N-oxidation (without deamination)
Wright et al. (1977) have discussed the role 
of N-hydroxyamphetamine (6) in the metabolic 
deamination of amphetamine in the light of the 
results of many workers. As well as
deamination, further in vitro metabolism of
l-phenyl-2-propanone oxime (4) to 2-nitro-l- 
phenylpropane (16) has been reported (Coutts, 
Dawe et al, 1976) and pathways involving 
N-oxidation and isomérisation were described 
(Figure 1.2).
1.5.3 The metabolism of chain and ring substituted 
amphetamines
Many of the reactions discussed for amphetamine 
apply to substituted amphetamines but chain and 
ring substitution can have a profound effect on 
the metabolism (Beckett and Brookes, 1970; 
Caldwell, 1976, Dring and Millburn, 1979) and
kinetics (section 1.6.1) of the compound 
depending on the nature and position of the 
substituting group. The examples discussed are 
shown in Figure 1.3.
1.5.3.1 Ring substituted amphetamines
As discussed previously (section 1.5.2.2) 
p-hydroxyamphetamine is a metabolite of 
amphetamine, however, it has been administered 
itself to man, rat and guinea pig (Sever et
al., 1976). In all the species, most of the 
dose was excreted unchanged or conjugated into 
urine with small recoveries of p-
hydroxynorephedrine (all species) and benzoic 
acid (rat and guinea pig). Thus the 
deamination of amphetamine seen in man
appeared to be blocked by the presence of the 
p-hydroxy group. The hallucinogen, p-methoxy-
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amphetamine is mainly metabolised by
0-demethylation (Hubbard et al., 1977; Dring 
and Millburn, 1979) particularly in man where 
no deamination has been reported at all except 
in a subject showing a genetic defect in drug 
oxidation (Kitchen et al., 1979). Some 
deamination was seen in dog and monkey 
(Hubbard et al, 1977). Midha et al. (1981) 
have shown extensive metabolism of
3-methoxyamphetamine in dog, monkey and man 
both on the ring and the side chain.
O-Demethylation is important as with the para 
isomer, but ring hydroxylation in the
4-position also occurs as well as deamination 
in all three species. Deamination of the para 
isomer in man has not been reported.
3-0-Methyl-cc-methyldopamine was found as a 
metabolite of 3-methoxyamphetamine as well as 
the hallucinogen 3,4-methylenedioxy-
amphetamine (Midha et al, 1977). 
cc-Methyldopamine has been cited as a key 
intermediate in the metabolism of the latter 
in dog and monkey (Midha et al, 1978) although
0-demethylation of 3-0-methyl-=-methyldopamine 
to c-methyldopamine has been considered as an 
explanation of the presence of the latter in 
rat brain (Marquardt et al., 1978). Direct 
deamination of 3,4-methylenedioxyamphetamine 
occurred in monkey only, whereas the 
deaminated products of =-methyldopamine and
3-0-methyl-°^methyldopamine were found in dog 
and monkey (Midha et al., 1978). The
psychotomimetic 1-(2,5-dimethoxy-4-methyl
phenyl)-2-aminopropane undergoes 0-demethy­
lation by rabbit liver homogenates to give
2-0-demethyl, 5-0-demethyl and bis-
(O-demethyl) metabolites, the psycotomimetic
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significance of which have been discussed 
(Zweig and Castagnoli, 1977). Nagamatsu et
al. (1978) did not report any in vivo
0-demethylated metabolites of 1-(2,5- 
dimethoxy-4-methylphenyl)-2-aminopropane in 
rabbit or guinea pig. Oxidation of the
4-methyl group to form 1-(2,5-dimethoxy-
4-carboxyphenyl)-2-aminopropane was the major 
reported pathway with deamination forming a 
very minor pathway in both species. Side 
chain oxidation has not been reported in the 
multiple ring substituted amphetamines and 
generally it seems that hydroxy- and methoxy- 
groups are preferentially metabolised by side 
chain oxidation, N-oxidation and deamination 
being reduced in relation to the degree of 
ring substitution. 4-Chloro-amphetamine also 
undergoes ring hydroxylation and has been 
shown to form 3,4-dimethoxy amphetamine and a 
8-hydroxylated metabolite, 4-chloronorephed- 
rine, in vivo in rat brain (Sherman and Gal, 
1976; Sherman et al, 1977). Substitution with 
the lipophilic m-trifluoromethyl- group giving 
norfenfluramine, increases the amount of 
overall metabolism (Beckett and Brookes, 1970) 
as well as apparently blocking ring 
hydroxylation. Tiflorex (1-(m-trifluoromethyl 
thiophenyl)-2-ethylaminopropane) undergoes
sulphoxidation and N-dealkylation but no ring 
hydroxylation has been reported (Andre et al., 
1979).
1.5.3.2 N-substituted amphetamines
A variety of mono- and di-N-alkyl substituted 
amphetamines have been the subject of 
metabolic studies (Figure 1.3). Beckett and 
Brookes (1970) showed that the urinary 
recovery of unchanged drug plus amphetamine
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decreased with increasing N-alkyl chain length 
implying that the extent of metabolism 
increased (N-ethyl>N-methy1>amphetamine
itself). Replacement of the N-ethyl group by 
an N-cyanoethyl group resulted in a more rapid 
and extensive N-dealkylation (Beckett, Shenoy 
and Salmon, 1972). N-Oxidation of N-methyl- 
and N-ethyl- amphetamine has been shown to 
occur in vivo (Coutts and Kovach, 1977; 
Beckett and Haya, 1978) and may be involved in 
the deamination and dealkylation process, a 
subject which is discussed more fully in the 
concluding chapter (section 7.6). Although 
the in vivo metabolic products of amphetamine 
and N-methylamphetamine are qualitatively 
similar, Coutts, Jones and Liu (1978) have 
isolated a nitrone intermediate from in vitro 
studies on the latter. Administration of 
N-(n-propyl) amphetamine to man resulted in 
both 1 - (4-hydroxyphenyl-2-(n-propylamino)
propane and 1 - (4-hydroxy-3-methoxyphenyl)-2- 
(n-propylamino)propane being excreted into 
urine (Coutts and Dawson, 1977). These two 
metabolites and the n-butyl analogues have 
been reported as products in in vitro 
metabolism of N-(n-propyl)- and N-(n-butyl)- 
amphetamine in rats (Coutts, Dawson, Kazakoff 
and Wong, 1976; Coutts, Dawson and Jones,
1978). In vitro metabolism also gave
N-oxygenated products of N-(n-propyl) 
amphetamine and also showed N-alkyl side chain 
oxidation to give N-(2-hydroxy-n-propyl) 
amphetamine (Coutts, Dawson and Beckett,
1976) . As the N-substituent becomes larger so 
the possibility of other metabolic routes 
increased and metabolism of the N-alkyl side 
chain itself becomes important.
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N-benzylamphetamine is metabolised by rabbit 
liver homogenates to a variety of 
N-dealkylated (forming amphetamine),
deaminated and N-oxidised metabolites (Beckett 
and Gibson, 1978). However, prenylamine 
(N-(3,3-diphenylpropyl) amphetamine) has been 
shown to give rise to at least 12 urinary 
metabolites in man which are products of ring 
hydroxylation and subsequent 0-methylation as 
well as C-N-C cleavage giving amphetamine and 
diphenylpropylamine. These are further 
metabolised by aromatic and side chain 
oxidation (Remberg et al., 1977). Mono- and 
di-dealkylation has been shown to occur with 
diprenyl (N-methyl-N-(prop-2,3-ene)-amphet­
amine) in man and accounted for most of the 
administered dose (Reynolds et al., 1978).
1.5.3.3 Side chain substituted amphetamines
Two examples of side-chain substituted 
amphetamines are phentermine ( cc-methy 1 amphet­
amine) and norephedrine (g-hydroxy-
amphetamine). Phentermine is metabolised to a 
lesser extent than amphetamine (Beckett and 
Brookes, 1970). Deaminated metabolites have 
not been reported but p-hydroxyphentermine has 
been identified in the urine of rats (Weischer 
and Opitz, 1967). In vitro N-oxidation has 
been extensively studied in rabbit and rat 
liver microsomes with different conclusions 
being reached regarding the involvement of 
cytochrome P450 in the reaction (Beckett and 
Belanger, 1976; Sum and Cho, 1977). The 
introduction of the hydrophilic hydroxyl group 
into the side chain of d-amphetamine (forming 
norpseudoephedrine) virtually blocks the 
metabolism in man (Beckett and Brookes, 1970) 
but N-oxidation and oxidative deamination has 
been shown in vitro (Beckett et al., 1974).
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1.5.3.4 Multi-substituted amphetamines
Many amphetamine analogues have combinations 
of ring, side-chain and nitrogen substituents. 
Triflorex (m-trifluoromethyl- thio-substituted 
N-ethyl amphetamine) has already been 
mentioned (section 1.5.3.1) and only 
N-dealkylation and sulphoxidation occurs in 
man with no deaminated or ring hydroxylated 
products being reported. Fenfluramine is also 
a ring and nitrogen substituted amphetamine 
and has been shown to undergo more extensive 
metabolism than ethylamphetamine (Beckett and 
Brookes, 1970) with deamination as a major
pathway in man (Bruce and Maynard f 1968). 
However, the m-trifluoromethyl group appears 
to block ring hydroxylation. N-Acetylation 
has also been reported in rat brain (Sherman 
and Gal, 1977).
Chlorphentermine is an example of a ring and 
side chain substituted amphetamine. The main 
biochemical reaction in vivo is N-oxidation to 
N-hydroxychlorphentermine (Dring and Millburn,
1979) in many species but is absent in rat. 
This may explain why ring hydroxylation of 
amphetamine is predominant in this species. 
The 8-hydroxylation reaction seen with 
p-chloroamphetamine (section 1.5.3.1) is 
apparently blocked by the presence of the 
^-methyl group. Chlorphentermine is more 
extensively metabolised than phentermine 
itself (Beckett and Brookes, 1970).
Mephentermine (N-methylated phentermine) and 
ephedrine (N-methylated norephedrine) are 
examples of side-chain and nitrogen 
substituted amphetamines. Like the N-alkylated 
amphetamines, N-oxidation of intact
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mephentermine occurs in vitro (Beckett and 
Belanger, 1977) and in vivo shows a slightly
more extensive metabolism than phentermine 
(Beckett and Brookes, 1970). The same authors 
reported that N-demethylation was the only 
route of metabolism of ephedr ine in man 
although Feller and Malspeis, (1977) studied
metabolism in the rabbit and found products of 
oxidative deamination.
1.5.4 Enantiomeric variations in the metabolism of the 
amphetamines
Enantiomeric differences in the disposition and 
mode of action of chiral drugs is a subject of 
considerable interest (Jenner and Testa, 1973)
and the apparent greater pharmacological 
activity of d-amphetamine, compared to its 
enantiomer, has been studied in terms of 
stereoselective metabolism to perhaps explain 
the difference. Earlier studies in man measured 
the relative recoveries of the enantiomers in 
urine and found lower amounts of d-amphetamine 
indicating a more extensive metabolism of that 
isomer (Beckett and Rowland, 1965; Gunne, 1967; 
Beckett and Brookes, 1970). Dring et al. 
(1970) , although they did not find any 
difference in the recoveries of the enantiomers, 
reported that production of benzoic acid from 
the 1-isomer was less than that of the d-isomer, 
suggesting a stereoselectivity in the 
deamination process. Beckett and Brookes (1970) 
also showed that the enantiomeric difference in 
urinary recovery of parent drug plus amphetamine 
was increased with increasing chain length again 
suggesting a stereoselective deamination with 
the d-isomer being favoured. In vitro studies, 
however, using rabbit liver microsomal
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preparations have shown 1-ethylamphetamine to be 
a much better substrate for deamination than 
d-ethylamphetamine (Beckett and Haya, 1978).
A stereoselectivity in the ring hydroxylation of 
amphetamine has been shown (Dring et al., 1970) 
with more 1-p-hydroxyamphetamine being excreted 
than d-isomer. This species variation in 
stereoselective metabolism of amphetamine 
enantiomers has been discussed in many reviews 
(Jenner and Testa, 1973; Caldwell, 1976; Dring 
and Millburn, 1979) and a comparative analysis 
of results compiled over a considerable period 
is difficult.
Stereoselectivity in N-oxidation has also been 
reported. In vitro C-oxidation by rat liver 
homogenates is favoured in the metabolism of 
d-N-(n-propyl)amphetamine whereas N-oxidation is 
favoured with the 1-isomer (Coutts, Dawson and 
Beckett, 1976). It has been generally accepted 
that N-dealkylation proceeds via an unstable 
carbinolamine (ie. C-oxidation) and this agrees 
with the preferential N-dealkylation seen with 
d-N-alkylamphetamines (Caldwell, 1976).
Dopamine-B-hydroxylase exhibits a product 
stereoselectivity forming 1-noradrenaline from 
the non-chiral dopamine. When present with 
amphetamine enantiomers it shows also a 
substrate stereospecificity favouring 
hydroxylation of the d-isomer only.
1-6 The Metabolism and Kinetics of Fenfluramine and
Benfluorex (780SE) in Man
Although fenfluramine has been used for the treatment 
of obesity since the mid-1960's relatively little has 
been published on its metabolism and kinetics and, like
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most of the other work cited in this chapter, the 
studies have been carried out using non-radioactive 
compound making it difficult to account for all of the 
administered ^compound. Published information on
benfluorex is also scanty. The discussion refers to 
man except where otherwise stated.
1-6.1 The kinetics of fenfluramine (also section 
1.5.1)
Beckett and Brookes (1967) showed the urinary 
excretion of fenfluramine to be dependent on pH 
and under conditions of controlled acidic urine
pH, recovered around 25% of the dose unchanged
within 48 hours. With the advent of a specific 
and sensitive analytical method (Campbell, 1970) 
it was shown that the drug (60mg dose) was well 
absorbed from the gastrointestinal tract with 
peak plasma levels occurring at 2-6 hours after 
dosing (Campbell, 1971). Definitive kinetic
studies with plasma analysis following 
intravenous dosing have not been performed but 
Beckett and Salmon (1972) using a three
compartment open model analysis on urinary 
excretion data, indicated a significant 
gastrointestinal or first-pass N-dealkylation. 
After the peak, fenfluramine levels in plasma 
decline exponentially with a half-life of 13-30
hours (Campbell, 1971).
With the drug being subject to first-pass 
metabolism and with no intravenous plasma data 
it is not possible to calculate plasma clearance 
or volume of distribution. However, the high 
lipid solubility and low plasma levels 
(Campbell, 1971) would suggest a high volume of 
distribution and the extensive metabolism would 
indicate (Beckett and Brookes, 1967) a
relatively high plasma clearance.
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1.6.2 The metabolism of fenfluramine (also section
1.5.3)
De-ethylation of fenfluramine to norfenfluramine 
(Beckett and Brookes, 1967) has already been
discussed. Bruce and Maynard (1968) found that 
66-93% of administered fenfluramine was excreted 
as m-trifluoromethylhippuric acid in man. 
Unconjugated m-trifluoromethylbenzoic acid was 
found in dogs. No other metabolites were 
reported in man until very recently when Midha 
et al. (1983) identified 1-(m-trifluoromethyl- 
phenyl)propan-2-ol and 1-(m-trifluoromethyl 
phenyl)-propan-1,2-diol.
Intraventricular administration of fenfluramine 
to rats gave rise to both norfenfluramine and 
m-tr if luorohippur ic acid as well as a new 
metabolite, N-acetylnorfenfluramine (Sherman and 
Gal, 1977). Incubation of fenfluramine with 
guinea pig liver microsomal fractions resulted 
in norfenfluramine ketoxime, a trace of 
N-hydroxynorfenfluramine and the major product,
fenfluramine nitrone (Beckett et al., 1973).
The routes of metabolism so far seen for 
fenfluramine are shown in Figure 1.4.
1.6.3 Enantiomeric differences in the metabolism and
kinetics of fenfluramine (also section 1.5.4)
After separate administration of the enantiomers
greater urinary recoveries of the 1- than
d-fenfluramine were found. However, recoveries 
of the norfenfluramine isomers were similar.
These results could be explained in terms of 
stereoselectivity in the dealkylation of 
fenfluramine, in the further metabolism of
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FIGURE 1 . 4 :  In vivo and in v itro  Metabolic 
Routes o f Fenfluramine
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norfenfluramine, in an alternative pathway of 
fenfluramine metabolism or, indeed, a 
combination of all three. Jenner and Testa 
(1973) reported a variation with time of the 
enantiomeric composition of fenfluramine and 
norfenfluramine in urine after doses of racemic 
fenfluramine and norfenfluramine; the ratio of 
d/1 declined with time for both compounds 
indicating stereoselective metabolism of both. 
Using a gas chromatographic method to resolve 
and quantitate the enantiomers of fenfluramine 
and norfenfluramine in plasma (Caccia and Jori,
1977) the pharmacokinetics of the separate 
isomers were studied following oral racemic 
doses in man (Caccia et al., 1979) and
intravenous or intraperitoneal racemic and 
separate enantiomeric doses in rat (Garattini 
and Caccia, 1977? Jori et al., 1978). After a 
single dose of the racemate to human volunteers 
no difference was seen in plasma concentrations 
and half-lives between the isomers. However, 
following chronic administration it was found 
that the plasma levels of 1-fenfluramine and
1-norfenfluramine were higher than those of the 
d-isomers. However, the reverse was seen in 
rats dosed acutely with racemate or the separate 
isomers with higher levels of d- compared with
1-isomer. This species difference is probably a 
reflection of the enantiomeric differences in 
metabolism of the amphetamines discussed 
previously (section 1.5.4).
1.6.4 Kinetics of benfluorex
After oral administration to man, unchanged 
benfluorex was not found in urine (Beckett, 
Shenoy and Brookes, 1972). Oral administration
of the radioactive compound resulted in >90% of
45
FIGURE 1.5 : In vivo and in v itro  Metabolic
Routes of Benfluorex
IN VITRO
46
the administered dose being eliminated into 
urine up to 72 hours after dosing, indicating an 
extensive absorption (Campbell and Richards,
1978).
1.6.5 Metabolism of benfluorex
In the study by Beckett et al (1972) , no
unchanged benfluorex was found and two 
metabolites were identified as N-(2-hydroxy
ethyl)-norfenfluramine (excreted as its
glucuronide and sulphate) and small quantities
of norfenfluramine leaving some 80% of the dose 
unaccounted for. When benfluorex was incubated 
with fortified guinea pig liver homogenates all
of the drug was hydrolysed to the alcohol some
of which was further metabolised to
norfenfluramine and the deamination products, 
m-trifluoromethylphenylpropan-2-one and m-tri 
fluoromethylphenylpropan-2-ol (Beckett and
Ogunbuna, 1973).
Campbell and Richards (1978) identified the
major metabolite in the urine of man to be
N-carboxymethylnorfenfluramine and described
species differences in the metabolism of
benfluorex. The known metabolic routes of
benfluorex are shown in Figure 1.5.
1.7 Aims and Objectives of the Present Work
Metabolic studies are much facilitated by using
radiolabelled compounds. The fenfluramine and 
benfluorex used in the following studies were labelled
with carbon-14 in the benzylic carbon. The fate of
compounds containing this carbon atom were followed and 
as it is a part of the intact phenyl isopropylamine 
skeleton, metabolites which do not contain this carbon 
are unlikely to have any pharmacological significance.
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The absorption, distribution and elimination of total 
radioactivity were determined in healthy volunteers 
after oral administration of radiolabelled racemic 
fenfluramine. In addition the composition of the 
radiolabelled material in blood, urine and faeces were 
studied. Where applicable, non-radioactive analytical 
techniques were applied certainly to study the kinetics 
of distribution and elimination of fenfluramine and 
norfenfluramine and thus to establish how much drug 
related material in plasma can be accounted for by 
those two pharmacologically active compounds.
With the realisation that d-fenf luramine is the 
anorectically active moiety in the racemic mixture has 
come the necessity to study enantiomeric differences in 
the metabolism and kinetics of fenfluramine. The same 
volunteers, therefore, were administered oral doses of 
both radiolabelled d- and radiolabelled 1- 
fenfluramine. The metabolic products were studied to 
attempt to identify any stereoselectivity in the 
various metabolic routes.
Intravenous dosing of non-radioactive d-fenfluramine to 
volunteers provided definitive pharmacokinetic data 
enabling the values of clearance and volume of 
distribution to be established as well as the presence 
or absence of a first-pass effect with oral dosing. 
These data will provide a good baseline for future 
kinetic studies involving age, renal and hepatic 
deficiency and so forth.
The absorption, distribution and elimination of total 
radioactivity were determined in man, rhesus monkey, 
baboon, dog and rat following oral administration of 
radiolabelled benfluorex. The composition of the 
radioactivity was determined in blood, urine and faeces 
of man only and the relevant metabolic profiles
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compared with the other species. By these studies the 
choice of toxicological species was validated.
It is hoped that this work will aid the safe and 
efficient use of these compounds in the treatment of
obesity. Compared to the quantity of information
accumulated over the years on the metabolism and 
kinetics of the amphetamines, the data to be presented 
in this thesis can be alikened to a pimple on an
elephant. It can only be hoped that there is a more
significant contribution to the understanding of the 
subject.
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CHAPTER 2 
METHODS
This chapter describes the methods and procedures 
adopted for the production of the data in this thesis. 
The description of methods are however, as a general 
format and do not include specific detail which can be 
found in the text associated with the particular 
studies.
All studies involved the use of radiolabelled 
compounds, thus a brief outline of the radiochemical 
synthesis of the compounds is included. The chapter 
contains the following sections
1. Radiochemical syntheses and physico-chemical 
properties including stability.
2. Radiopurity checks on radioactive material and 
formulation of doses for human and animal studies.
3. Procedures for human and animal radioactive 
studies.
4. Isolation procedures.
5. Analytical methods (radioactive).
6. Analytical methods (non-radioactive).
7. Pharmacokinetic analysis.
8. Materials.
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2.1 Radiochemical Syntheses and Physico-chemical Properties 
including Stability
14
2.1.1 Synthesis of [ C]-(+) fenfluramine
Fenfluramine (1-m-trifluoromethylphenyl-2-N-ethyl 
aminopropane) labelled with carbon-14 at the 
benzylic position was synthesised in seven
stages starting with Ba14C03 (Hawkins and 
Midgley, 1974). Acidification was used to
liberate ^4COz which was reacted with m- 
trifluoromethylphenyl magnesium bromide to give 
the benzoic acid which was converted to the 
aldehyde through the acid chloride. 
Condensation with nitroethane produced
1-m-trifluoromethylphenyl-2-nitropropene which 
gave the phenylacetone on treatment with iron
powder, ferric chloride and concentrated
hydrochloric acid. Finally, the phenylacetone 
was isolated and condensed with ethylamine. 
Fenfluramine was isolated with a radiochemical 
purity in excess of 98%.
2.1.1.1 HPLC separation of (+) and (-) 
[ C]-fenfluramine from a racemic mixture
The separation and isolation of the pure
optical isomers from racemic
14
[ C]-fenfluramine has been described by 
Arnould et al., (1980) . The method is
applicable to small quantities (less than 
lOOmg) of the racemic mixture and employs
derivatisation and high performance liquid 
chromatography to achieve separation.
The first stage in the separation involves 
derivatisation with (-)menthyl chloroformiate 
with triethylamine as a catalyst. Gas
51
chromatography confirmed a conversion of some 
94% of the racemic fenfluramine to the 
derivative. The separation of the derivatives 
was achieved by high performance liquid 
chromatography on a reversed phase preparative 
column using a methanol - water gradient 
elution.
Once separated, the epimers were completely 
hydrolysed by heating with an acetic acid - 
40% bromhydric acid mixture (2:1) and the pure 
enantiomer obtained in a chloroform extract of 
the dried hydrolysate which was first 
redissolved in 5M sodium hydroxide. Optical 
purities are quoted as 98% and 90% for the (+) 
and (-) isomers respectively.
2.1.2 Synthesis of [14C]-(+) 780SE
The route of synthesis of [14C]-780SE
(l-m-trifluoromethylphenyl-2- N-benzoyloxyethyl- 
amino propane) was identical to that of
[14C]-fenfluramine up to the stage of isolation 
of 1-m-trifluoromethyIphenylacetone. Then a
solution of the ketone and ethanolamine in
n-butanol was refluxed and treated with sodium
borohydride. The resulting mixture was worked
up in the same fashion as described for 
fenfluramine, to provide the N-hydroxyethylamino 
derivative. This was dissolved in benzene,
treated with excess ethereal hydrochloric acid 
and evaporated to dryness. The residual oily 
hydrochloride was treated with benzoyl chloride. 
After precipitation with di-isopropyl ether the
product was filtered, washed and recrystallised 
from ethyl acetate. Thin layer chromatography 
showed a radiochemical purity in excess of 99%.
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2.1.3 Physico-chemical Properties
Throughout this thesis occasional references are 
made to various physico-chemical properties of 
the compounds. The standard methods employed in 
the determination of these properties are 
described in this section.
2.1.3.1 Determination of pKa of fenfluramine
A knowledge of the pKa of a compound is 
important in the understanding of both the 
chemical aspects of solubility and analysis, 
and in the biological aspects of 
pharmacodynamic and pharmacokinetic behaviour.
The pKa of a compound is defined as the pH at 
which the compound is 50% ionised; at that pH 
the buffering capacity of the compound is at 
its greatest. This can be demonstrated as a 
point of inflexion on a pH titration curve. 
Thus a system was set up to produce a pH 
titration curve. A 0.01M solution of drug in 
0.001M hydrochloric acid was placed in a small 
beaker and vigorously agitated with a magnetic 
stirrer. A pH electrode was positioned in the 
solution giving an initial reading of 2.8 pH 
on a pH meter. The titrant (0.1M potassium 
hydroxide) was introduced into this solution 
at a constant rate (O.Sml.min )^ , using a LDC 
Constametric III high performance liquid 
chromatography constant flow pump. The pH 
titration curve was followed on the pH meter 
and a permanent trace obtained on a chart 
recorder. The points of inflexion on the 
curves (Figure 2.1) determined the pKa of 
fenfluramine to be 9.4. This result was 
checked by producing a pH titration curve
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using an acid titrant introduced into a basic 
suspension of the drug and agreed with a 
previously published value (Vree et al., 
1969).
2.1.3.2 Solubility and extraction data
Solubility data is essential for formulation 
of doses and devising extraction procedures 
prior to chromatographic analysis. The 
solubility of both drugs (as their 
hydrochloride salts) was checked by 
progessively adding known volumes of various 
solvents to a fixed quantity (lOOmg) of drug 
until it had all dissolved. Fenfluramine 
hydrochloride was freely soluble in water, 95% 
ethanol and chloroform but not in non-polar 
solvents including diethyl ether. Benfluorex 
was soluble in chloroform and methanol, only 
sparingly soluble in water and totally 
insoluble in ethyl acetate and other less 
polar solvents.
Extraction of fenfluramine from aqueous media 
was effected by the method described by Ramsey 
and Campbell (1971). The aqueous sample is 
basified with 5M sodium hydroxide so that the 
free base of the drug can be rapidly and 
extensively extracted into numerous organic 
solvents including diethyl ether, chloroform 
and butyl acetate. Further details of the 
extraction behaviour of fenfluramine and 
norfenfluramine, its de-ethylated metabolite, 
are given later in this chapter when the 
analytical procedures are described (section 
2.6) .
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2.1.3.3 Partition coefficients
Another useful parameter when devising
extraction procedures and interpreting 
pharmacokinetic data is the partition
coefficient. For both d- and 1-fenfluramine, 
the partition was studied between octan-l-ol 
and 0.1M phosphate buffer at pH 7.4. The 
phosphate buffer was prepared by adding 0.1M 
sodium dihydrogen orthophosphate to 0.1M 
disodium hydrogen orthophosphate until the 
desired pH was attained. This was determined 
accurately by using a pH electrode and meter.
The partition coefficients of non-radioactive 
d- and 1-fenfluramine were determined, by UV 
spectrophotometry, between octan-l-ol and 0.1M 
sodium phosphate buffer (pH '7.4) . Solutions
(Img.ml of each compound were made up in 
the phosphate buffer. Aliquots (4 x 5ml) of 
each solution were placed in round-bottomed 
ground-glass-stoppered tubes (20ml) and 
octan-l-ol (5ml) was added to each. The tubes 
were rotated gently, in a Buhler rotating 
apparatus, at 37°C for 16 hours. After this 
time the phases were separated by centrifuging 
at 3000 rpm for 60 minutes in a MSB 
Super-Minor swing-head centrifuge.
The concentration of fenfluramine in each 
phase was determined by UV spectrophotometry. 
Then, the distribution coefficient:-
DC = org 
[D]aq
where [D]Qrg is the concentration of drug in
the organic (octan-l-ol) layer and [D] is
aq
56
the concentration of drug in the aqueous 
(buffer) layer.
The partition coefficient was calculated from:
PC = DC. (1 + i o p K a " p H )
As the pKa of fenfluramine is known to be 9.4 
and the buffer is pH 7.4 then in this case:
PC = 101.DC
Spectrophotometrie measurements were based on 
the difference between absorption maxima and 
minima of a UV scan of sample or standard
solutions against a suitable blank. Each 
sample or standard solution was scanned over 
the wavelength range 220 to 280nm. f and the
absorbance determined at the maxima (264 and
270nm) and the minimum (267nm). The difference 
between the mean of the maxima and the minimum 
absorbances gave the derived value used in 
calculations of calibration curves or 
concentration determinations. Two sets of 
standards were made up, one in buffer and the 
other in octanol. The buffer calibration 
comprised solutions of fenfluramine
hydrochloride in buffer at concentrations 
(relative to free base) of 0.15, 0.20 and
0.25mg.ml 1. To prepare the octanol 
calibration, solutions of fenfluramine 
hydrochloride in buffer at concentrations of 
0.5, 0.75 and l.Omg.ml-^ were first made up.
An aliquot (2ml) of each solution was basified 
with 5M sodium hydroxide (0.5ml) and the 
fenfluramine free base extracted with octanol 
(2ml). Thus solutions of fenfluramine free
base in octanol were prepared at
concentrations of 0.5, 0.75 and l.Omg.ml”1 . 
Table 2.1 shows the results of this study.
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2.1.3.4 Stability and storage in organic solvents and 
various aqueous and biological environments.
Information on the stability of compounds in 
various media is essential for the correct 
usage and interpretation of chromatographic 
and metabolic data. Breakdown of analytes in 
biological samples can lead to erroneous 
analytical measurements and thus incorrect 
pharmacokinetic analysis. Similarly, in 
metabolic studies, breakdown products can be 
mislabelled as metabolites. If stability is a 
problem, steps must be taken to avoid 
breakdown, for instance, by rapid analysis, 
freezing and using anti-oxidants or 
bacteriostats. To describe the various 
stability checks here would be both lengthy 
and tedious. As the projects developed and 
the consequences of sample breakdown became 
apparent, so various stability checks were 
implemented and these will be mentioned, where 
applicable, in the relevant parts of the text. 
Chemical stabilisers were not used and indeed 
seen to be not necessary; instead biological 
samples were stored at -20°C and analysed 
quickly. In summary, no stability problem has 
been seen with fenfluramine or its 
metabolites. However, 780SE undergoes some 
rapid breakdown in fresh plasma, the 
significance of which will be discussed in 
Chapter 5.
2.1.3.5 Plasma protein binding
Many methods have been devised to study the 
binding characteristics of drugs to proteins 
and these can be broadly classified under two 
headings : those which involve a separation of
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the unbound material and those which do not. 
Non separation methods include spectroscopic 
techniques such as UV, visible, fluorescence, 
NMR and ESR as well as optical rotary 
dispersion and circular dichroism. The 
separation methods include: gel filtration,
ultrafiltration, sedimentation in an 
ultracentrifuge and equilibrium dialysis.
The simple method of equilibrium dialysis was 
first used by Davis (1943) and Klotz (1946) 
for studying the binding of low molecular 
weight compounds to biopolymers. Since then 
many improvements have been made with special 
attention being paid to reducing the amount of 
time taken to reach the diffusion equilibrium 
and to improving the reproducibility of 
results by standardisation of experimental 
conditions.
A Dianorm Equilibrium Dialyser (Esslab Ltd., 
Essex) of cell specification D2000 (2x2ml) and 
a twenty cell capacity variable drive unit (3 
to 30 rpm) was used. Radioactive fenfluramine 
hydrochloride (d- or 1-) was added to plasma 
to give a concentration of approximately 
lOOng.ml \  Dialysing membrane (Spectrapor 2, 
molecular weight cut-off 12,000-14,000 ; MSE 
Scientific Instruments, Sussex) was washed in 
distilled water for 1 hour and cut into half 
segments (6cm) before soaking in the dialysing 
buffer (isotonic sodium phosphate buffer, 7.4
pH) for at least 1.5 hours before use. 
Dianorm cells, with each half separated by a 
half-segment of the dialysis membrane, were 
set up and mounted into the cell holder. 
Plasma (2ml) was added to the "lid" half of 
each cell and buffer (2ml) to the "base"
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halves. Dialysis was performed at 37°C in a 
Gallenkamp humidity oven for 4 hours at a 
drive speed of 16 rpm. After dialysis, 
triplicate aliquots (100^1) of buffer and 
plasma were analysed by liquid scintillation 
counting. Four determinations of binding were 
carried out for each isomer. Equilibrium time 
was checked by dialysing [^^C]-fenfluramine 
hydrochloride in buffer against pure buffer 
and checking the activity in both sides of the 
cell after 4 hours; these were always equal.
After equilibration, the concentrations 
(DPM.ml™1) of drug in both dialysate ( [D] ) and 
plasma ([P]) were determined by liquid 
scintillation counting of triplicate aliquots 
(200^1). The protein binding was then 
expressed as:
% binding = ^  j°| -100
The protein binding to fresh human plasma was 
significantly lower (p<0.01) for
d-fenfluramine (36.4 + 0.6%) than the 1-isomer 
(40.7 + 0.8%).
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2.2. Radiopurity Checks on Radioactive Material and
Formulations of Doses for Human and Animal Studies
There are many points to consider when formulating a 
radioactive dose for human and animal studies :
i) Purity of radioactive material: impurities in
the dose can obviously lead to erroneous 
pharmacokinetic and metabolic interpretation of 
radioactive data.
ii) Dose route : the proposed route of administration 
places restrictions on the dose formulation. 
Intravenous doses generally have to be of small 
volume, unless a constant infusion is envisaged. 
Also the dose vehicle has to be isotonic and of 
physiological pH. Oral doses, however, have
fewer restrictions ; larger volumes can be used 
and pH altered to ensure solubility.
iii) Physical limitations : the size of the animal
dictates the maximum volume of the dose, with 
smaller animals the solubility of the drug 
becomes important in relation to the dose level 
required.
2.2.1 Radiopurity
Prior to the formulation of any radioactive
14
dose, the radiopurity of the [ C] -material was 
checked by thin layer chromatography (TLC 
systems 1 and 2, section 2.5.3, Table 2.4) 
followed by quantitation by radioscanning or 
autoradiography and TLC plate scraping with
liquid scintillation counting of the silica 
fractions (all these methods are described in 
section 2.5). A purity of >97%, with no impurity 
exceeding 1%, was considered acceptable.
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2.2.2 Formulations
The water solubility of fenfluramine 
hydrochloride made it possible to dissolve the 
compounds directly in distilled water (50ml) for 
oral administration to humans. The exact 
radioactive content of the dose could then be 
determined by liquid scintillation counting of 
several aliquots of either the dose solution 
itself or a dilution of the same.
780SE is relatively insoluble in water, but if 
the dose was first dissolved in absolute 
ethanol, this solution could be diluted with 
water such that the final concentration of 
alcohol was 10%. Again determination of the 
exact radioactive content was achieved by liquid 
scintillation counting of aliquots of dilutions 
of the dosing solutions.
Details of doses administered to various species 
are shown in Table 2.2.
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TABLE 2.2 : DETAILS OF DOSES OF FENFLURAMINE AND 780SE 
ADMINISTERED ORALLY TO HUMAN VOLUNTEERS AND ANIMALS
DRUG ISOMER SPECIES DOSE
(mg)
RADIOACTIVE DOSE 
(tiCi)
Fen (±) Human 60 30
Fen ( + ) Human 30 30
Fen (-) Human 30 30
780SE ( + ) Human 120 40
780SE (+) Rhesus Monkey 15.00 30-50
780SE (+) Baboon 19,25 25-30
780SE ( + ) Dog (Beagle) 56.25 30-50
780SE ( + ) Rat (Wistar) 1.63 10-15
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2.3 Procedures for Human and Animal Radioactive Studies
2.3.1 Human volunteer studies
All fenfluramine and 780SE radioactive studies 
in humans followed the same format. The dosing 
solution (~30iiCi) was taken at 8.00-9.00 a.m., 
the subject having fasted for 12 hours prior to 
the dose. Subjects were instructed to take no 
food or drink (other than water in moderation) 
until 4 hours after dosing. Control samples of 
urine, blood and faeces were obtained before 
dosing. After dosing, blood samples (20ml) were 
taken (Table 2.3) at specified times, 
immediately centrifuged and the red cells and 
plasma separated and stored at -20°C. Total 
voided urine was collected in preweighed 
containers up to certain specific times, each 
sample was weighed, the pH determined and the 
sample stored at -20°C. All faeces were 
collected and stored at -20°C. All samples were 
collected up to the end of the study period 
which was normally 7 days after dosing.
2.3.2 Animal studies
During the development of 780SE, it became 
necessary to perform a chronic toxicity study in 
a suitable animal species. Studies were set up 
to look at the metabolism of the compound in the 
rat (Wistar), dog (Beagle), rhesus monkey and 
baboon. Oral doses were administered by 
intubation (details of doses on Table 2.2) to 
fasted animals, control samples of blood, urine 
and faeces having been previously obtained. All 
animals were housed individually in metabolism 
cages suitable for the species, to enable 
effective separation of urine and faeces. Blood
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TABLE 2.3 : DETAILS OF BLOOD SAMPLING SITES ON HUMAN
VOLUNTEERS AND ANIMALS
SPECIES SITE OF SAMPLE VOLUME TAKEN 
(ml)
Human Anticubital fossa 20-30
Dog Anticubital/Saphenous vein 5-10
Rhesus Monkey Anticubita1/Saphenous vein 2-3
Baboon Anticubital/Saphenous vein 2-5
Rat Tail vein
coo1r—1 
O
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samples were taken (Table 2.3) at specified 
times, centrifuged and the red cells and plasma 
stored separately at -20ÔC. Total daily urine 
and faeces were collected separately and stored 
at -20°C. Samples were collected up to 96 hours 
after dosing. Up to the end of the study, the 
metabolism cages were washed daily with a 
methanolrwater (1:1) mixture and these cage 
washings retained for analysis.
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2.4 Isolation Procedures
This section refers to the purification and separation 
of radioactive drug-related compounds from urine and 
plasma samples. No attempt was made to isolate the 
radioactive components from faeces which contained only 
small quantities (generally <10% of the dose) in all 
studies.
Before the metabolites could be separated and isolated 
by chromatographic techniques, samples had to be first 
extracted and then concentrated.
2.4.1 Sequential solvent extraction of the radioactive 
metabolites of fenfluramine from urine before 
and after hydrolysis
A representative pool of 0-48 hour urine samples 
was prepared for each separate set of samples,
i.e. one sample per subject per dose. Duplicate 
aliquots (10ml) of each were placed in round 
bottomed ground-glass stoppered tubes (30ml). 
The initial radioactive content of each sample
was determined by liquid scintillation counting 
of duplicate aliquots (100^1) of each pooled
sample. Each sample was then basified by adding 
5M sodium hydroxide (1ml) and extracted by 
shaking for 10 minutes with diethyl ether 
(10ml). After centrifugation (2000g for 5 
minutes) the ether layer was aspirated into a 
screw-topped sample vial (20ml). This procedure 
was repeated with fresh ether (10ml) to ensure
complete extraction and the two basic ether 
extracts pooled in each case. This same 
extraction procedure was carried out on the 
aqueous residues after acidification with 
concentrated hydrochloric acid (1ml) and again 
the two sequential acidic ether extracts in
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each case were pooled and stored separately. A 
further volume of concentrated hydrochloric acid 
(2ml) was then added to each tube and the 
samples incubated for 90 minutes in a heating 
block at 100°C. After cooling, the ether 
extraction procedure was repeated and the two 
acid hydrolysed ether extracts kept. Finally, 
each sample was basified with 5M sodium 
hydroxide (6ml) and the same ether extraction 
procedure employed. Thus, at the end of this 
sequential extraction procedure, each original 
urine sample was represented by duplicate 
samples of two basic and two acidic ether 
extracts and an aqueous residue. The radioactive 
content of each extract and the residue was
determined by liquid scintillation counting of 
duplicate weighed aliquots (approximately lOOmg) 
the total weight of each sample having been 
noted. Thus, the radioactivity in each extract 
could be expressed as a percentage of the 
original total. The aqueous residue was 
neutralised and extracted with Amberlite XAD-2 
resin as described in the following section
(2.4.2). The extraction scheme is shown
diagrammatically in Figure 2.2.
2.4.2 Extraction of radioactive metabolites of
fenfluramine and 780SE from human and animal 
urine using Amberlite XAD-2
Amberlite XAD-2 was found to be suitable for 
isolating metabolites of 780SE from urine. The
resin, as supplied, first required at least 5 
rinses with distilled water to remove chloride 
ions. Then 2-3g of resin were added to a urine 
sample (50-100ml) in a conical flask and the 
mixture magnetically stirred slowly for 30 
minutes. After this time, aliquots of the
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FIGURE 2.2 : EXTRACTION SCHEME FOR THE URINARY METABOLITES
OF FENFLURAMINE
Sample (10ml)
5N NaOH (1ml) 
Diethyl ether (2 x 10ml)
Basic and neutral 
metabolites
Acidic metabolites
Acidic and neutral 
metabolites
Residual sample 
ION HC1 (2ml)
Diethyl ether (2 x 10ml)
Residual sample 
90°C for 1 hour
Acid hydrolysed sample 
Diethyl ether (2 x 10ml)
Residual hydrolysed 
sample
5N NaOH (6ml)
Diethyl ether (2 x 10ml)
▼
Basic metabolites
V
Unextracted metabolites
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extracted urine were counted (liquid 
scintillation counting) to ensure that >95% of 
the radioactivity had been adsorbed by the 
Amberlite XAD-2. The remaining aqueous sample 
was aspirated to waste by judicious use of a 
pasteur pipette attached to water-tap suction. 
The resin was then rinsed twice with distilled 
water (20ml) to remove any remaining unextracted 
endogenous material. Samples of washings were 
counted to ensure that no radioactivity was lost 
in this process. After removing as much water 
as possible from around the resin, methanol 
(20ml) was added to it and the mixture stirred 
slowly for 20 minutes. After this time, the 
methanol was drawn off using a pasteur pipette 
and transferred into a measuring cylinder. This 
methanol extraction process was repeated twice 
and the 3 extracts pooled in the measuring 
cylinder. The volume of the total methanol 
extract was noted and aliquots counted to 
determine the extraction efficiency. If the 
recovery of radioactivity, from the original 
urine sample, was less than 90%, further 
methanol extractions were carried out until this 
recovery was achieved.
The pooled methanol extracts (60-100ml) were 
then concentrated to 5-10ml by rotary 
evaporation using a low heat (40°C) to aid the 
process. The sajnple was further concentrated to
l-2ml, under a stream of nitrogen, in a glass 
scintillation vial at room temperature.
2.4.3 Extraction of radioactive metabolites of 780SE 
from human plasma samples
The concentration of radioactivity in plasma 
samples obtained during a human volunteer study
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(subject DBG), was high enough to enable the use 
of Amberlite XAD-2 resin. The procedure was 
essentially the same as for extraction of urine 
described earlier. The plasma was first diluted 
1:1 with distilled water. It was necessary to 
extract the diluted plasma (20ml) with 3 
sequential amounts (Ig) of resin, in order to 
remove at least 90% of the radioactivity from 
the samples. Methanol extraction of the XAD-2 
proceeded in the usual way. Concentration was 
achieved by repeated rotary evaporation and 
dilution of the sample with methanol, until the 
required volume (100-200^1) could be achieved, 
being at least 50% methanol.
2.4.4 Enzyme hydrolysis of conjugated metabolites in 
samples of urine
Many metabolites are excreted as conjugates of 
endogenous compounds. These conjugates are 
hydrophilic and therefore difficult to extract. 
They show poor chromatographic properties and it 
is advantageous to hydrolyse the conjugate and 
liberate the phase I metabolite prior to 
isolation for identification. Both enzyme and 
acid hydrolysis have been used; the acid 
hydrolysis procedure was used during the 
isolation of fenfluramine metabolites and has 
been described in section 2.4.1.
For enzyme hydrolysis the following procedure 
was followed. A sample (up to 100ml) of urine 
was adjusted to pH 5.5 by the addition of 
glacial acetic acid. Some extract of Sue Helix 
pomatia (100|il) , having both (3-glucuronidase and 
sulphatase activity, was added to the sample. 
The mixture was incubated in a shaking water 
bath (50 cycles sec-1) at 37°C for 24
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hours. Negative controls were included using 
1,4-saccharo-lactone and phosphate as inhibitors 
of glucuronidase and sulphatase respectively. 
After this time the sample was extracted with 
Amberlite XAD-2 resin or solvent as already 
described.
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2.5 Analytical Methods - Radioactive
2.5.1 Liquid scintillation spectrometry
Aqueous samples were analysed for radioactive 
content by direct liquid scintillation counting 
in either a Packard model 3385 or 300 
scintillation counter. Aliquots of samples were 
placed in a glass scintillation vial (20ml) and 
scintillation fluid (12ml of Scintran T) added.
Sample preparation varied according to the type 
of sample. Urine and plasma samples were 
analysed by counting aliquots of 100^1 or 1ml, 
both of which formed an homogenous mix with the 
scintillation fluid. The activity of dosing 
solutions was assessed by counting 50^1 aliquots 
of a suitable dilution of the dose. Scrapings 
of thin layer chromatography plates were 
analysed by placing the silica fragments into 
distilled water (4ml) in a scintillation vial 
and allowing to stand for at least 12 hours to 
allow the aggregates to disintegrate completely; 
immersion in an ultrasonic bath facilitated this 
process. Scintillation fluid (10ml) is then 
added to form a stable gel for liquid 
scintillation counting.
Samples of red blood cells, faeces and tissues 
were first combusted before being counted; this 
process is described separately in this section
(2.5.2).
Quench correction was by use of an external 
standard, automatically introduced at the 
beginning of the counting process for each 
sample. This generated an external standard
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ratio for each sample. This was referred to a
previously prepared quench correction curve
relating ratio to counting efficiency. A
separate quench correction curve was required
for each sample type ; this was generated by
counting a series of suitable blank samples
containing a known amount of activity 
14
([ C]-hexadecane standard) and being quenched 
to varying degrees by the addition of different 
volumes of chloroform.
A quality control check was carried out on the 
external standard quench correction method. 
After counting a batch of samples, a few of 
those samples (5%) were spiked with 
[^C]-hexadecane internal standard and 
recounted. For these samples the disintegrations 
min ^ (dpm) had been calculated by both external 
and internal standardisation; the results were 
within 2% error limits.
2.5.2 Combustion of solid samples prior to LSC
Solid samples were pretreated to make them 
suitable for liquid scintillation counting. 
This was achieved by combustion such that [14C] 
was oxidised to ^4C02 which was subsequently 
trapped in an organic base and mixed with
scintillation fluid for counting.
Any solid sample was thoroughly homogenised 
before aliquots were taken for combustion. Red 
blood cells were adequately homogenised after 
freezing and thawing. Faeces were homogenised
for 30 minutes using a Stomacher paddle 
homogeniser; often the addition of a measured 
quantity of water was necessary to ensure 
adequate homogenisation. With very small, dry
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faecal samples, e.g. rat, it was found 
advantageous to homogenise the sample in 5% 
carboxymethylcellulose (in water). After 
homogenisation, aliquots (100-500mg) of sample 
were accurately weighed into Packard Combusto- 
cones.
The prepared samples were combusted using a
Packard Tricarb Model 306 Sample Oxidiser. The 
14
CO 2 was trapped in 35% ethanolamine in 
methanol (8ml) and mixed with scintillation
fluid (12ml) which comprised PPO (0.01%) and 
dimethyl POPOP (0.55%) in toluene containing
methanol (33%).
Before each batch of samples, a check was made 
on the combustion efficiency of the machine. 
This was done by spiking aliquots of suitable 
blank material with a known amount of
radioactivity, combusting and counting them and 
comparing the results with those obtained by
counting combusted blank samples to which the 
same amount of radioactivity had been added 
after combustion.
A quality control check was carried out on the 
combustion process to ensure a consistent 
efficiency of combustion. This was effected by 
interspersing spiked samples of known activity 
throughout the sample batch.
2.5.3 Separation of radioactive components from a 
mixture by thin layer chromatography (TLC)
All TLC was carried out on glass-backed plates 
(20 x 20cm) coated with silica G254 (0.25mm) .
The plates were marked with an origin (2cm from 
the bottom of the plate) and the silica scored
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in a line 16cm from the origin. Samples to be 
chromatographed were applied to the origin as 
bands (1.5 x 0.5cm). Care was taken not to 
overload the sample band. Spots of suitable 
non-radioactive reference compounds were 
interspersed with samples on the origin. As 
soon as the applied samples had dried, the plate 
was placed in a glass TLC tank containing the 
requisite solvent system (Table 2.4) and allowed 
to develop until the solvent front had reached 
the scored line. The plate was then removed and 
allowed to dry thoroughly before further 
analysis. As well as separating radioactive 
metabolites, TLC was used to check the purity of 
radioactive compounds.
The 'cold1 reference compounds were located by 
fluorescence under UV (254nm) irradiation, 
using a UV lamp (Ultra-Violet Products, Inc., 
California, U.S.A.).
2.5.4 Localisation and subsequent quantitation of 
radioactive components on TLC plates by 
autoradiography
Kodirex X-ray film was used to produce a 
radioactive 'map' of a TLC plate.
After marking assymetrically with 3 or 4 spots 
of radioactive ink, the thoroughly solvent free 
TLC plate was placed against the X-ray film such 
that the silica was in contact with the emulsion 
on the film. Adhesive tape was used to hold 
the film firmly to the plate and the assembly 
was wrapped in a light-proof bag and stored in a 
light-proof drawer at room temperature. Storage 
times varied from a few hours to several weeks 
depending on the amount of radioactivity on the
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TABLE 2.4 : SOLVENT SYSTEMS USED TO DEVELOP THIN LAYER
CHROMATOGRAPHIC PLATES
System No. Solvents Ratios Application
1 Dichloromethane 70 Fenfluramine
Methanol 30 Metabolites
0.880 Ammonia 1 and Radiopurity
2 Toluene 10
Ethyl Acetate 40 Fenfluramine
Acetic Acid 10 Metabolites
Water 5 and Radiopurity
3 Butanol 90 780SE
Methanol 10 Metabolites
Water 10 and Radiopurity
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plate. After storage, the X-ray film was
developed (DX-80 diluted 1:10), washed in tap 
water, fixed, (G334 diluted 1:10) and finally 
washed thoroughly for 20 minutes in a continuous 
stream of tap water. Excess water was removed 
from the developed plates, which were then hung 
and allowed to dry thoroughly. By matching the 
radioactive ink spots on the TLC plate with the 
corresponding spots on the X-ray film, the
radioactive areas on the plate could then be 
accurately located. Quantitation of these 
defined areas was effected by scraping them 
separately into scintillation vials and treating 
them as already described (2.5.1).
2.5.5 Localisation and simultaneous quantitation of 
radioactive components on TLC plates by
radioscanning
An alternative method of locating the 
radioactive areas in a chromatogram was by 
radioscanning using a Berthold TLC plate 
scanner. The plate was placed on the adjustable 
platform so that the instrument detector head 
was in line with, and at one end of, the 
chromatogram of interest. The sensitivity, time 
constant and scan speed were set according to 
the level of radioactivity on the plate and the 
scan initiated. The scan was plotted with areas 
of radioactivity indicated by peaks on the 
radioscan.
Quantitation of radioactivity was achieved by 
two methods according to the type of analysis 
required. Radiopurity was calculated by radio 
scanning in the integration mode. This method 
was ideal where the abundance of one
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major component in a chromatogram was required. 
Where several components were present, as in a 
typical metabolic profile, plate scraping was 
used as described in section 2.5.1.
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2.6 Analytical Procedures (non-radioactive)
2.6.1 The measurement of fenfluramine and
norfenfluramine in plasma and urine by gas 
chromatography with nitrogen specific detection
Caccia et al., (1977) have described a method
for simultaneous measurement of the optical 
isomers of fenfluramine and norfenfluramine from 
racemic mixtures, by forming pentafluoroprop- 
ionyl-l-prolyl derivatives which can be 
separated on an OV 225 liquid phase. However, 
where only one optical isomer is present or 
separation of the isomers is not required, a 
more rapid method can be used.
The method of Campbell (1970) allows the 
measurement of fenfluramine and norfenfluramine 
in samples of plasma and urine down to a level 
of Sng.ml \  However, this method suffers from 
three major disadvantages. Firstly there is a 
sample concentration step which has to be 
carefully monitored as all the compounds of 
interest are volatile. Secondly, detection is 
by flame ionisation, giving a large solvent 
front which, at higher sensitivity, can 
obliterate the norfenfluramine peak if great 
care is not taken over the sample injection 
technique. Sample introduction dynamics thus 
becomes critical with low level samples. 
Thirdly, in order to measure lower levels of 
compound in plasma in man, it is necessary to 
use a large sample volume (5ml). This increases 
the solvent front problem and, of course, can 
lead to problems of adequate blood sample 
collection.
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By using nitrogen specific detection in place 
of flame ionisation, the response factor of 
the compounds was considerably increased. 
This enabled the method to be modified to 
eliminate all the above problems.
2.6.1.1 Apparatus
Glass tubes were kept free of detergent. 
Initially they were acid washed, rinsed and 
dried then silanised using 2%
dichloromethylsilane in 1,1,1-trichloroethane. 
After rinsing with diethyl ether and being 
allowed to dry, the tubes were ready for use.
Separation was achieved on a glass column 
(1.9m x 6mm O.D. x 2mm I .D. ) packed with 10% 
Apiezon L and 10% potassium hydroxide on Gas 
Chrom Q (100-120 mesh). The column was 
mounted in a Hewlett Packard Model 5880 Gas 
Chromatograph (GC) and a constant flow 
(30ml.min of oxygen-free-nitrogen carrier 
gas maintained through the column. The 
carrier gas was filtered through a molecular 
sieve (Acrytic Puritube; Phase Separations 
Ltd.) before entering the GC. The column oven 
temperature was maintained at 150°C. Sample 
introduction was through a silicone rubber 
septum using a glass microsyringe. This could 
be done either manually or by autoinjection 
using a Hewlett Packard Model 7672A 
Autosampler. The injector block temperature 
was maintained at 250°C. The GC was fitted 
with a nitrogen specific detector. The 
hydrogen and air flow were maintained at 3 and 
60ml.min ^ respectively. The detector block 
temperature was maintained at 300°C.
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2.6.1.2 Extraction from plasma
Duplicate aliquots (1ml) of the plasma sample 
or a standard were measured into round 
bottomed tubes. Internal standard
(N,N-d iethylaniline ; 65ng) in 0.005M sulphuric 
acid (100p.l) was added followed by 5M sodium 
hydroxide (SOOjil) and diethyl ether (3ml). 
The tubes were stoppered and the mixture
shaken vigorously for 10 minutes. After
centrifugation (3000g) for 5 minutes the ether 
layer was transferred into a tapered tube 
(15ml) containing 0.5M sulphuric acid (1ml). 
The tube was stoppered and shaken vigorously 
for 10 minutes. After standing for about 1 
minute, the ether layer was aspirated and
discarded.
Butyl acetate (100p.l) and 5M sodium hydroxide 
(500^1) were added to the remaining acid layer 
and the mixture vortex-mixed on an
IKA-Vibrax-VXR mixer set at 1200 cycles min”*1' 
for 5 minutes. After standing for about 1 
minute, the majority of the lower, aqueous 
layer was drawn off using a pasteur pipette, 
so that final separation of the phases could 
be achieved more easily in the narrower
tapered part of the tube. The tube was 
centrifuged (2000g) for 2 minutes to
completely separate the phases. The top, 
butyl acetate layer was transferred to a 
tapered sample vial for automatic injection 
(3(il) or into a 1ml glass, screw-topped vial
prior to manual injection (3|il).
Using radioactive fenfluramine, recoveries of 
>95% of drug were found in the final extract. 
Comparison of expected and observed peak
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height ratios of fenfluramine to 
norfenfluramine confirmed >95% recovery of 
norfenfluramine in the final extract.
This whole procedure was also applied to 
saliva samples with equal success.
2.6.1.3 Extraction from urine
Because of the higher quantities of the drug 
in urine and the ease of extraction from this 
fluid with solvents, it was possible to 
simplify the initial extraction phase and
carry out the entire procedure for one sample
in one tube. A rapid extraction procedure has 
been described by Ramsey and Campbell (1971). 
However, this is unsuitable for nitrogen 
specific detection because it uses chloroform 
as the extraction solvent.
Duplicate aliquots (0.5ml) of the urine sample 
or a standard were measured into tapered tubes 
(15ml). Internal standard (N,N-diethylaniline: 
0.65|ig) in 0.005M sulphuric acid (lOOjil) was 
added followed by 5M sodium hydroxide (200^1) 
and diethyl ether (2ml). The tubes were 
vortex mixed (1500 cycles min"”1 for 10 
minutes) and then centrifuged (2000g for 2 
minutes). The lower aqueous layer was drawn
off and discarded using a pasteur pipette. 
Then, 0.5M sulphuric acid (0.5ml) was added to 
each tube and the mixtures vortexed (1500 
cycles min 1) for 10 minutes and centrifuged 
(2000g) for 2 minutes. The top, solvent layer 
was aspirated off as in the plasma method, and 
then 5M sodium hydroxide (100p.l) and butyl
acetate (200^1) added and the mixtures again 
vortexed (1500 cycles min ^) for 10 minutes
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and centrifuged (2000g) for 2 minutes. The 
butyl acetate fractions were transferred to 
suitable sample vials. Final recoveries of 
>95% were found for both fenfluramine and 
norfenfluramine as previously described with 
plasma.
2.6.1.4 Preparation of calibration curves
Standards were prepared starting with a 
Img.ml ^ stock solution of fenfluramine and 
norfenfluramine as hydrochloride salts in 
water. For plasma the stock solution was 
diluted 1:100 with water. An aliquot (200|il) 
of this solution was diluted to 10ml with 
fresh human plasma. Aliquots of this sample 
were diluted accordingly with more fresh human 
plasma to give a suitable range of standards 
(2^5^-lOOng.ml )^ . For urine, an aliquot 
(100^1) of the stock solution was diluted to 
10ml with freshly voided human urine. Further 
dilutions were made with more fresh urine to 
give the required standard range (0.05-2.0^g. 
ml . The plasma or urine standards were 
then taken through the appropriate extraction 
procedure (sections 2.6.1.2 and 2.6.1.3) and 
the extracts chromatographed. Calibration 
curves were constructed by measuring the peak 
heights of norfenfluramine, fenfluramine and 
internal standard on the chromatograms, and 
plotting peak height ratios (drug/internal 
standard) against the amount of drug in the 
standard.
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2.6.1.5 Results
There was no difference in the response 
factors between the racemate and individual 
isomers of either fenfluramine or
norfenfluramine, thus the described method is 
applicable to all these forms. Using small 
plasma sample volumes (1ml), concentrations of 
norfenfluramine and fenfluramine of 2.Sng.ml”1 
were detected enabling measurement of plasma 
concentrations of these compounds up to 48h 
after a single dose (30mg). This limit can be 
further lowered by using larger sample
volumes. The higher concentrations of
fenfluramine and norfenfluramine found in 
urine and the relative ease of extraction,
enabled even lower sample volumes and a 
simplified, rapid extraction procedure to be 
used. The limit of sensitivity was lOOng.ml”1.
The chromatograms obtained were clean with the 
lack of solvent front enabling a short 
chromatogram time (5 min). Linear calibration 
curves were obtained for both compounds in 
urine and plasma, with high correlation 
coefficients (r>0.998) and a low percentage 
error in the slope (0.89 to 1.26% for the 95% 
confidence limits). The coefficients of 
variation ranged from 3.3% (at lOOng.ml”1 of 
fenfluramine) rising to 12.0% (at 2.Sng.ml”1 
of fenfluramine) in plasma and from 2.5% (at 
Ijig.ml 1 of fenfluramine) to 7.4% (at 
0. lug.ml 1 of fenfluramine) in urine, the 
overall mean values being 7.1% and 6.9% in 
plasma and 4.5% and 4.8% in urine for 
norfenfluramine and fenfluramine respectively 
(Table 2.5). In practice the assay has been 
shown to be applicable to plasma, saliva and
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TABLE 2.5 : COEFFICIENTS OF VARIATION* OBTAINED ON
NORFENFLURAMINE AND FENFLURAMINE ASSAYS IN URINE AND PLASMA
Fluid Plasma Plasma Urine Urine
Compound NFF FF NFF FF
Concentration"1" (ng.ml Coefficient of Variation (%)
2.5 9.7 12.0 - -
10 10.0 8.8 ND ND
30 4.0 3.6 ND ND
100 4.9 3.3 6.6 7.4
300 ND ND 4.0 4.4
1000 ND ND 2.9 2.5
Mean 7.1 6.9 4.5 4.8
NFF - Norfenfluramine 
FF - Fenfluramine 
ND - Not Determined
* - Between 4 and 8 determinations at each concentration
+ - Concentration of standard before extraction;
extraction efficiency >95% in all cases.
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urine samples from human volunteers and 
patients or from animal species, including rat 
and dog.
Fresh blood samples were taken by any suitable 
method, and were transferred to
lithium-heparinised sample tubes and 
immediately centrifuged to separate the plasma 
from the red blood cells. Because there was a 
relatively low whole blood to plasma ratio 
(1.5:1) of fenfluramine, slight haemolysis of 
a sample was unlikely to affect the final 
result. All samples were stored frozen at 
-20°C for up to 6 months, until analysis could 
proceed.
Endogenous interfering compounds were rare and 
were normally eliminated by repeating the back 
extraction procedure. The drug, amphetamine 
has a retention time which lies between that 
of fenfluramine and norfenfluramine. By 
increasing the chromatography time (by 
decreasing the column oven temperature), this 
compound can also be adequately resolved so as 
not to interfere with the chromatography of 
fenfluramine and norfenfluramine. By using 
automated injection techniques, as many as 200 
chromatograms can be run over 24 hours which 
typically represents 150 actual samples.
2.6.2 The measurement of 1 - (m-trifluoromethylphenyl) 
propane-1 2-diol in urine by gas chromatography 
with flame ionisation detection.
This compound was found to be the major 
urinary metabolite of fenfluramine (Chapter 
3) . It was therefore desirable to develop an 
analytical method to follow the kinetics of
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this compound. A simple, rapid procedure is 
described for the analysis of the compound in 
urine; the method is not sensitive enough to 
detect the much lower concentrations in 
plasma. The high polarity of the compound 
made it difficult to chromatograph. However f 
this problem was overcome by derivatising the 
hydroxyl groups, thus producing a relatively 
non-polar derivative. A number of derivatising 
reagents were tried most of which gave rise to 
multiple derivatives. This is, perhaps, not 
surprising when one considers that carbons 1 
and 2 of the propane chain are both optically 
active. Thus the racemic compound can exist 
in four optically active forms and the 
derivatives of these may well be separated on
a GC column. A successful derivatising agent
was found to be methyl boronic acid ; this has 
the advantage of being a small molecule which 
bridges the hydroxyl groups thus increasing 
the lipophilicity of the compound and 
* locking' the conformation of the molecule 
giving only one apparent derivative on GC. 
The presence of the trifluoromethyl moiety 
means that the molecule is relatively volatile 
and as such chromatographs at low 
temperatures. This resulted in the need for
temperature programming, in order to 
incorporate a suitable internal standard in 
the procedure.
2.6.2.1 Apparatus
Standard 1-(m-trifluoromethylphenyl)propane-1,
2-diol was prepared by oxidation of
m-trifluoromethyl-isoallyl benzene.
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The internal standard (1-(4-me thoxyphenyl) 
propane-2, 3-diol) was prepared from estragole 
epoxide.
Separation of the derivatives was achieved on
a glass column (1.4m x 6mm O.D. x 2mm I.D.)
packed with 5% OVl on Gas Chrom Q (80-100
mesh). The column was mounted in a Hewlett
Packard Model 5710 gas chromatograph. A
 1
constant flow (30ml.min ) of oxygen- 
free-nitrogen carrier gas was maintained 
through the column, having first been filtered 
through a molecular sieve. The column oven 
temperature was programmed to enable the 
elution of analyte and internal standard in a 
reasonable time. Following sample injection 
the oven temperature was maintained at 115°C 
for 4 minutes during which time the analyte 
was eluted. The temperature then increased at 
30°C.min ^ to 170°C where it was maintained 
for 2 min during which time the internal 
standard eluted. The temperature was then 
allowed to restabilise at 115°C prior to the 
next sample injection. Sample introduction 
was through a silicone rubber septum using a 
glass microsyringe. Detection of the
separated components was by flame ionisation. 
The flame was maintained by burning hydrogen 
(30ml.min""1) in oxygen (240ml.min”1) .
2.6.2.2 Extraction procedure
The diol is excreted in urine as a conjugate, 
it was therefore necessary to hydrolyse the 
sample to liberate the free diol. Duplicate 
aliquots (2ml) of urine sample or standard 
were placed in glass round bottomed tubes 
(20ml) and concentrated hydrochloric acid
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(200^1) added to each sample. The tubes were 
stoppered firmly and then placed in a water 
bath at 90°C for Ih. After this time, the 
samples were allowed to cool to room 
temperature. Then internal standard (4pg) in 
aqueous solution (100^1) and diethyl ether 
(3ml) were added. The samples were shaken 
vigorously for 15 min. After centrifugation 
(2000g) for 5 min, the organic layer was 
transferred to 15ml tapered tubes. Methane 
boronic acid (lOO^ig) in acetone (1ml) was 
added and the mixture reduced to about 1ml 
under a stream of nitrogen. The sample was 
then transferred to a small (1ml) glass 
screw-topped vial prior to injection of 
aliquots (3^1) on GC.
2.6.2.3 Preparation of calibration curves
A range of standards from O.2~lO^g.ml~^ were 
made up in urine. A stock solution was 
prepared by dissolving authentic l-(m-tri 
fluoromethylphenyl)propane-1,2-diol (lOmg) in 
the minimum of methanol and diluting to 100ml 
with water. Volumes of this stock solution 
were diluted with freshly voided human urine 
to give the required standard concentrations. 
The internal standard solution was prepared by 
dissolving (4mg) in the minimum of methanol 
and diluting to 100ml with water. The urine 
standards were taken through the extraction 
procedure (2.6.2.2) and the extracts 
chromatographed. Calibration curves were
constructed by measuring the peak heights of 
the diol and the internal standard and
plotting peak height ratios (drug/internal
standard) against the amount of diol in the 
standard.
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2 . 6 . 2 . 4  R e s u l t s
Using small urine volumes (1ml) a sensitivity 
-Iof 0. 2\ig .ml was achieved. The chromatograms 
were clean and had a total run time, between 
injections of 15 minutes. Linear calibration 
curves were obtained, over the range 
0.2-lOp.g.ml ^ , with high correlation 
coefficients (>0.998) and a low percentage 
error in the slope (<1% for 95% confidence 
intervals). The coefficients of variation 
varied from 9% (at 0.Sng.ml”1) down to 3% (at 
lOug.ml”1).
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2 . 7  P h a r m a c o k i n e t i c  A n a l y s i s
2.7.1 Pharmacokinetic analysis of radioactive data
Pharmacokinetic parameters, describing plasma 
concentration data for both total radioactivity 
and the respective intact drug determined by 
non-radioactive methods, were derived using the 
method of residuals (Gibaldi and Perrier, 1975) 
employing a program written for a Wang 2200
mini-computer. The terminal decline phase of 
the semi-logarithmic plot was determined by a 
least squares regression analysis on the
relevant data points. This defined the intercept 
(Cz) and the exponential
X = loge 2 Slope z
z log,o2
of the terminal phase " and then the terminal 
half-life was defined as:
tie = M â l
X z
Some data showed an earlier, more rapid decline 
phase which was defined by plotting
semi-logarithmically the difference curve 
between the measured data points and the
terminal phase over that period (t vs C -
C^e V )  and applying the same regression 
analysis. Thus a second intercept '(C) and 
exponential:
X l = — ±22-2 
slope 1
were derived and the half-life of this phase was 
calcuated as before. The remaining data points
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(absorption phase) were subtracted from the 
already defined phases and the resulting values 
were plotted semi-logarithmically (t vs (C e^zt
—  A t ^
+ C 1e A1 )-C. A regression analysis gave the 
exponential, ka, whence the half-life of
absorption was:
tia =
2 ka
The lag time (tlag) was defined as the time at
which first order absorption started, thus a 
plasma concentration vs. time curve having one 
absorption and one decline phase was described 
by the general equation :
C = C (o)[e-xz (t-tlag) - e_ka(t-tlag)]
and one having one absorption phase and two 
decline phases by the general equation :
C=
C 1e“Ai(t"tlag)+Cze“Az {t"tlag)- (C1+Cz)e"ka(t“tlag)
The area under the plasma-time curve to infinite 
time (AUC^) was determined by two methods. One 
was the sum of exponentials (integration):
AUC = + £z_ - (C1 + C z>
X1 X z ka
the other was the trapezoidal rule : 
AUC = (C(n) " C (n-1)1 (t(n)- t (n-l)1 + cze ^
X
z
t
(i)
94
for i data points each being given the notation
n such that at the time, t=t^, the measured
plasma concentration C fl_. = C, x. The
(t) in)
exponential term simplifies to give the 
equation:
AUC = (C (n) ~C (n-1) ) (t(n)~t (n-l) )+Cze 
2 >'Z
2.7.2 Pharmacokinetic analysis of oral and intravenous 
d-fenfluramine plasma data
The study is described and discussed later in 
the thesis (section 4.3). The data were
analysed using a program written for a Hewlett 
Packard 1000 Series A mini computer (Ings,
Pidgen and Johnson, 1980). Instead of the
method of residuals already described, each
plasma profile was curve-fitted by an iterative 
program which minimised the sum of squares. A 
reciprocal weighting factor was used throughout.
Oral profiles had a first order absorption term 
with one or two exponential terms describing the 
declining plasma levels as described by the 
equation:
c ■ E cie~ Xit
where C is the plasma concentration at time t, 
C\ is the coefficient and is the exponential 
constant for the nth term. The absorption phase 
was described by a negative exponential term.
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The maximum plasma levels (C__v ) and the time of
these (tjnax^  were taken from the actual
analytical data. The area under the curve
either to the last measured time point or to
infinity, was calculated by both the trapezoidal
rule (described in section 2.7.1; Yeh and Kwan,
1978) and by the sum of exponentials
(integration). The half-life (ti) of each
2
decline phase was defined by the equation :
tl = 0 ^ 1 1
2 X
A similar curve-fitting method was used on the 
intravenous infusion data, but a zero order 
input was used. The parameters of clearance 
(Cl) and volume of s distribution by area 
(V-, x) were calculated as follows :
D v 3 L S 3. /
Cl = 2°se 
AUC
V . Ç l
D(area) z
where z is the slope of the terminal phase.
Finally, the absolute bioavailability (F) of 
either oral formulation was derived by the 
equation :
F (%) = A0Cpo x Doseiv x 100 
AUC.V Dosepo
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2 . 8  M a t e r i a l s
All radioactive and non-radioactive parent drugs and 
reference compounds were supplied by Les Laboratoires 
Servier, France, with the exception of 
m-trifluoromethylbenzoic acid which was supplied by 
British Drug Houses Ltd., UK. Radioactive (14C) 
hexadecane reference was obtained from Amersham 
International Ltd., U.K.
Scintran scintillation cocktail was supplied by British 
Drug Houses Ltd. Other scintillation chemicals were 
supplied by Koch-Light Laboratories, UK (Triton X-100) , 
United Technologies Packard, UK (PPO) and Sigma Ltd., 
UK (dimethyl POPOP). Sigma Ltd. also supplied the
8-glucoronidase (Sue helix pomatia) and d-saccharic 
acid-1,4-lactone.
Autoradiograph X-ray film (Kodirex), developer (DX-80) 
and fixer (G334) were supplied by Kodak Ltd., UK.
Phase Separations Ltd. supplied Gas Chrom Q support and 
OVl stationary phase whereas Apiezon L came from Pye
Unicam Ltd., UK. Pierce and Warriner Ltd., UK,
supplied the methane boronic acid.
Apart from ethyl acetate (Analar grade) which was 
supplied by May and Baker Ltd., UK, all other solvents 
and reagents were Analar grade and came from British
Drug Houses Ltd., UK.
All animals were the standard stock of Huntingdon 
Research Centre, UK, where they were housed throughout 
the studies.
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CHAPTER 3
14THE METABOLISM AND KINETICS OF [ C]-dl-FENFLURAMINE
HYDROCHLORIDE IN MAN
This chapter reports data obtained from studies in which 
male and female volunteers were administered oral 
[■^C]-dl-fenfluramine hydrochloride. The absorption of 
radioactivity from the gut, its distribution in plasma and 
red blood cells and its eventual excretion are all discussed 
with a pharmacokinetic evaluation. The plasma concentration 
versus time profiles of parent drug and its deethylated, 
metabolite are described in relation to the total 
radioactivity profile. The radioactive metabolic products 
excreted into urine have been isolated, separated,
quantified and the most abundant metabolites identified. 
The urinary excretion profiles of fenfluramine, 
norfenfluramine, which is also pharmacologically active and 
the major urinary metabolite are described.
3.1 Dose Preparation and Study Design
The radiopurity of the [^C]-dl-fenfluramine 
hydrochloride was checked (Methods 2.2) and found to be 
>98%. Each dose was prepared in the same way. A small 
quantity (approximately SOjiCi) of the radiolabelled
compound was dissolved in distilled water (10ml). 
Aliquots (20|il) of this solution were analysed by 
liquid scintillation counting to determine the 
concentration of radioactivity. Based on this
measurement a volume of solution containing 30jiCi was 
transferred into a volumetric flask (50ml) into which 
was weighed unlabelled drug (approximately 60mg).
After making up the volume with distilled water, 
aliquots (5 x 100^1) of this dosing solution were 
counted to determine the exact radioactive dose (Table
3.1). At the time of dosing the solutions were poured
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TABLE 3.1 : SUBJECT AND DOSING DETAILS
SUBJECT AT MB
Sex M F
Age (yr) 38 50
Height (cm) 169 178
Body Weight (kg) 78 68
* Dose dl-fenfluramine (mg) 51.7 51.0
Dose dl-fenfluramine (jiCi) 29.7 29.0
* - Expressed as free base fenfluramine
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into a glass beaker and the subjects were instructed to 
swallow their dose as quickly as possible and to avoid 
retaining any dose solution in the mouth. The 
volumetric flasks were rinsed twice with distilled 
water (50ml) and the rinsings transferred into the 
glass beaker and also swallowed quickly. The
approximate final dose for each volunteer was the same 
(50mg, 30|iCi) .
Two healthy volunteers were entered into the study. 
Both had no history of cardiac, hepatic or renal 
dysfunction. Blood samples were taken before and after 
each study to confirm no haematological or biochemical 
abnormalities. Neither subject had taken any regular 
medication nor taken part in any other drug trial for 
four weeks prior to the start of these studies. The 
subjects fasted for 12 hours before dosing and did not 
eat until 4 hours after. No other medication, or
alcohol were permitted from 24 hours before dosing
until the end of the study and neither subject was a
smoker. Subject details are shown in Table 3.1.
Blood samples (20ml) were taken by venepuncture from 
the anti-cubital fossa at 0, 1, 2, 3, 4, 6, 8, 12, 24, 
28, 32, 48, 72, 96, 120, 144 and 168 hours, then
separated into plasma and red cells and stored at -20°C 
until analysis. The bladder was emptied immediately 
prior to dosing and total voided urine was collected 
into preweighed plastic screw-top bottles at 1, 2, 4,
8, and 12 hours and thereafter every 12 hours until 7 
days after dosing. Total faeces were collected into 
preweighed plastic sample bags over the 7 day study 
period. The time of each void was noted and the 
samples weighed. Both urine and faeces were stored 
frozen at -20°C until analysis could proceed.
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TABLE 3.2 : THE CONCENTRATIONS OF RADIOACTIVITY IN THE PLASMA 
OF HUMAN VOLUNTEERS FOLLOWING ORAL ADMINISTRATION OF [14C]- 
d1-FENFLURAMINE HYDROCHLORIDE (60mg) IN AQUEOUS SOLUTION
Subject AT MB
Sex M F
Time (h) *ng equivalents.ml”
1 135 111
2 160 148
3 161 168
4 162 157
6 146 140
8 149 138
12 114 122
24 92 100
28 89 82
32 98 77
48 82 50
72 51 33
96 27 19
120 15 9
144 9 6
168 NS 2
* - Fenfluramine free base 
NS - No Sample
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TABLE 3.3 : BASIC PHARMACOKINETIC ESTIMATES* ON THE PLASMA 
RADIOACTIVITY VERSUS TIME DATA OBTAINED FROM HUMAN VOLUNTEERS 
DOSED WITH [14C]-dl-FENFLURAMINE HYDROCHLORIDE (6Omg) IN
AQUEOUS SOLUTION
SUBJECT AT MB
Sex M F
Parameter
C 156 163z
A 0.018 0.024z
Ci 48 76
A1 0.303 0.495
ka 1.308 1.066
ti (h) 38.4 29.3
2 S
t, (h) 0.53 0.65
2 a
Lag time t^ag (h) 0.00 0.19
AUC _1 
(ng equiv.h.ml )
. 8642 6834—1,
Cmax (obSe) 162 168
(ng equiv.ml”1)
tmax
* - All plasma radioactivity data has been fitted to the 
general equation :
C=C1e”Xl (t"tlag) +C e"xz (t”tlag)- (C^C ) e“kak (t“tlag)
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3.2 The Absorption of Radioactivity from the 
Gastro-Intestinal Tract
This section describes the appearance of radioactivity 
in the blood after administration of dl-, d- and
showed a rapid rise in the concentration of 
radioactivity in plasma after dosing (Figures 3.1 and
3.2), with subject AT having no lag time and subject MB 
showing a lag time of 0.19h (Table 3.3). The half-lives 
of absorption were similar being 0.53 and 0.65h for AT 
and MB respectively. Peak plasma concentrations of 
radioactivity of 162ng equivalents.ml~^ were reached 
after 4h in subject AT, although there was a broad peak 
over 2-4h (Table 3.2). Subject MB shows a well defined 
peak at 3h with a concentration of 168ng 
equivalents.ml-1. The high urinary recovery (Table 
3.10) and low faecal recovery (Table 3.12) indicate 
virtually complete absorption of the radioactive dose.
3.3 The Distribution of Radioactivity in Plasma and Red 
Blood Cells
This section describes the plasma and red blood cell 
concentration - time profiles for total radioactivity 
following doses of dl-, d- and 1-fenfluramine to both 
volunteers. All plasma data has been successfully 
fitted to the general equation:
1-fenfluramine to both volunteers. Both subjects
C= C^e“ Xi(t-tiag)+ c  e'Xz 3 z
-A (t-t
lag - (C1+C2),e
1 
o
o
o
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TABLE 3.4 : THE DISTRIBUTION OF RADIOACTIVITY INTO THE RED 
BLOOD CELLS OF HUMAN VOLUNTEERS FOLLOWING ORAL ADMINISTRATION 
OF [14C]-dl-FENFLURAMINE HYDROCHLORIDE (60mg) IN
AQUEOUS SOLUTION
Subject AT MB
Sex M F
Time (h) *ng equivalents.g^
1 26 22
2 69 62
3 57 82
4 80 70
6 61 101
8 61 73
12 93 66
24 62 49
28 63 71
32 58 53
48 48 26
72 33 16
96 21 8
120 10 11
144 6 2
168 NS NS
* - Fenfluramine free base 
NS - No Sample
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TABLE 3.5 : THE RED BLOOD CELL/PLASMA RATIO OF RADIOACTIVITY 
IN HUMAN SUBJECTS FOLLOWING SEPARATE ORAL DOSES OF [14C]-dl- 
FENFLURAMINE HYDROCHLORIDE (6Omg) IN AQUEOUS SOLUTION
Subject AT MB
Sex M F
Time (h)
1 0.19 0.20
2 0.43 0.42
3 0.35 0.49
4 0.49 0.45
6 0.42 0.72
8 0.41 0.53
12 0.82 0.54
24 0.67 0.49
28 0.71 0.87
32 0.59 0.69
48 0.59 0.52
72 0.65 0.48
96 0.78 0.42
120 0.67 1.22
144 0.67 0.33
168 NS NS
NS - No Sample
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After maximum plasma concentrations had been reached 
subject AT showed a biexponential decline with a short 
preliminary phase predominating up to approximately 12h 
(Figure 3.1) then a slower decline with a terminal 
half-life of 38.4h. The first phase for subject MB of 
the biexponential decline predominated for a shorter 
time (up to 6h); thereafter plasma concentrations fall 
with a half-life of 29.3h (Table 3.3).
The area under the plasma concentration versus time
-1curve to infinite time was 8642ng equiv.h.ml for AT 
and 6834ng equiv.h.ml ^ for MB.
Radioactivity distributed into red blood cells (Table 
3.4) reaching measured peaks of 93 and lOlng 
equivalents.g ^ at 12h and 6h in subjects AT and MB 
respectively (Figures 3.1 and 3.2). The concentrations 
fluctuated quite markedly over the first 24h after 
dosing. The red blood cell to plasma ratio 
of radioactive concentration ranges between 0.19 and 
0.82 in AT and 0.20 and 1.22 in MB (Table 3.5).
3.4 The Fate of the Radioactive Label
3.4.1 Isolation of urinary metabolites
Metabolites were isolated from urine by solvent 
extraction (Methods 2.4). The quantitation of 
the solvent extracts is summarised in Table 3.6. 
The first basic extract removed 21.7% and 30.9% 
respectively from the urine of AT and MB. A 
further 29.4% and 27.2% respectively was removed 
by acidifying the urine and extracting again. 
Acid hydrolysis enabled further extraction of 
32.1% and 29.0% from each subject respectively. 
Only a further 3.0% and 2.8% was recovered by 
basifying the urine and extracting again leaving 
13.6% and 9.4% in the aqueous residues of AT and
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TABLE 3.6 : THE AMOUNT OF RADIOACTIVITY IN SEQUENTIAL 
ETHER EXTRACTS OF POOLED URINES FROM TWO VOLUNTEERS DOSED 
ORALLY WITH [14C]-dl-FENFLURAMINE HYDROCHLORIDE
SUBJECT AT MB
Sex M F
Extract % of 14C
extracted
Basic 1* 21.7 30.9
Acidic 1 29.4 27.2
Acidic 2* 32.1 29.0
Basic 2 3.0 2.8
Total extracted 86.2 89.9
Residue (aqueous) 13.6 9.4
Total 99.8 99.3
+ - Extracts 1 and 2 equivalent to pre- and post- acid 
hydrolysis respectively.
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MB respectively.
3.4.2 Chromatographic separation of metabolites
The metabolic patterns for each extract, were 
similar for both subjects with the same major 
metabolites appearing (Figures 3.3, 3.4, 3.5,
3.6). Each different type of extract showed 
major components having different Rf values from 
those in the other extracts (Tables 3.6 and
3.7). The first basic extract contained two 
major compounds (Figure 3.3) in each case, with 
Rf values of 0.60 and 0.69 in the basic TLC 
system (Methods 2.5). The pre-hydrolysis acidic 
extract showed four components (Figure 3.4) 
having Rf values of 0.16, 0.23, 0.60 and 0.83 in 
the acidic TLC system (Methods 2.5). After acid 
hydrolysis, ether extraction removed a further 
two components (Figure 3.5) of Rf value 0.79 
and 0.88. The final basic extract contained 
just one component (Figure 3.6) of Rf 0.60. For 
ease of reference, each of these components has 
been coded by simply adding the prefix A or B to 
the Rf value (x 100) according to whether the 
component is chromatographed in the acidic (A) 
or basic (B) TLC solvent system.
Each reference compound (lOOmg) was added to a 
sample of fresh urine (10ml) and these urines 
were extracted in the same way as the 
radioactive urine samples. Thus fenfluramine, 
norfenfluramine, m-trifluoromethylphenyl acetone 
1-(m-trifluoromethylphenyl)-1,2-propane diol and 
1-(m-trifluoromethylphenyl)-2-hydroxy-2-amino 
propane were extracted at basic pH and 
m-trifluoromethylbenzoic and m-trifluoromethyl 
hippuric acids were extracted at acidic pH. 
These extracts of reference compounds were
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FIGURE 3.3: AUTORADIOGRAPHIC LOCATION OF RADIOACTIVE AREAS 
FOLLOWING CHROMATOGRAPHY OF BASIC EXTRACTS OF 
UNHYDROLYSED 0-48h POOLED URINES FROM TWO 
VOLUNTEERS FOLLOWING ORAL ADMINISTRATION  
OF 14C dl-FENFLURAMINE HYDROCHLORIDE
SUBJECT
ISOMER 
Rf VALUE
MBAT
dl dl
.9
.8
B69.7
B60.6
.5
.4
.3
. 2
.1
> U
(2355
> 1 0 % >20 >30%
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FIGURE 3.4: AUTORADIOGRAPHIC LOCATION OF RADIOACTIVE  
AREAS FOLLOWING CHROMATOGRAPHY OF AC ID IC  EXTRACTS  
OF UNHYDROLYSED 0-48h POOLED URINES FROM TWO 
VOLUNTEERS FOLLOWING ORAL ADMINISTRATION  
OF 14C dl-FENFLURAMINE HYDROCHLORIDE
SUBJECT
ISOMER 
Rf VALUE
AT MB
dl dl
.9
A83
.8
.7
AGO.6
.5
.4
.3
A23
.2
A16
.1
> 1 % > 1 0 % >2 0 % >30%
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FIGURE 3.5: AUTORADIOGRAPHIC LOCATION OF RADIOACTIVE  
AREAS FOLLOWING CHROMATOGRAPHY OF ACID IC EXTRACTS  
OF ACID HYDROLYSED 0-48h POOLED URINES FROM TWO 
VOLUNTEERS FOLLOWING ORAL ADMINISTRATION  
OF lhC dl-FENFLURAMINE HYDROCHLORIDE
SUBJECT
ISOMER 
Rf VALUE
MBAT
dl dl
A88
A79
> 1 % >10% >20% > 30%
113
FIGURE 3.6: AUTORADIOGRAPHIC LOCATION OF RADIOACTIVE  
AREAS FOLLOWING CHROMATOGRAPHY OF BASIC EXTRACTS  
OF ACID HYDROLYSED 0-48h POOLED URINES FROM TWO 
VOLUNTEERS FOLLOWING ORAL ADM INISTRATIO N  
. OF 14C dl-FENFLURAMINE HYDROCHLORIDE
SUBJECT
ISOMER 
Rf VALUE
AT MB
dl dl
.9
.8
.7
.6 B60
.5
.4
0 .3
0.2
0. 1
>1% >10% >2 0 % >30%
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chromatographed in both TLC solvent systems. 
Comparisons of the relative Rf values would 
suggest that metabolites B60 and B69 were 
norfenfluramine (Rf-0.62) and fenfluramine
(Rf-0.69) respectively. Similarly AGO and A83 
co-chromatographed with m-trifluoromethyl- 
hippuric (Rf-0.60) and m-trifluorobenzoic 
(Rf-0.83) acids respectively. The neutral 
compound 1-(m-trifluoromethylphenyl)-1,2-propane 
diol had a similar Rf value (0.78) to metabolite 
A79 in the basic TLC system. The other neutral 
compound, m-trifluoromethylphenylacetone,
chromatographed with Rf values of 0.89
(metabolite A88) and 0.92 in acidic and basic 
solvent systems respectively. The remaining 
reference compound, 1 - (m-trifluoromethylphenyl)- 
l-hydroxy-2-amino propane, chromatographed in
the basic TLC system with an Rf of 0.48, which 
did not correspond with any extracted material. 
Several other minor radioactive components were 
seen but each constituted <1% of the 
radioactivity in the urine samples and have been 
ignored in this text.
3.4.3 Confirmation of some metabolite identities by 
mass spectrometry
Metabolite B69
Co-chromatography of Metabolite B69 with a 
reference sample using the basic solvent system 
indicated that this component was unchanged 
fenfluramine. Mass spectrometry using chemical 
desorption, and electron impact ionisation 
(Figure 3.7) confirmed this identification.
Metabolite B60
Thin layer chromatography indicated this 
metabolite to be norfenfluramine. Chemical
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FIGURE 3.7: ELECTRON IMPACT IONISATION AND 
CHEMICAL DESORPTION SPECTRA OF 
METABOLITE B69 (FENFLURAMINE)
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FIGURE 3.8: ELECTRON IMPACT IONISATION  
AND CHEMICAL DESORPTION SPECTRA OF 
METABOLITE B60 (NORFENFLURAMINE)
i) Electron Impact Ionisation
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FIGURE 3.9: ELECTRON IMPACT IONISATION SPECTRA  
OF TRIM ETHYLS ILYLATED M-TRIFLUOROMETHYL  
HIPPURIC ACID AND METABOLITE A60
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FIGURE 3.10: ELECTRON IMPACT IONISATION SPECTRA OF 
N-BUTYLBORONATED L- M -TRIFLUO RO M ETHYL-PHENYL  
PRO P A N -1 ,2-D IOL AND METABOLITE A79
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desorption mass spectrometry confirmed a 
molecular weight of 203, and electron impact 
ionisation yielded all the ions characteristic 
of the de-ethylated metabolite (Figure 3.8).
Metabolite A60
Gas chromatographic separation of the trimethyl 
silyl derivative of Metabolite A60 produced a 
peak identical to that of an authentic sample of 
m-trifluoro-methy1 hippuric acid, similarly 
derivatised. The mass spectrum of this component 
was essentially the same as the reference 
compound (Figure 3.9) confirming the identity of 
Metabolite A60 as m-trifluoromethyl hippuric 
acid.
Metabolite A79
Metabolite A79 co-chromatographed by thin layer 
chromatography with a reference sample of 1-(m- 
trifluoromethyl-phenyl)-1,2 propane diol. 
Unseparated endogenous impurities in the 
isolated sample made the mass spectrum obtained 
by direct insertion uninterpretable. However, 
after derivatisation with butyl boronic acid, 
GC-MS on a capillary column showed a spectrum 
identical to that of the reference compound 
(Figure 3.10) corresponding to the cyclic 
boronate derivative.
3.4.4 Quantitation of metabolites
Metabolites were quantitated by plate scraping 
and liquid scintillation counting (Methods 2.5). 
Before hydrolysis, the most abundant extracted 
metabolite was m-trifluoromethylbenzoic acid 
(18.2% for AT, and 20.5% for MB). Unhydrolysed 
metabolites in the basic extract were more 
abundant for MB (norfenfluramine-11.0%;
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TABLE 3.7 : QUANTITATION OF THE MAJOR METABOLITES IN 
ETHER EXTRACTS1 OF UNHYDROLYSED AND ACID HYDROLYSED POOLED 
URINES FROM TWO VOLUNTEERS DOSED ORALLY WITH 
[14C]-dl-FENFLURAMINE HYDROCHLORIDE
SUBJECT AT
Sex M
Metabolite % of original
2Code sample
Unhydrolysed 
A16 (+A19)3 
A23
A60 (TFM-hippuric 
acid)
A83 (TFM-benzoic 
acid)
B60 (Norfen
fluramine)
B69 (Fenfluramine)
<1.0 <1.0
27.5 23.7
2.9 3.3
1.8 ‘ 1.7
1. Extracts were sequential, i.e. basic extraction
followed by acidic extraction on unhydrolysed samples 
and vice versa on hydrolysed samples.
2. The metabolite code denotes Rf (xlOO) in either the 
acidic (A) or basic (B) TLC solvent systems.
Hydrolysed 
A19 (+A16)3 
A79 (TFM Diol)
ABB (TFM Propanol) 
B60 (Norfen­
fluramine)
3.0
2.4
3.7
18.2
6.9
8.6
1.9
3.0
<1.0
20.5
11.0
17.8
MB
F
3. Quantification did not allow resolution between these 
metabolites ; the least abundant metabolite is shown in 
parenthesis in each case.
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fenfluramine-17.8%) than for AT
(norfenfluramine-6.9%; fenfluramine-8.6%). The 
remaining unhydrolysed extracted material was in 
the acidic fraction with AT and MB samples 
having 3.0% and 1.9% of A16 (including the minor 
metabolite A19 - see Figure 3.4), 2.4% and 3.0% 
of A23 and 3.7% and <1.0% of m-tr if luoromethyl 
hippuric acid respectively. Fewer hydrolysed 
metabolites were seen, indeed only
norfenfluramine was present in the basic extract 
(1.8% in AT and 1.7% from MB) . The major 
component was 1- (m-trifluoromethylphenyl)-1, 
2-propane diol (27.5% in AT and 23.7% in MB) 
then 1 - (m-trifluoromethylphenyl)propane-2-ol
(2.9% in AT and 3.3% in MB) and A19 (including 
A16 which is minor) which accounts for <1.0% in 
each case.
3.5 The Excretion of Radioactivity in Urine and Faeces
The total recovery of radioactivity was 92.8% and 93.0% 
of the doses in AT and MB respectively at 240h after 
dosing (Tables 3.10 and 3.11; Figure 3.11). The 
majority of this was found in urine (92.2% and 92.8%) 
with less than 1% of the dose in faeces. Subject AT 
eliminated radioactivity into urine at a maximum rate 
of 2.48% of dose.h ^ over the l-2h collection period 
after which the elimination rate dropped steadily with 
32.1% recovered at 24h, 72.4% at 72h and 90.3% at 144h 
(Tables 3.9 and 3.10). Subject MB showed a higher 
maximum elimination rate of 3.40% of dose.h ^ over the
l-2h collection period and a faster excretion than AT 
over the first 48h of collection (Tables 3.9 and 3.10) 
with 40.9% recovered at 24h. After this time the 
recoveries became similar to AT with 79.9% at 72h and 
91.1% at 144h.
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TABLE 3.8 : THE EXCRETION OF RADIOACTIVITY INTO THE URINE OF
HUMAN VOLUNTEERS FOLLOWING ORAL ADMINISTRATION OF [14C]-dl-
FENFLURAMINE HYDROCHLORIDE (6Omg) IN SOLUTION
MB 
F
Time (h) % of dose
0-1 1.5 1.0
1-2 2.5 3.4
2-4 4.3 4.9
4-8 7.1 8.6
8-12 4.1 4.1
12-24 12.7 19.0
24-36 12.2 16.0
36-48 10.2 10.7
48-60 9.4 6.5
72-84 5.9 4.0
84-96 3.5 2.7
96-108 + 2.0
108-120 5.6 1.2
120-132 2.1 0.7
132-144 0.9 0.5
144-156 0.7 0.4
156-168 0.4 0.3
168-240 0.9 1.0
Subject AT
Sex M
+ - Sample included in next collection period
NS - No Sample
TABLE 3.9: THE EXCRETION RATE OF RADIOACTIVITY INTO THE
URINE OF HUMAN VOLUNTEERS FOLLOWING ORAL ADMINISTRATION OF
[14C]-dl-FENFLURAMINE HYDROCHLORIDE (6Omg) IN SOLUTION
Subject AT MB
Sex M F
Mid Point (h) % of dose h. ^
0.5 1.50 1.02
1.5 2.48 3.40
3 2.15 2.45
6 1.78 2.14
10 1.02 1.01
18 1.06 1.58
30 1.02 1.34
42 0.85 0.90
54 0.78 0.54
66 0.71 0.47
78 0.49 0.34
90 0.29 0.23
102 ND 0.17
114 ND 0.10
126 0.17 0.06
138 0.07 0.04
150 0.06 0.03
162 0.03 0.02
204 0.01 0.01
ND - Not Determinable
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TABLE 3.10 : THE CUMULATIVE EXCRETION OF RADIOACTIVITY INTO
THE URINE OF HUMAN VOLUNTEERS FOLLOWING ORAL ADMINISTRATION
OF [14C]-d1-FENFLURAMINE HYDROCHLORIDE (60mg) IN SOLUTION
Subject AT MB
Sex M F
Time (h) Cumulative % of dose
1 1.5 1.0
2 4.0 4.4
4 8.3 9.3
8 15.4 17.9
12 19.5 21.9
24 32.1 40.9
36 44.4 57.0
48 54.6 67.7
60 63.9 74.3
72 72.4 79.9
84 78.3 84.0
96 81.8 86.7
108 + 88.7
120 87.3 89.8
132 89.4 90.6
144 90.3 91.1
156 90.9 91.5
168 91.3 91.8
240 92.2 92.8
+ - Sample included in following collection period
TABLE 3.11 : THE EXCRETION OF RADIOACTIVITY INTO THE 
FAECES OF HUMAN VOLUNTEERS FOLLOWING ORAL ADMINISTRATION OF 
[14C]-d1-FENFLURAMINE HYDROCHLORIDE (60mg) IN AQUEOUS SOLUTION
Subject AT MB
Sex M F
Time (h) % of dose
24 NS <0.1
48 NS 0.2
72 0.5 NS
96 NS NS
120 0.1 <0.1
144 <0.1 NS
168 <0.1 <0.1
Total 0.6 0.2
NS - No sample produced
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3 . 6  N o n - r a d i o a c t i v e  A n a l y s e s
3.6.1 The kinetics of____ dl-f en flur amine______and
dl-norfenfluramine in plasma
As well as determining the total radioactivity 
in plasma, the actual concentrations of both 
fenfluramine and norfenfluramine were measured 
by gas chromatography (Methods 2.6), thus the 
oral pharmacokinetics of the compounds can be 
described. The following results are summarised 
in Table 3.12. A general equation has not been 
fitted to the norfenfluramine data, however, the 
terminal half-lives have been estimated from the 
data points on the decline portion of the plasma 
curve (Table 3.13).
The first blood sample was taken at 1 hour after 
dosing and fenfluramine was found in those 
samples at plasma concentrations of 9ng.ml”^ and 
7ng.ml ^ in subjects AT and MB respectively. 
Norfenfluramine was absent in the MB sample at 
this time and subject AT only showed a small 
amount (<2. 5ng .ml”'L) .
Fenfluramine concentrations increased quickly, 
with absorption half-lives of 0.9 and 0.7 hours 
respectively, to a peak at 3 to 4 hours after 
dosing. Subject AT had a peak concentration of 
54ng.ml ^ and MB showed 45ng.ml ^ . 
Norfenfluramine concentrations peaked rather 
later (14ng.ml ^ at 24 hours in AT; 13ng.ml”"*" at 
8 hours in MB), in fact Figures 3.12 and 3.13 
clearly show a plateau rather than a peak. 
Subject AT had concentrations of ll-14ng.ml ^ 
from 8-28 hours after dosing whereas MB showed 
similar concentrations (12-13ng.ml )^ over an 
earlier time period (4-12 hours). After peak
128
TABLE 3.12 : THE CONCENTRATIONS OF FENFLURAMINE (F) AND
NORFENFLURAMINE (NF) IN THE PLASMA OF HUMAN VOLUNTEERS
14FOLLOWING ORAL ADMINISTRATION OF [ C] -d 1-FENFLURAMINE 
HYDROCHLORIDE (6Omg) IN AQUEOUS SOLUTION
Subject AT MB AT MB
Sex M F M F
Analyte NF NF F F
Hours after dose Plasma concentration (ng.ml~^)
1 <2.5 0 9 7
2 3 7 32 29
3 5 7 54 45
4 7 12 51 45
6 9 12 45 44
8 11 13 48 39
12 13 12 39 33
24 14 NS 26 NS
28 11 9 19 18
32 9 9 17 16
48 11 5 15 9
72 5 2.5 12 5
96 5 0 6 2.5
120 2.5 0 3 0
144 <2.5 0 0 0
168 NS 0 NS 0
NS - No Sample
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TABLE 3.13 : BASIC PHARMACOKINETIC PARAMETERS DERIVED FROM 
PLASMA LEVEL DATA ON FENFLURAMINE AND NORFENFLURAMINE 
OBTAINED AFTER ORAL ADMINISTRATION OF d1-FENFLURAMINE (60mg)
TO HUMAN VOLUNTEERS
SUBJECT AT MB AT MB
Sex M F M F
Analyte Norfen Norfen Fen Fen
Parameter
C z 19.5 18.7 38.2 33.0
A
z 0.017 0.027 0.020 0.027
C 1 - - 38.5 25.3
- - 0.119 0.085
ka
- - 0.745 1.034
V
(h) 40.1 25.5 34.9 26.0
tla
(h) - - 0.9 0.7
Lag time t (h) - - 0.8 0.9
lAUC(O-t) (ng.h.ml 1) 893 555 1976 1372
2 AUC (ng.h.ml”1) - - 2091 1447
Cmax (ng.ml”1) 14 13 54 45
fcmax (h) 24 8 3 3-4
. AUC(O-t) calculated to last measured time point using th
trapezoidal rule.
2. AUC calculated by the sum of exponentials.
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levels had been reached, plasma concentrations 
of fenfluramine have been fitted to a 
biexponential model in both subjects (Figures 
3.12 and 3.13). Subject AT showed a terminal 
half-life in plasma of 34.9 hours with an 
initial decline phase of half-life 5.8 hours 
lasting up to 20 hours after dosing ; these data 
are based on fitted data (Table 3.13). The 
actual measured points fluctuated around the 
curve (Figure 3.12) suggesting a 
redistribution phenomenon, possibly variations 
in urinary pH which are known to markedly alter 
the excretion of the drug (Beckett and Brookes, 
1970) . The data of subject MB showed less 
fluctuation (Figure 3.13) and the fitted curve 
was in closer correlation with the measured 
points than with AT; the terminal half-life was 
26.0 hours with an earlier decline phase up to 
24 hours after dosing of half-life 8.2 hours 
(Table 3.13). The last measurable concentrations 
of fenfluramine are 3ng.ml~^ at 120 hours and 
2.5ng.ml ^ at 96 hours for AT and MB 
respectively. Subject AT has detectable levels 
of norfenfluramine up to 120 hours (2.5ng.ml-1) 
whereas MB only shows measureable levels up to 
72 hours (2.5ng.ml-^).
The areas under the plasma concentration versus 
time curves, up to the last measured time point, 
have been calculated using the trapezoidal rule 
(Table 3.13). Subject AT has a larger area the 
fenfluramine versus time curve (1976ng .h .ml*"1) 
than MB (1372ng.h.ml 1) . The areas under the 
norfenfluramine versus time curves were lower 
than for fenfluramine and again subject AT gave 
a higher value (B93ng.h.ml~l) than MB 
(555ng.h.ml ). Comparison of these areas with
the area under the total radioactivity versus
133
time curve gave an indication of the relative 
abundances of fenfluramine and norfenfluramine 
in plasma. Firstly, each norfenfluramine
AUC(O-t) was adjusted to 1016 (AT) and 632 (MB) 
ng equivalent to fenfluramine free base ml-1 
plasma, so that all the areas had relatively the 
same units. Subject AT showed a total 
radioactivity area of 8642ng equiv.h.ml-1 
whereas the total of the fenfluramine and 
norfenfluramine areas amounted to 2992ng 
equiv.h.ml thus 65.4% of the radiolabelled 
material in plasma is unidentified. Subject MB 
showed a lower total area for fenfluramine and 
norfenfluramine (2004ng equiv.h.ml"^) but also a 
lower total radioactivity area (6834ng 
equiv.h.ml )^ leaving 70.7% of radioactivity in 
plasma unidentified. This figure represents an 
overall estimate of unidentified material over 
the entire time course of the study. Comparison 
of the levels of fenfluramine, norfenfluramine 
and total radioactivity at individual time 
points (Tables 3.2 and 3.12) shows that the 
percentage of unidentified material in plasma 
remained quite constant throughout each study 
except at 1 hour after dosing (Figure 3.14).
In both subjects, at this time, levels of total 
radioactivity had risen considerably (135 and 
lllng equiv.ml-1 in AT and MB respectively) 
whereas fenfluramine concentrations were still 
low (9 and 7ng.ml ^ respectively) and 
norfenfluramine was below the level of 
detection. Thus, at 1 hour after dosing, less, 
than 10% of the radiolabelled material was 
accounted for by fenfluramine and
norfenfluramine, compared with 30-50% at later 
times, indicating a first pass metabolism, the 
product of which was not norfenfluramine as 
might have been expected.
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3.6.2 The elimination of dl-£enfluramine and 
dl-norfenfluramine into urine
The total recovery of fenfluramine at 168 hours 
after dosing was 7.2 6mg and 8.52mg in subjects 
AT and MB respectively (Table 3.14). These 
figures represented 14% and 17% of the 
administered dose. At 48 hours, most of the 
fenfluramine had been eliminated (5.28mg and 
6.82mg respectively) and even at 24 hours more 
than half the final recovery was accounted for 
(4.61mg and 4.35mg respectively). The maximum
elimination rate was seen over the 1-2 hour
-1 -1 collection period (652jig.h and 380p,g.h
respectively). Thereafter the excretion rate
declined although there was a sharp increase in
the female subject over the 12-24 hour
collection period (Table 3.14). The male subject
showed a fluctuation in elimination rate over
the 108-132 hour period which coincided with an
increased fluid intake at that time. Half-lives
of 33.0 and 21.7 hours were derived from
semi-logarithmic plots of the amount of
fenfluramine remaining to be excreted (ARE^en)
with time (Figure 3.17) which agrees reasonably
with the plasma half-lives (Table 3.13).
The total recovery of norfenfluramine was 3.34mg 
and 5.34mg in AT and MB respectively, which 
represented 6% and 10% of the dose.
Norfenfluramine was eliminated less rapidly than 
fenfluramine with approximately 30% of the final 
total excreted after 24 hours in each subject. 
By 48 hours 1.6Img (approximately 50%) had been 
excreted by AT and 3.59 (approximately 70% by 
MB. The elimination rates (Table 3.15) showed 
maximum values at 4-8 hours and 12-24 hours 
after dosing respectively, although fluctuations
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TABLE 3.14 : EXCRETION OF FENFLURAMINE IN THE URINE OF HUMAN 
VOLUNTEERS FOLLOWING ORAL ADMINISTRATION OF [14C]-d1-FENFLURAMINE
HYDROCHLORIDE (60mg)
Subject AT MB
Parameter Amount Excretion Amount Excretion
(H9) Rate (iig.h”1) (jig) Rate (ng .h™"1)
Time Period 
After Dose (h)
0 - 1 38 38 15 15
1 - 2 652 652 380 380
2 - 4 880 440 690 345
4 - 8 1358 340 687 172
8 - 1 2 452 113 280 70
12 - 24 1234 103 2297 191
24 - 36 381 32 1619 135
36 - 48 288 24 847 71
48 — 60 459 38 276 23
60 - 72 384 32 536 45
72 - 84 236 20 173 14
84 - 96 55 5 218 18
96 - 108 <51 <4 169 14
108 - 120 426 36 144 12
120 - 132 206 17 127 11
132 - 144 89 7 57 5
144 - 156 64 5 <66 <6
156 - 168 59 5 <62 <5
Total 7261 — 8515 —
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TABLE 3.15 : EXCRETION OF NORFENFLURAMINE IN THE URINE OF HUMAN 
VOLUNTEERS FOLLOWING ORAL ADMINISTRATION OF [14C]-d1-FENFLURAMINE
HYDROCHLORIDE (6Omg)
Subject AT MB
Parameter Amount Excretion Amount Excretion
(H9) Rate (tig.h-1) (ng) Rate (ng.h-1)
Time Period 
After Dose (h)
0 - 1 <3 <3 0 0
1 - 2 68 68 65 65
2 - 4 131 65 131 66
4 - 8 286 72 196 49
8 - 1 2 109 27 103 26
12 - 24 594 49 1205 100
24 - 36 250 21 1147 96
36 - 48 268 22 741 62
48 - 60 379 32 293 24
60 - 72 362 30 600 50
7 2 - 8 4 208 17 198 17
84 - 96 66 6 234 19
96 - 108 <51 <4 253 21
108 - 120 307 26 82 7
120 - 132 182 15 88 7
132 - 144 90 8 <29 <2
144 - 156 <53 <4 0 0
156 - 168 44 4 0 0
Total 3344 — 5336
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TABLE 3.16 : EXCRETION OF 1- (m-trifluoromethylphenyl)-propane 
-1,2-diol IN THE URINE OF HUMAN VOLUNTEERS FOLLOWING ORAL 
ADMINISTRATION OF [14C]-d1-FENFLURAMINE HYDROCHLORIDE (60mg)
Subject AT MB
Parameter Amount Excretion Amount Excretion
(|ig) Rate (jig.h”1) (tig) Rate (tig.h”1)
Time Period 
After Dose (h)
0 - 1 10 10 0 0
1 - 2 11 11 <15 <15
2 - 4 206 103 418 208
4 - 8 592 148 1800 450
8 — 12 868 217 1402 350
12 - 24 2976 248 1858 154
24 - 36 2990 249 2972 248
36 - 48 3036 253 2962 246
4 8 — 60 1900 158 2046 170
60 — 72 2389 199 1182 98
72 - 84 1913 159 2224 186
84 — 96 775 65 458 38
96 - 108 285 24 <50 <4
108 - 120 <181 <15 0 0
Total (tig) 17951 17321
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were seen in the data over the first 72 hours or 
so after dosing.
The most abundant metabolite was 1-(m-trifluoro 
methylphenyl) propane-1,2-diol for which the 
recoveries were 17.95mg (35% of dose) and 
17.32mg (34% of dose) in AT and MB respectively 
(Table 3.16). Like norfenfluramine,
approximately 30% of the overall total was 
recovered in the first 24 hours with a further 
30% being excreted over the next 24 hours after 
which the excretion rate declined. Based on the 
mean excretion rate data a half-life of 46 hours 
was calculated for this metabolite.
Figures 3.15 and 3.16 shows the contribution of 
fenfluramine, norfenfluramine and 1-(m-trifluoro 
methylphenyl)propane-1,2-diol to the overall 
mean excretion rate of total radioactivity. In 
addition the difference plot, ie. residual *^C, 
has been shown in red and it can be seen that 
the peak mean excretion rate occurs early (1-2 
hours after dosing) . The residual activity is 
composed mostly of m-trifluoromethylbenzoic acid 
and m-trifluoromethylhippuric acid (section 3.4) 
and thus it appeared that an early rapid 
metabolism of fenfluramine to those products had 
occurred.
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CHAPTER 4
THE METABOLISM AND KINETICS OF THE OPTICAL ISOMERS OF
FENFLURAMINE IN MAN
The importance of stereoselective differences in the
metabolism and kinetics of pharmacologically active
molecules has already been discussed (Chapter 1) . With the
finding that d-fenfluramine was active as an anoretic agent
and that the 1-isomer was not, comparative metabolic and
kinetic studies were considered to be of value in perhaps
explaining the observed pharmacological differences between
the isomers. The radioactive studies described in this
chapter involved the same two volunteers as took 
14
[ C]-dl-fenfluramine (described in Chapter 3) who were each 
given doses of [14C]-d- and [14C]-1-fenfluramine. Each of 
the doses were separated from each other by at least 4 
weeks. Stereoselective differences in the absorption, 
distribution and elimination of total radioactivity are 
described together with a qualitative and quantitative 
comparison of the metabolic products of the isomers. Urine 
and plasma samples were analysed for fenfluramine and 
norfenfluramine and the absorption of the drug and the 
distribution and elimination of both drug and deethylated 
metabolite are described for both isomers.
Each study design was the same as described for the racemic 
compound (Chapter 3.1). Faecal collection was considered 
unnecessary during the 1-fenfluramine study because of 
continued low recoveries of radioactivity via this route 
(<1% of dose) . The actual doses are shown in Table 4.1. 
Although the radioactive doses were the same as for the 
racemate, the dose weights were only 3Omg (hydrochloride) ; 
there were two reasons for this. Firstly, 3Omg
d-fenfluramine had been shown to be equipotent, in anorectic 
activity, to a 6 Omg dose of the racemate, which was the 
standard therapeutic dose. Also, knowing that enantiomeric
144
TABLE 4.1 : SUBJECT AND DOSING DETAILS
SUBJECT AT MB
Sex M
Age (yr)
Height (cm)
Body weight (kg)
38
169
78
50
178
68
* Dose d-fenfluramine
(mg) 25.55
Dose d-fenfluramine
(pCi) 30.43
26.51
29.01
* Dose 1-fenfluramine
(mg) 25.17
Dose 1-fenfluramine
(pCi) 28.24
25.76
30.13
* - Expressed as free base fenfluramine
145
interchange does not occur, the data already described after 
60mg of racemic compound should reflect the addition of the 
data from the 30mg d- and 1-fenfluramine studies, unless the 
isomers have an effect on each other's metabolism.
Also described is a non-radioactive study in 12 healthy 
volunteers who took oral doses of 30mg of d-fenf luramine 
hydrochloride (capsule and solution) followed by a 20mg 
intravenous infusion. The study was designed to determine 
the relative bioavailability of the capsule formulation as 
well as the absolute availability of orally administered 
d-fenfluramine in solution and also to calculate the 
definitive intravenous pharmacokinetics.
4.1 The Fate of the Radioactive Label
4.1.1 The absorption of radioactivity from the 
gastro-intestinal tract
This section describes the appearance of 
radioactivity in plasma and red blood cells after 
administration of d- and 1-fenfluramine to both 
volunteers.
4.1.1.1 d-fenfluramine
The appearance of radioactivity in plasma 
(Figures 4.1 and 4.2) was rapid with 
half-lives of absorption of 0.92 and 0.68h for 
AT and MB respectively and lag times of 0.10 
and 0.52h (Table 4.3). Subject MB achieved 
the highest concentration of lOOng equiv.ml 
after 4h but AT had a comparable value (90ng 
equiv.ml"^) at the same time after dosing 
(Table 4.2). High urinary and low faecal 
recoveries indicated total absorption of the 
radioactive dose (Tables 4.11 and 4.12).
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TABLE 4.2 : THE CONCENTRATIONS OF RADIOACTIVITY IN THE PLASMA
OF HUMAN VOLUNTEERS FOLLOWING ORAL ADMINISTRATION OF [14C]-d-,
AND [14C]-1-FENFLURAMINE IN AQUEOUS SOLUTION
Subject AT MB AT MB
Sex M F M F
Isomer d d 1 1
Dose (mg) 25.55 26.51 25.17 25.76
Time (h) ng equiv.fen .free base ml”'1"
1 49 44 72 52
2 76 82 78 64
3 86 97 80 75
4 90 100 83 52
6 84 92 77 67
8 81 82 71 53
12 73 68 65 58
24 64 40 40 37
28 59 34 62 39
32 54 41 NS 38
48 36 27 NS 29
72 20 13 NS 17
96 8 8 17 12
120 4 3 8 7
144 NS 3 NS 6
168 NS 1 NS 5
NS - No Sample
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TABLE 4.3 : BASIC PHARMACOKINETIC ESTIMATES* ON THE PLASMA 
RADIOACTIVITY VERSUS TIME DATA OBTAINED FROM HUMAN VOLUNTEERS 
DOSED WITH [14C]-d- AND [14C]-1-FENFLURAMINE IN AQUEOUS SOLUTION
SUBJECT AT MB AT MB
Sex M F M F
Isomer d d 1 1
Dose (mg) 25.55 26.51 25.17 25.76
Parameter
C i 104 80 76 60
X1 0.024 0.026 0.017 0.016
C 2 21 43 15 11
X2 0.745 0.141 0.141 0.094
C 3 125 123 91 71
0.753 1.019 1.690 1.507
(h) 28.6 26.9 39.9 42.1
2 6
ti= (h) 0.92 0.68 0.41 0.46
2 a
Lag time t^ (h) 0.10 0.52 0.00 0.00
AUC , 4167 3133 4443 3693
(ng equiv.ml .h)
Cpmax {obs-> 90 100 83 75
(ng equiv.ml )
tmax (obs.)-(h) 4 4 4 3
* - All plasma radioactivity data has been fitted to the 
general equation:
C= C^e X1 (t tlag) + C ze~Xz (t tlag) - +Cz)e ka (t ^lag*
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4.1.1.2 1-fenfluramine
Maximum plasma concentrations were reached 
after 4 and 3h in subjects AT and MB
respectively (Table 4.3) and the peak 
concentrations are comparable at 83 and 75ng 
equiv.ml ^ (Table 4.2). There is no lag time 
seen with the fitted data and the half-lives 
of absorption are very similar at 0.41 and
0.46h respectively (Table 4.3). Once again,
high urinary recoveries (Table 4.11) indicate 
total absorption of the radioactive dose.
4.1.2 The distribution of radioactivity in plasma and 
red cells
This section describes the plasma and red blood 
cell concentration - time profiles for total 
radioactivity following doses of d- and 
1-fenfluramine to both volunteers. All plasma
data has been successfully fitted to the general 
equation:
C = C 1e"Al(t“tlag)+Cze"‘Az (t-tlag) - (C^C^) e ^ a  (t"tlag)
4.1.2.1 d-fenfluramine
After peak plasma concentrations, a short 
preliminary decline lasting up to 12h was 
found in both subjects, (Figures 4.1 and
4.2). The terminal half-lives were 28.6 and 
26.Bh in AT and MB respectively (Table 4.3). 
Subject MB showed a smaller area under the 
plasma concentration - time curve (3133ng 
equiv.ml ^.h) than AT (4167ng equiv.ml”^.h).
The red blood cell to plasma ratio for 
radioactivity was similar for both subjects 
ranging from 0.35 to 0.63 in AT and 0.20 to
0.73 in MB (Table 4.5). Peak red blood cell
151
TABLE 4.4 : THE DISTRIBUTION OF RADIOACTIVITY INTO THE RED
BLOOD CELLS OF HUMAN VOLUNTEERS FOLLOWING ORAL ADMINISTRATION
OF [14C]-d— AND [14C]-1-FENFLURAMINE IN AQUEOUS SOLUTION
Subject AT MB AT MB
Sex M F M F
Isomer d d 1 1
Dose (mg) 25.55 26.51 25.17 25.76
Time (h) ng equiv.fen.free base g~^
1 17 9 NS SL
2 42 37 NS SL
3 48 52 47 57
4 50 50 45 56
6 53 60 NS 62
8 50 52 NS 58
12 42 47 52 49
24 35 29 45 35
28 29 22 37 32
32 28 22 36 30
48 16 11 24 19
72 9 3 15 11
96 5 2 NS 10
120 NS < 1 3  5
144 NS <1 NS 3
168 NS <1 NS 3
NS - N o  Sample
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TABLE 4.5 : THE RED BLOOD CELL/PLASMA RATIO OF RADIOACTIVITY
IN HUMAN SUBJECTS FOLLOWING SEPARATE ORAL DOSES OF [14C]-d-
AND [14C]-1-FENFLURAMINE IN AQUEOUS SOLUTION
Subject AT MB AT MB
Sex M F M F
Isomer d d 1 1
Dose (mg) 25.55 26.51 25.17 25.76
Time (h) Red Blood Cell/Plasma Ratio (^4C)
1 0.35 0.20 ND NS
2 0.55 0.45 ND NS
3 0.56 0.54 0.59 0.76
4 0.56 0.50 0.54 1.08
6 0.63 0.65 ND 0.93
8 0.62 0.63 ND 1.09
12 0.58 0.69 0.80 0.84
24 0.55 0.73 1.13 0.95
28 0.49 0.64 0.60 0.82
32 0.52 0.54 ND 0.79
48 0.44 0.41 ND 0.66
72 0.45 0.23 ND 0.65
96 0.63 0.25 ND 0.83
120 ND ND 0.38 0.71
144 NS ND NS 0.50
168 NS ND NS 0.60
NS - No Sample
ND - Not Determinable
153
levels occurred at 6 hours after dosing 
(Table 4.4) in both subjects.
4.1.2.2 1-fenfluramine
After peak concentrations, a biexponential 
decline was found of which the early phase 
lasts up to 12h after dosing. Both subjects 
had longer terminal half-lives relative to 
the other isomer (39.9 and 42. Ih
respectively). The areas under the plasma 
concentration versus time curves were 4443 
and 3693ng equiv.ml""*".h respectively (Table
4.3) .
The red blood cell to plasma ratio of 
radioactivity ranged from 0.38 to 1.13 in AT 
and from 0.50 to 1.09 in MB (Table 4.5). 
Measured peak red blood cell levels occurred 
at 12 hours and 6 hours after dosing 
respectively (Table 4.4).
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4 . 1 . 3  The r a d i o a c t i v e  m e t a b o l i c  p r o d u c t s  i n  u r i n e
4.1.3.1 Solvent extraction of radioactivity
The quantitation of the solvent extracts is 
summarised in Table 4.6. Between 13.5% and 
31.5% of radioactivity was removed by the 
first basic extraction with each 
subject showing a greater extraction with 
1-fenfluramine than the d-isomer. The first 
acidic extraction removed a further 26.2% to 
35.0% of the activity, slightly more being 
evident from the d-fenfluramine samples. 
After hydrolysis, further extraction removed 
26.5% to 44.0% with considerably more
activity in the d-fenfluramine extracts.
Basification and further extraction only gave 
a further 2.4% to 6.4% although the
1-fenfluramine extracts contained more
than twice the activity of the d-isomer
samples. Residual activity, after sequential 
extraction, ranged from 10.7% to 16.5% of the 
original radioactivity.
4.1.3.2 Separation and location of metabolites of d-, 
and 1-fenfluramine
The same thin layer chromatography solvent 
systems were used as described for the 
separation of the metabolites of racemic 
fenfluramine (section 2.5). Thus
chromatographic profiles can be compared 
between the isomers and the racemic compound. 
In fact the metabolic patterns seen for both 
isomers, for each type of extract, for both 
subjects, were similar to each other and to 
those seen for the racemic compound (Figures 
4.3, 4.4, 4.5 and 4.6). There were no
qualitative differences in metabolic profiles 
between either isomer or the racemate; the
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FIGURE 4.3: AUTORADIOGRAPHIC LOCATION OF RADIOACTIVE  
AREAS FOLLOWING CHROMATOGRAPHY OF BASIC EXTRACTS  
OF UNHYDROLYSED 0-48h POOLED URINES FROM TWO 
VOLUNTEERS FOLLOWING ORAL ADM INISTRATIO N  
OF 14C d -  AND l-FENFLURAMINE  
HYDROCHLORIDE
SUBJECT
ISOMER 
Rf VALUE
MBAT
.9
B69
B60C^Vr/ïa GZZZZZ>
.5
.4
.3
.2
.1
>1% >10% > 2 0 >30%
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FIGURE 4.4: AUTORADIOGRAPHIC LOCATION OF RADIOACTIVE  
AREAS FOLLOWING CHROMATOGRAPHY OF ACID IC  EXTRACTS  
OF HYDROLYSED 0-48h POOLED URINES FROM TWO 
VOLUNTEERS FOLLOWING ORAL ADMINISTRATION  
OF 14C d -  AND l-FENFLURAMINE  
HYDROCHLORIDE
SUBJECT
ISOMER 
Rf VALUE
AT MB
.9
- A A  C  \ • «Va A 88
.8
A 79
.7
.6
.5
.4
.3
A 19. 2
.1
> U  >10% >20% >30%
ClfTSr)
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FIGURE 4.5: AUTORADIOGRAPHIC LOCATION OF RADIOACTIVE  
AREAS FOLLOWING CHROMATOGRAPHY OF AC ID IC  EXTRACTS  
OF. UNHYDROLYSED 0-48h POOLED URINES FROM TWO 
VOLUNTEERS FOLLOWING ORAL ADM INISTRATIO N  
OF 14 C d -  AND l-FENFLURAMINE  
HYDROCHLORIDE
SUBJECT
ISOMER 
Rf VALUE
AT MB
.9
.8
.7
.6
.5
.4
.3
d" »« •■ « 9
.2
cj. . izm . r r j
.1
A83
AGO
A23
A 16
>1% >10% >20% >30%
FIGURE 4.6: AUTORADIOGRAPHIC LOCATION OF RADIOACTIVE  
AREAS FOLLOWING CHROMATOGRAPHY OF BASIC EXTRACTS  
OF ACID HYDROLYSED 0-48h POOLED URINES FROM TWO 
VOLUNTEERS FOLLOWING ORAL AD M INISTRATIO N  
OF “  C d -  AND l-FENFLURAMINE  
HYDROCHLORIDE
SUBJECT AT MB
ISOMER d  1 a  i
Rf VALUE
0.9 -
i—COo
0.7 -
0.6" (T,
iLOo
0.4 -
0.3 -
0.2 -
0.1 -
> n  >10% >20% >30%
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TABLE 4. 6 :  THE AMOUNT OF RADIOACTIVITY IN SEQUENTIAL ETHER 
EXTRACTS OF POOLED URINES FROM TWO VOLUNTEERS DOSED 
ORALLY WITH [14C]-d- AND [14C]-l-FENFLURAMINE HYDROCHLORIDE
SUBJECT AT MB AT MB
Sex M F M F
Isomer d d 1 1
Extract"1" % of 14C Extracted
Basic 1 13.5 19.6 17.5 31.5
Acidic 1 35.0 33.1 31.5 26.2
Acidic 2 44.0 38.8 31.6 26.5
Basic 2 2.4 2.6 6.4 5.4
Total extracted 94.9 94.1 87.0 89.6
Residue (aqueous) 10.7 10.9 16.5 11.9
Total 105.6 105.0 103.5 101.5
+ - Extracts 1 and 2 refer to pre- and post acid hydrolysis 
respectively.
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same metabolites were found for [^c] -d-, 
[^4C]-1- and [^4C]-dl-fenfluramine. The 
separation and location of these components 
on thin layer chromatography plates has 
already been described for the racemate 
(Chapter 3.4) together with the comparison of 
metabolites with reference compounds. Mass 
spectrometry confirmed the identities of the 
metabolites as described in Chapter 3.
4.1.3.3 Quantitation of d-fenfluramine metabolites
The major component of extracts of 
unhydrolysed samples was m-trifluoro- 
methylbenzoic acid (21.6% for AT and 17.4% 
for MB; Table 4.7). The other components of 
acidic extracts were A16 (including A19 
accounted for 5.4% of the AT sample and 2.5% 
of MB), A23 (3.3% and 3.0%) and
m-trifluoromethyl hippuric acid (1.3% and
7.7%). The components of basic extracts
comprised norfenfluramine (4.3% from AT and
6.9% from MB) and fenfluramine (6.6% and
11.6%). Basic extraction of acid hydrolysed 
samples (Table 4.8) showed one main
component, norfenfluramine but it only 
accounted for <1.0% of the activity in the
original urine samples. The major metabolite 
was 1 - (m-trifluoromethylphenyl)propan-1,2-diol 
(37.5% in AT and 32.4% in MB). As with
dl-fenfluramine samples, two other components 
were found, A19 (including A16) at 1.1%
abundance in each case and m-trifluoro 
methylphenylpropan-2-ol (3.6% from AT and 
3.1% in MB).
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TABLE 4.7 : QUANTITATION OF THE MAJOR METABOLITES IN ETHER 
EXTRACTS OF UNHYDROLYSED POOLED URINES FROM TWO VOLUNTEERS 
DOSED ORALLY WITH [14C]-d- AND [14C]-l-FENFLURAMINE
HYDROCHLORIDE
SUBJECT AT MB AT MB
Sex M F M F
Isomer d d 1 1
Metabolite 14
% of C Extracted
code2
A16 (+A19)3 5.4 2.5 6.7 6.6
A23 3.3 3.0 2.7 2.7
A60 (TFM Hippuric) 1.3 7.7 11.3 1.6
A83 (TFM Benzoic) 21.6 17.4 7.4 11.4
B60 (Norfen) 4.3 6.9 5.2 10.1
B69 (Fen) 6.6 11.6 8.0 18.9
1. Extracts were sequential i.e. basic extraction followed 
by acidic extraction on the same sample.
2. The metabolite code denotes the Rf (xlOO) in either the 
acidic (A) or basic (B) TLC solvent system.
3. Quantification did not allow resolution between these 
metabolites but metabolite A16 was more abundant than A19.
NOTE: Any neutral compounds will appear in the basic extract 
and be chromatographed by the basic solvent system and 
thus carry the prefix B.
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TABLE 4.8 : QUANTITATION OF THE MAJOR METABOLITES IN ETHER 
EXTRACTS OF ACID HYDROLYSED POOLED URINES FROM TWO VOLUNTEERS 
DOSED ORALLY WITH [14C]-d- AND [14C]-l-FENFLURAMINE
HYDROCHLORIDE
SUBJECT AT MB AT MB
Sex M F M F
Isomer d d 1 1
Metabolite
code2 % of 14C Extracted
A19 (+A16)3 1.1 1.1 <1.0 <1.0
A79 (TFM Diol) 37.5 32.4 27.8 20.8
A88 (TFM Propanol) 3.6 3.1 1.9 1.8
B60 (Norfen) <1.0 <1.0 4.0 2.8
1. Extracts were sequential i.e. acidic extraction followed 
by basic extraction on the same sample which had already 
undergone acidic and basic extraction prior to hydrolysis.
2. The metabolite code denotes Rf (xlOO) in either the 
acidic (A) or basic (B) TLC solvent system.
3. Quantification did not allow resolution between these 
metabolites but metabolite A19 was more abundant than A16.
NOTE: Any neutral compounds will appear in the acidic extract
and be chromatographed by the acidic solvent system and 
thus carry the prefix A.
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4.1.3.4 Quantitation of 1-fenfluramine metabolites
The most abundant metabolites in extracts of 
unhydrolysed urines (Table 4.7) were
norfenfluramine for AT (11.3%) and 
fenfluramine for MB (18.9%).
m-Trifluoromethylbenzoic acid was not as 
apparent as with dl- and d-fenfluramine,
accounting for 7.4% (AT) and 11.4% (MB) of 
total radioactivity. Extracts of unhydrolysed 
AT sample also showed A16 (including A19; 
6.7%) , A23 (2.7%), norfenfluramine (5.2%) and 
fenfluramine (8.0%) and MB sample extracts
also contained A16 (including A19; 6.6%) , A23 
(2.7%) , m-trifluoromethyl hippuric acid
(1.6%) and norfenfluramine (10.1%). The
major metabolite extracted after acid
hydrolysis (Table 4.8) was 1- (m-trifluoro
methylphenyl)-propan-1,2-diol (27.8% in AT 
and 20.8% in MB). There were also small
quantities of m-trifluoromethylphenylpropan 
-2-ol (1.9 and 1.8% respectively) and
norfenfluramine (4.0 and 2.8% respectively).
4.1.4 The excretion of radioactivity in urine and
faeces
The excretion of radioactivity into urine and 
faeces are shown in tables 4.9 to 4.12, and
figures 4.7 and 4.8 respectively.
4.1.4.1 d-fenfluramine
The total recovery (urine + faeces) of 
radioactivity was 93.3% and 92.9% at 168h, in 
AT and MB respectively and less than 1% of
the dose was found in faeces (Tables 4.11
and 4.12). Subject AT showed a maximum 
elimination rate into urine of 2.22% of
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TABLE 4.9 : THE EXCRETION OF RADIOACTIVITY INTO THE
URINE OF HUMAN VOLUNTEERS FOLLOWING ORAL ADMINISTRATION OF
[14C]-d- AND [14C]-l-FENFLURAMINE IN SOLUTION
Subject AT MB AT MB
Sex M F M F
Isomer d d 1 1
Dose (mg) 25.55 26.51 25.17 25.76
Time (h) 
0-1 0.8
% of
0.4
dose
1.3 0.9
1-2 1.9 1.6 1.6 2.3
2-4 3.8 4.9 2.5 3.5
4—8 8.9 11.5 4.7 5.9
8-12 7.1 6.7 3.9 6.7
12-24 18.2 19.6 9.6 17.5
24-36 + 17.5 10.2 10.6
36-48 27.2 8.3 12.1 8.6
48-60 8.1 7.0 8.9 8.2
60-72 5.5 4.1 7.3 6.6
72-84 3.2 3.7 + 4.3
84-96 3.5 2.4 17.1 4.8
96-108 2.1 2.1 4.7 3.8
108-120 1.2 0.8 3.8 1.0
120-132 0.4 0.8 1.8 1.5
132-144 0.2 0.5 1.1 0.7
144-156 0.1 0.3 NS 0.8
156-168 0.2 0.1 NS 0.2
168-240 NS NS NS NS
Sample included in next collection period
NS - No Sample
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TABLE 4.10 : THE EXCRETION RATE OF RADIOACTIVITY INTO THE
URINE OF HUMAN VOLUNTEERS FOLLOWING ORAL ADMINISTRATION OF
[14C]-d— AND [14C]-l-FENFLURAMINE IN SOLUTION
Subject AT MB AT MB
Sex M F M F
Isomer d d 1 1
Dose (mg) 25.55 26.51 25.17 25.76
Mid Point (h) % of dose.h”1
mo
0.79 0.41 1.31 0.90
1.5 1.87 1.58 1.60 2.29
3 1.90 2.43 1.27 1.73
6 2.22 2.87 1.16 1.48
10 1.78 1.66 0.97 1.66
18 1.52 1.63 0.80 1.46
30 ND 1.46 0.85 0.88
42 ND 0.69 1.01 0.72
54 0.68 0.58 0.74 0.69
66 0.46 0.34 0.61 0.55
78 0.27 0.31 ND 0.36
90 0.29 0.20 ND 0.40
102 0.17 0.17 0.39 0.32
114 0.10 0.07 0.32 0.09
126 0.04 0.07 0.15 0.13
138 0.02 0.04 0.09 0.06
150 0.01 0.02 NS 0.07
162 0.01 0.01 NS 0.02
NS - No Sample
ND - Not Determinable
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TABLE 4.11 : THE CUMULATIVE EXCRETION OF RADIOACTIVITY INTO 
THE URINE OF HUMAN VOLUNTEERS FOLLOWING ORAL ADMINISTRATION
OF [14C]-d- AND [14C]-l-FENFLURAMINE IN SOLUTION
Subject AT MB AT MB
Sex M F M F
Isomer d d 1 1
Dose (mg) 25.55 26.51 25.17 25.76
Time (h) Cumulative % of dose
1 0.8 0.4 1.3 0.9
2 2.7 2.0 2.9 3.2
4 6.5 6.9 5.5 6.6
8 15.4 18.3 10.1 12.6
12 22.5 25.0 14.0 19.2
24 40.7 44.6 23.5 36.7
36 + 62.1 33.7 47.3
48 67.9 70.4 45.8 55.9
60 76.0 77.3 54.8 64.1
72 81.5 81.4 62.1 70.7
84 84.7 85.2 + 75.0
96 88.2 87.5 79.2 79.8
108 90.3 89.6 83.9 83.6
120 91.5 90.4 87.7 84.6
132 91.9 91.2 89.5 86.1
144 92.2 91.7 90.6 86.8
156 92.3 92.0 NS 87.6
168 92.4 92.2 NS 87.8
240 NS NS NS NS
+ - Sample included in following collection period 
NS - No Sample
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TABLE 4.12 : THE EXCRETION OF RADIOACTIVITY INTO THE FAECES 
OF HUMAN VOLUNTEERS FOLLOWING ORAL ADMINISTRATION OF 
[14C]-d-FENFLURAMINE IN AQUEOUS SOLUTION
Subject AT MB
Sex M F
Isomer d d
Dose (mg) 25.55 26.5
Time (h) % of dose
24 0.0 0.0
48 0.1 NS
72 0.6 0.3
96 0.1 0.3
120 0.1 0.1
144 NS 0.0
168 NS 0.0
NS - No sample produced
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dose.h \  over 4-8h after dosing; this rate 
fell steadily with 40.7% recovered at 24h, 
81.5% at 72h and 92.2% at 144h (Table 4.9? 
Figure 4.7). Subject MB also showed a maximum 
excretion rate at 4-Bh but it was higher at 
2.87%. This subject excreted 44.6% of the 
radioactive dose after 24h, 81.4% at 72h and 
91.7% at 144h (Figure 4.8).
4.1.4.2 1-fenfluramine
Total recoveries (Table 4.11) in urine were 
90.6% after 144h and 87.8% at 168h in AT and 
MB respectively. Faeces were not collected 
from either subject. Urinary recovery had 
reached 23.5% at 24h, 62.1% at 72h and 90.6% 
at 144h in AT, whereas MB showed 36.7%, 70.7% 
and 86.8% at those respective times (Figures 
4.7 and 4.8). Both subjects showed maximum 
urinary excretion rates, over l-2h after 
dosing, reaching 1.60 and 2.29% of dose.h”1 
in AT and MB respectively (Table 4.10).
The Fate of Fenfluramine
As for the studies described for the racemic compound, 
unchanged fenfluramine and its deethylated metabolite, 
norfenfluramine were analysed by gas chromatography 
(section 2.6) in both plasma and urine over the course 
of each study. The kinetics of parent drug and the 
pharmacologically active metabolite, norfenfluramine, 
were investigated with respect to both isomers. The 
results are shown in tables 4.13 and 4.14. The 
pharmacokinetic evaluation is shown in table 4.15.
4.2.1 The absorption of fenfluramine from the 
gastro-intestinal tract
Concentrations of d-fenfluramine rose quickly
1 4
after dosing with [ C]-d-fenfluramine. At 1 
hour after dosing subject MB showed a 
concentration of Sng.ml ^ of d-fenfluramine 
which continued to increase to an observed peak 
level of 24ng.ml“1 at 4 hours, with an 
absorption half-life of 0.8 hours. A
concentration of 17ng .ml of d-f enfluramine was 
found in the plasma of subject AT at 2 hours 
after dosing and the observed maximum 
concentration was 22ng.ml_1 at 4 and 6 hours 
after dosing. The absorption half-life was not 
defined because there were too few data points. 
The 1-isomer also entered the sytemic 
circulation quickly after dosing with plasma
levels of 6 and 12ng.ml ^ occurring at 2 hours 
after dosing in AT and MB respectively. Peak 
concentrations of 35 and 20ng.ml”1 were seen at 
6 hours and at 3, 4 and 6 hours after dosing
respectively. The half-li^fes of absorption were
0.6 and 0.2 hours respectively.
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TABLE 4.13 : THE CONCENTRATIONS OF FENFLURAMINE IN THE PLASMA 
OF HUMAN VOLUNTEERS FOLLOWING ORAL ADMINISTRATION OF 
[14C]—d- AND [14C]-l-FENFLURAMINE HYDROCHLORIDE IN AQUEOUS
SOLUTION
SUBJECT AT MB AT MB
Sex M F M F
Isomer d d 1 1
Dose (mg) 25.55 26.51 25.17 25.76
Time (h) ng free base.ml~^
1 SL 3 5 SL
2 17 10 6 12
3 SL 21 28 20
4 22 24 30 20
6 22 19 35 20
8 20 20 30 19
12 14 15 21 12
24 9 7 20 10
28 7 5 15 12
32 SL 4 16 8
48 <2.5 SL 10 5
72 0 2.5 9 SL
96 0 <2.5 6 <2.5
120 0 0 2.5 0
144 NS 0 NS 0
168 NS 0 NS 0
-1
(ng.h.ml ) 534 540 1400 689
NS - No Sample 
SL - Sample Lost
+ - Calculated by trapezoidal rule
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TABLE 4.14 : THE CONCENTRATIONS OF NORFENFLURAMINE IN THE 
PLASMA OF HUMAN VOLUNTEERS FOLLOWING ORAL ADMINISTRATION OF 
[14C]-d- AND [14C]-l-FENFLURAMINE HYDROCHLORIDE IN AQUEOUS
SOLUTION
SUBJECT 
Sex 
Isomer 
Dose (mg)
AT
M
d
25.55
MB
F
a
26.51
AT
M
1
25.17
MB
F
1
25.76
Time (h) ng free base.ml”1
1 SL 0 0 SL
2 9 2.5 2.5 0
3 SL 4 5 0
4 10 4 7 0
6 10 8 7 3
8 11 7 3 4
12 7 8 3 NM
24 8 3 8 10
28 9 3 4 15
32 SL 3 6 10
48 <2.5 SL 8 2.5
72 0 <2.5 6 SL
96 0 0 5 0
120 0 0 0 0
144 0 0 0 0
168 0 0 0 0
(ng .h.ml™"1) 427 251 517 366
NS - No Sample 
SL - Sample Lost 
NM - Not Measured
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TABLE 4.15 : BASIC PHARMACOKINETIC ESTIMATES ON THE PLASMA
FENFLURAMINE VERSUS TIME DATA OBTAINED FROM HUMAN VOLUNTEERS
DOSED WITH [14C]-d- AND [14C]-1-FENFLURAMINE HYDROCHLORIDE IN
AQUEOUS SOLUTION
SUBJECT AT MB AT MB
Sex M F M F
Isomer d d 1 1
Dose 25.55 26.51 25.17 25.76
Fenfluramine Parameters
C (o) 28.6 30.9 32.5 22.3
0.050 0.064 0.021 0.031
V ND 0.87 1.16 3.47
tie (h) 13.9 10.9 33.1 22.7
tia (h) 
2 ND 0.8 0.6 0.2
H a g  <h > ND 1.1 1.2 1.6
+ -1 
AUC (ng.h.ml ) 534 540 1400 689
Cmax ("g-1"1"1) 22 24 35 20
tmax <h > 4,6 4 6 3,6
Norfenfluramine Parameters
+AUC (ng .h .ml*”1) 427 251 517 366
Cmax («g-®!-1) 11 8 8 15
H a x  (h) 8 6,12 24,48 28
ND - Not determinable because of lack of data
+ - Calculated by trapezoidal rule to last measured time point
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4.2.2 The distribution______of fenfluramine______and
norfenfluramine in plasma
After the peak levels, plasma concentrations of 
both isomers of fenfluramine declined 
monoexponentially. All data has, therefore, been
fitted to the general equation:
c = C ^ e - ^ - t l a g *  - e ^ a ^ l a g » ]
In subject AT, the biological half-life of 
d-fenfluramine (13.9h) was shorter than the 
1-^  isomer (33. Ih) and the area under the curve 
was smaller (534ng.h.ml-1 and 1400ng.h.ml”1 
respectively) . The same pattern was seen for 
subject MB with a longer half-life of 22.7h for 
1-fenfluramine (10.9h for d-fenfluramine) and a 
slightly larger area under the curve of
689ng.h.ml 1 compared to the d-isomer 
(540ng.h.ml”1).
The peak plasma concentrations of
norfenfluramine occurred later with the 1-isomer 
(24 and 48h and at 24h in subjects AT and MB 
respectively). The peak concentrations were 
later and lower than fenfluramine in all cases 
and were similar considering the analytical
precision at these low levels (Table 4.14). The
areas under the curves were lower for 
d-norfenfluramine (427ng.h.ml”1 and 251ng.h.ml”1 
in AT and MB respectively) than for the 1-isomer 
(517ng.h.ml 1 and 366ng.h.ml 1 respectively).
Subtracting the known fenfluramine and 
norfenfluramine concentrations from total 
radioactivity, graphs of the residual 
unidentified drug-related material can be 
plotted (Figures 4.11 and 4.12). It can be seen
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from these mean (across subjects) plots that 
this residual, unidentified material represents 
a greater proportion of the total radioactivity 
than either fenfluramine or norfenfluramine for 
both isomers. This is particularly true of the 
d-isomer where concentrations of residual 
material are constantly greater than twice those 
of d-fenfluramine; with the 1-isomer these 
concentrations are often very similar. The 
levels of residual, unidentified material after 
d-fenfluramine are consistently higher than 
those after the 1-isomer even though total 
radioactivity concentrations are lower (compare 
figures 4.11 and 4.12).
4.2.3 The urinary excretion of fenfluramine and 
norfenfluramine
The concentrations of the enantiomers of 
fenfluramine and norfenfluramine were determined 
by gas chromatography (Tables 4.16 and 4.19) 
from these were derived the total amount 
excreted in each urine sample (Tables 4.17 and
4.20) and the excretion rates (Tables 4.18 and
4.21). The total recovery of 1-fenfluramine 
(1777pg and 4415jig in AT and MB respectively) 
was greater than that of d-fenf luramine (1540^ig 
and 2814|ig respectively within each subject. 
Total recoveries of d-norfenfluramine (1477^g 
and 2343p.g in AT and MB respectively were 
slightly less than those of d-fenfluramine. 
Recoveries of 1-norfenfluramine were higher than 
the d-isomer and, in subject AT, (2148|ig) were 
higher than d-fenfluramine. In subject MB, 
however, the 1-norfenfluramine recovery (2650p.g) 
was much less than 1-fenfluramine. Maximum 
excretion rates of d-fenf luramine (SS^ig.h-1 and 
ISOjig.h ^ in AT and MB respectively) occurred at
181
TABLE 4.16 : THE CONCENTRATIONS OF FENFLURAMINE IN THE URINE
OF HUMAN VOLUNTEERS FOLLOWING SEPARATE ORAL ADMINISTRATION OF
[14C]-d- AND [14C]-1-FENFLURAMINE HYDROCHLORIDE (30mg)
SUBJECT AT MB AT MB
Isomer d d 1 1
Actual dose (mg) 25.55 26.51 25.17 25.76
Time period ng free base.ml-1
after dose (h)
0 - 1 56 <50 262 113
1 - 2 522 710 309 1200
2 - 4 1614 2499 687 2027
4 - 8 2438 2005 985 3495
8 — 12 402 475 554 787
12 - 24 318 553 285 1458
24 - 36 + 410 193 332
36 - 48 147 124 228 284
48 - 60 97 114 189 245
60 — 72 95 132 192 317
72 - 84 65 81 + 164
84 — 96 75 77 306 208
96 — 108 51 69 ND 158
108 - 120 54 <50 ND 86
120 - 132 <50 0 ND <50
132 - 144 <50 0 ND 0
ND - Not Determined
+ - Sample included in next collection period
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TABLE 4.17 : THE AMOUNTS OF FENFLURAMINE EXCRETED INTO THE URINE
OF HUMAN VOLUNTEERS FOLLOWING SEPARATE ORAL ADMINISTRATION OF
[1 4 C ] - a -  AND [14C]-1-FENFLURAMINE HYDROCHLORIDE
SUBJECT 
Isomer 
Actual dose (mg)
AT
d
25.55
MB
d
26.51
AT
1
25.17
MB
1
25.76
Time period tig free base
after dose (h)
0 - 1 2 <17 30 8
1 - 2 36 38 20 46
2 - 4 108 300 79 207
4 - 8 332 361 168 496
8 - 1 2 99 200 161 472
12 - 24 202 664 150 1400
24 - 36 + 574 189 355
36 - 48 292 136 192 312
48 - 60 95 130 140 230
60 - 72 60 158 114 254
72 - 84 49 116 + 105
8 4 - 9 6 112 60 534 258
96 - 108 118 77 ND 189
108 - 120 35 <59 ND 83
120 - 132 <30 0 ND <95.00
132 - 144 <20 0 ND 0.00
Total (tig) 1540 2814 1777 4415
ND - Not Determined
+ - Included in next collection period
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TABLE 4.18 s THE EXCRETION RATES OF FENFLURAMINE INTO URINE
OF HUMAN VOLUNTEERS FOLLOWING SEPARATE ORAL ADMINISTRATION OF
[14C]-d- AND [14C]-1-FENFLURAMINE HYDROCHLORIDE (30mg)
SUBJECT AT MB AT MB
Isomer d d 1 1
Actual dose (mg) 25.55 26.51 25.17 25.76
Mid-point of ng free base .h"*"*"
collection (h)
0.5 2 <17 30 8
1.5 36 38 20 46
3 54 150 39 103
6 83 90 42 124
10 25 50 40 118
18 17 55 12 117
30 + 48 16 30
42 12 11 16 26
54 8 11 12 19
66 5 13 10 21
78 4 10 + 9
90 10 5 22 21
102 10 6 ND 16
114 3 <5 ND 7
126 <2 0 ND <8
138 <2 0 ND 0
ND - Not Determined
+ - Included in next collection period
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6 and 3 hours after dosing respectively. The
1-isomer showed peak excretion rates of 42[xg.h~^
and 124^g.h~^ respectively at 6 hours. Peak
norfenfluramine excretion rates were much lower
than those for fenfluramine. Peak excretion
rates of d-nor fenfluramine (34^g .h-"*"
-1and 39jig.h ) occurred earlier (3 to 6 hours
after dosing) than those of 1-norfenfluramine
_ i _ 1
(21^g.h and SOjig.h ) which did not occur
until 42 and between 10 and 18 hours after
dosing respectively.
Subtracting the excretion rates of fenfluramine 
and norfenfluramine from those of total 
radioactivity results in excretion rate data for 
the remaining drug-related material ie. 
1- (m-trifluoromethylphenyl)propan-1,2-diol and 
acidic metabolites. The mean (across subjects) 
excretion rate data for d- and 1-isomers are 
shown in figures 4.13 and 4.14. Most of the 
radioactivity in urine was accounted for by 
material other than fenfluramine and 
norfenfluramine ; this is especially true at the 
earlier collection times, for example up to 1 
hour, fenfluramine and norfenfluramine only 
accounted for 2% and 17% of radiolabelled 
material eliminated after d- and 1-fenfluramine 
respectively. These two figures reflect the 
fact that the mean total d-fenfluramine and 
d-norfenfluramine accounts for a lower 
percentage of radiolabelled material than the 
total of the 1-isomers, suggesting a greater 
overall deamination of the d-isomers.
Linear regression of semi-logarithmic plots of 
the amounts of d- and 1-fenfluramine remaining 
to be excreted into urine (Figures 4.15 and 
4.16), gave half-lives of 31.5h and 19.3h for
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TABLE 4.19 : THE CONCENTRATIONS OF NORFENFLURAMINE IN THE 
URINE OF HUMAN VOLUNTEERS FOLLOWING SEPARATE ORAL 
ADMINISTRATION OF [14C]-d- AND [14C]-l-FENFLURAMINE
HYDROCHLORIDE (30mg)
SUBJECT AT MB AT MB
Isomer d d 1 1
Actual dose (mg) 25.55 26.51 25.17 25.76
Time period ng free base.ml”1
after dose (h)
0 - 1 67 <50 248 71
1 - 2 134 199 216 336
2 - 4 460 654 287 1119
4 - 8 991 859 281 1264
8 — 12 278 283 262 330
12 - 24 317 382 251 622
24 - 36 + 382 211 338
36 - 48 199 159 294 210
48 — 60 157 158 255 228
60 - 72 154 177 343 416
72 - 84 105 127 + 158
84 — 96 103 122 549 164
96 — 108 72 96 ND 84
108 - 120 <50 <50 ND <50
120 - 132 0 <50 ND 0
132 - 144 0 0 ND 0
ND - Not Determined
+ - Included in next collection period
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TABLE 4.20 : THE AMOUNTS OF NORFENFLURAMINE EXCRETION INTO
THE URINE OF HUMAN VOLUNTEERS FOLLOWING SEPARATE ORAL
ADMINISTRATION OF [14C]-d- AND [14C]-1-FENFLURAMINE
HYDROCHLORIDE (30mg)
SUBJECT AT MB AT MB
Isomer d d 1 1
Actual dose (mg) 25.55 26.51 25.17 25.76
Time period ng free base
after dose (h)
0 - 1 3 <17 28 5
1 - 2 9 11 9 13
2 - 4 30 78 33 114
4 - 8 135 155 48 179
8 - 1 2 69 119 76 198
12 - 24 201 493 132 597
24 - 36 + 535 206 362
36 - 48 382 175 247 231
oVO100 153 180 189 214
60 - 72 97 212 203 333
72 - 84 78 182 + 101
84 - 96 153 95 977 203
96 - 108 167 108 ND 100
108 - 120 <33 <59 ND <48
120 - 132 0 <59 ND 0
132 - 144 0 0 ND 0
Total (ng) 1477 2343 2148 2650
ND - Not Determined
+ - Included in next collection time
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TABLE 4.21 : THE EXCRETION RATES OF NORFENFLURAMINE INTO URINE
OF HUMAN VOLUNTEERS FOLLOWING SEPARATE ORAL ADMINISTRATION OF
[14C]-d- AND [14C]-l-FENFLURAMINE HYDROCHLORIDE (30mg)
SUBJECT AT MB AT MB
Isomer d d 1 1
Actual dose (mg) 25.55 26.51 25.17 25.76
Mid-point of tig free base.h-^
collection (h)
o in 3 <17 28 5
1.5 9 11 9 13
3 15 39 17 57
6 34 39 12 45
10 17 30 19 50
18 17 41 11 50
30 + 45 17 30
42 16 15 21 19
54 13 15 16 18
66 8 18 17 28
78 7 15 + 8
90 13 8 41 17
102 14 9 ND 8
114 <3 <5 ND <4
126 0 <5 ND 0
138 0 0 ND 0
ND -  N o t  D e t e r m i n e d
+ -  I n c l u d e d  i n  n e x t  c o l l e c t i o n  p e r i o d
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d-fenfluramine and 46.2h and 25.7h for 
1-fenfluramine in AT and MB respectively which 
as with the plasma data, shows a slower 
excretion for 1-fenfluramine than for the 
d-isomer, although the half-life estimates are 
rather greater for each isomer, particularly in 
subject AT.
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4.3 The Definitive Pharmacokinetics of d-Fenfluramine
The urinary excretion profiles of fenfluramine and its 
deethylated metabolite, norfenfluramine, have been 
described by Beckett and Brookes (1970). Their data 
indicated a pH dependent excretion and extensive 
metabolism (particularly with no urinary pH control). 
However, the analytical method (Beckett and Brookes, 
1967) lacked the sensitivity required for the accurate 
measurement of these compounds in plasma and thus 
definitive kinetics could not be attempted. Bruce and 
Maynard (1962) reported another very sensitive gas 
liquid chromatography procedure involving the formation 
of heptafluorobutyryl derivatives and electron capture 
detection. Although applicable to plasma, this method 
has practical drawbacks and its use has not been 
extensively cited. Campbell (1970) described a more 
rapid and simple procedure for measuring fenfluramine 
and norfenfluramine in urine and plasma. Using this 
method, pharmacokinetic parameters were determined 
following acute oral doses of dl-fenfluramine (60mg) to 
human volunteers (Campbell, 1971). Plasma fenfluramine 
concentrations reached a peak (63 + 4.5ng.ml"~^) at 2-4 
hours after dosing before declining exponentially with 
a half-life of 20.3 hours (range 13.8 - 30.1 hours). 
Norfenfluramine was detectable in the plasma of all 
subjects at 2 hours after dosing, reaching maximum 
concentrations (mean 16ng.ml )^ after 4-6 hours and 
thereafter maintaining a constant level for 24 - 32
hours. One subject was also given an intravenous bolus 
of dl-fenfluramine (60mg) and comparison of the 
resulting oral and intravenous plasma fenfluramine 
versus time curves (Campbell, 1978) indicated an 
absolute availability in the region of 70%, a plasma 
clearance of approximately 500ml.min ^ and a high 
volume of distribution (600 litres).
194
The pharmacological activity of fenfluramine in man has 
been shown to reside in the d-isomer (Silverstone and 
Turner, 1981). Caccia et al. (1977) developed a gas 
chromatographic procedure to separate and quantitate 
the optical isomers of both fenfluramine and
norfenfluramine. Recently this method has been used to 
examine the steady-state kinetics of both isomers 
during chronic dosing with racemic fenfluramine (Caccia 
et al., 1979). The results show the steady-state level 
of 1-fenfluramine to be higher (0 - 100%) than the
d-isomer, with intersubject differences. Thus the 
clearance of d-fenfluramine is higher than the
1-isomer. Obviously d-fenfluramine kinetics are not 
predictable and, based on data from the racemic 
compound, a definitive pharmacokinetic study on the 
d-isomer was required. This section details a study on 
12 healthy volunteers who were given two oral doses 
(30mg in solution and capsule formulations) and a slow 
intravenous infusion (20mg over 3 hours) of 
d-fenfluramine hydrochloride. The analytical method 
described in section 2.6 was used, which is more rapid 
than the method of Caccia et al (1977) . The method 
does not separate the isomers, which is not important 
for this study as the d-isomer alone is being measured 
and isomeric transformation is not known to occur with 
fenfluramine.
From the results of the study, the absolute 
availability of the drug (solution versus intravenous
infusion) and the relative bioavailability of the oral 
formulation (capsule versus solution) were determined 
as well as definitive intravenous kinetics.
4.3.1 Study design
Each subject received the two oral formulations 
of d-fenfluramine hydrochloride in a balanced 
crossover design with one week between each
195
treatment. After a minimum period of one week
following the final oral dose, the subjects each 
received the compound (approx 20mg) as a 
constant-rate intravenous infusion (approx 35ml) 
over a 3 hour period.
4.3.2 Plasma kinetics
The pharmacokinetic analysis methods are 
described in chapter 2, section 7. The mean 
plasma levels are presented graphically in 
figures 4.17 and 4.18. Pharmacokinetic
parameters are shown in tables 4.22 and the raw 
data in tables 4.23 to 4.28.
4.3.2.1 Intravenous dosing
An intravenous infusion of d-fenfluramine of 
approximately 20mg over 3 hours was designed to 
give similar maximum plasma levels (30ng.ml 
at a similar time (3h) to that observed after 
an 30mg oral dose. The mean maximum plasma 
levels determined after the intravenous
infusion were 30.3 + 6.3ng.ml The
occurrence of secondary peaks, however,
especially after the ingestion of food, 
sometimes caused the time to maximum plasma
levels to occur a little later (3.8 + 1.6h)
after the infusion had been stopped.
Once the intravenous infusion was stopped, the 
plasma levels of intact d-fenfluramine declined 
in either a monophasic (5 subjects) or a 
biphasic (7 subjects) manner. The half-life 
for the initial decline phase in those subjects 
where it occurred was 2.85 + 2.34h whereas the 
half-life of the terminal phase for all 
subjects was 15.5 + 6.6h (Table 4.22).
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TABLE 4.22 : PHARMACOKINETIC PARAMETERS DERIVED FROM PLASMA 
FENFLURAMINE AND NORFENFLURAMINE DATA FROM VOLUNTEERS DOSED 
ORALLY AND INTRAVENOUSLY WITH d—FENFLURAMINE
Dose Route 
Dose Type 
Dose (mg)
Oral
Solution
28.50
Oral
Capsule
29.14
Intravenous 
Infusion 
19.12 + 1.41
Fenfluramine Parameter
H  init (h) 1.29 + 0.98 1.45 + 1.35 2.85 + 2.34
t|6 (h)
Craax (n9-na~1)
19.7
30.5
+
+
10.5
7.1
17.0
28.6
+
+
8.1
7.5
15.5
30.3
+
+
6.6
6.3
tmax (h) .
1 AUC (ng.h.ml ±)
3.0 + 1.5 3.0 + 1.1 3.8 + 1.6
581 + 218 538 + 255 464 + 142
2AUC (ng.h.ml-1) 564 + 216 520 + 251 —
Cl (ml.min-1) - - 745 + 232
VD(area) ^
- - 913 + 379
Bioavailability (%) 82.9 + 16.7 71.2 + 19.8 -
Norfenfluramine Parameter
tie (h) 
Cmax
max (h)
^AUC (ng.h.ml-1)
47.3 + 16.5 
16.8 + 3.0 
7.6 + 5.7 
1088 + 366
37.7 + 12.6
16.4 + 3.8
12.2 + 1 3 . 3  
1085 + 451
31.1 + 15.8
12.5 + 4.4
9.3 + 8.5 
640 + 354
1 - Calculated to infinity by trapezoidal rule
2 - Calculated to infinity by integration
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The area under the curve measured to infinite
time was 464 + 142ng.ml \ h  which when related
to dose, gave a relatively high plasma
—  1
clearance value of 745 + 232ml.min . The
volume of distribution based on area was also 
large with a mean value of 913 + 3 7 9  litres.
The plasma levels of the de-ethylated 
metabolite, d-norfenfluramine, were generally 
lower than those of the intact drug up to 
approx. 12-24h after dosing and more variable. 
Consequently, it was not possible to fit these 
data to a sum of exponentials and an empirical 
approach had to be adopted.
The mean maximum plasma levels of 
d-norfenfluramine of 12.5 + 4.4ng.ml~^ occurred 
later than those of the intact drug (9.3 +
8.5h). They then declined with a mean terminal 
half-life of 31.1 + 15.8h which was somewhat
longer than that observed for the intact drug.
. For many of the subjects, the plasma levels 
showed a prolonged plateau rather than a 
definite peak indicating that the metabolite 
was still being formed during this time. 
Thereafter, the d-norfenfluramine was 
elimination rate limited.
The area under the curve for d-norfenfluramine 
calculated to infinity was 640 + 354ng.ml \ h  
(Table 4.22).
4.3.2.2 Oral dosing
When administered orally, levels of intact 
d-fenfluramine rapidly appeared in plasma 
(Figure 4.17), reaching a maximum of 30.5 + 7.1 
and 28.6 + 7. 5ng .ml ^ for the solution and the 
capsule formulation respectively. Maximum
198
plasma levels were reached with mean + s.d. 
values of 3.0 + 1.5 and 3.0 + l.lh for the 
solution and capsule respectively.
Once the maximum plasma levels had been reached 
they declined either in a monophasic or 
biphasic manner. When there was a biphasic 
decline, the half-life of the initial phase was 
1.29 + 0.98h for the solution and 1.45 + 1.35h 
for the capsule. The half-life of the terminal 
phase of d-fenf luramine was 19.7 + 10.5h when 
administered as a solution and 17.0 + 8. Ih when 
administered as a capsule.
The area under the curve to infinity was 
calculated by two techniques, the trapezoidal 
rule and direct integration. The mean values 
for the solution and capsule for the area under 
the curve calculated to infinity measured by 
the trapezoidal rule were 581 + 218 and 538 + 
255ng.ml .h respectively. On the other hand, 
the areas under the curve to infinity
calculated by direct integration were 564 + 2 1 6  
and 520 + 251ng.ml \ h  respectively.
When each of the area determinations to 
infinite time, calculated by the trapezoidal 
rule, following an oral dose was related to the 
corresponding area following an intravenous 
infusion, it was shown that the absolute
bioavailability of the solution was 82.9 +
16.7% and that of the capsule was 71.2 + 19.8%.
It was noted that the absolute bioavailability 
values for subject 12 were atypical and there 
was also evidence that the intravenous cannula 
was not patent. This subject's data was
therefore not included in the mean
199
bioavailability calculations.
As was observed following the intravenous
infusion, the d-norfenfluramine levels were
generally lower than those of the intact drug
up to approximately 12h after dosing and more
variable thus, an empirical approach had,
again, to be employed. The mean maximum plasma
levels of d-norfenfluramine (16.8 + 3.0ng.ml ^
—1
and 16.4 + 3.8ng.ml for the solution and
capsule respectively) occurred later than those 
of the intact drug, being at 7.6 + 5.7h for the 
solution and 12.2 + 13.3h for the capsule.
The half-life of d-norfenfluramine, (47.3 +
16.5h and 37.7 + 12.6h for the solution and
capsule respectively) also tended to be longer 
than that of the intact drug. However, its 
determination was complicated by the fact that 
the metabolite formation was probably still
occurring, for some time after dosing
(Figure 4.18).
The area under the curve measurements also 
reflected the variability in plasma levels with 
1088 + 366 and 1085 + 451ng.ml ^.h for the
solution and capsule respectively when
calculated to infinity. Norfenfluramine levels 
after intravenous dosing were lower than after 
oral dosing (Figure 4.18).
-4
.1
 
y:
 
M
ea
n 
P
la
s
m
a
 
C
o
n
c
e
n
tr
a
ti
o
n
s
 
o
f
200
4-»
+>
+»
4-
O °0o
6 6 
o
( v_| uu Su) • u o u o o  * uo_-j
H
o
u
rs
 
A
ft
e
r 
D
o
s
e
F
IG
U
R
E
 
*4
.1
 
S
: 
M
ea
n 
P
la
s
m
a
 
C
o
n
c
e
n
tr
a
ti
o
n
s
 
o
f
201
+»
+»
6 6
C L - I U J Bu) • u o u o o * UOJ.JOKI
H
o
u
rs
 
A
ft
e
r 
D
o
s
e
TA
BL
E 
4.
23
 
z 
CO
NC
EN
TR
AT
IO
NS
 
OF
 
d
-F
EN
FL
UR
AM
IN
E 
IN 
PL
AS
MA
 
FO
LL
OW
IN
G 
AN
 
IN
TR
AV
EN
OU
S
IN
FU
SI
ON
 
OF
 
d
-
F
E
N
F
L
U
R
A
M
I
N
E
 
H
Y
D
R
O
C
H
L
O
R
I
D
E
202
r4 CO CN CD CN r-4 CO m CD r-4 r-4 cn CN in in
CN • • • • • • • • * • • • • cn • • e Q Q
i-4 r- 00 CD CN CD CN cn CN O O r~ z CO CN CN Z Z
i-4 r-4 CN CN CN r-4 r-4 r-4 r-4 i-4 V V
r4 CD CN r- CN cn CO r-4 00 CO CN CD CD in
r4 • • • • • cn • • • • • in • • • • • •. Q
r-4 CO OY CO CN r- CO CN 00 cn cn 2 r-4 r-~ TP CO in CN Z
CN CO 00 CO CO CN CN CN CN r~4
1-4 o cn CO r-4 CD r- r-4 CN cn CN Tp r- 00 CD 00 r-4 CD
O • • • • • • • • • e • cn • • • • • • •
r-4 CD in r- 00 CO CO o CD CD TP CD z CO o o CD CO in CN
r-4 r-4 r-4 CN CN CO CN CN CN CN CN CN r-4
O cn CN 00 r-4 o O r-4 O CD O O r~- cn in
• • « * • • • • « • • cn • • • • • Q Q
cn in CN 00 o r- cn o in z o r-4 CD CO CN Z Z
r~4 r4 r-4 CN r-4 r-4 CN r-4 CN r-4 V
r4 in r^- r- CD CD r-4 r-4 00 CN r-4 r-4 00 CO TP CN CD
1 • * • • • • • • • • • ' cn • • • • e Û Q00 r4 CO r- CD 00 m CN r-4 in CN r-4 z CD cn cn cn CN z Z
e r-4 i-4 r-4 CN CN CN CN CN CN i-4 r-4
0
to in r-4 <3* O CD m r-4 in r-4 cn TP in CO r-4 CO m
(0 • • * • • * • e • ■ • cn ■ • • • • Q Q
Oi i-4 00 CD in Tf o 00 CD CO Z 00 r- C'­ TP CN Z Z
r4 r-4 CN CO CO CO CO CN CN CN r-4 r~4 V
0
0u in 00 00 CN CN r- r-4 r- 00 CN CN r- en in
44 • • • • • e • • * • • • • cn • • Q Q Q
* CN 00 CD cn CO in CD o in 00 in CD o z CN CN Z Z Z
C V i-4 CN CN CO CO CO co CN r-4 r-4 r-4 r-4 V
0
44
CN CO CO CO o CD CO 00 TP cn cn 00 CN in
cn • • • • • • • • • • • • • cn • • Q Q Qc r-4 r-4 o CO in in CN cn in o CN z CO CN Z Z Z
i—1 n4 CN CN CN CN CN CN CN r-4 r-4 i-4 r-4 V
CN r-~ 00 r-4 CD CO o r-4 Tp cn TP TP TP in
• • • • • • • • • • • cn • • e • • Q Q
CD o in 00 r* CN r- m o z r~ TP CO TP CN Z Z
r4 r4 CN CN CO CO CN CN CN CN r-4 r-4 V
O 00 m o CD o on in i-4 TP «31 O o in in
• • • • „ e • • • • • • • • cn • • • Q Qn in CD o CN CO 00 CD TP TP r-4 r-4 z m CN CN Z Z
r~4 i-4 CN CN CN r-4 r4 r-4 r-4 i—1 r-4 V V
in 00 r-4 00 m r-4 00 CN cn i-4 in r-4 cn in
• • • • • • • « • • • cn • • • • • Q QCN CN C'­ 00 CD r- TP CN cn r- cn cn z in m r- CD CN Z Z
V r-4 r-4 CN CN CN ■—I i-4 r-4 r-4 CN r-4 V
in en CO 00 in 00 CO cn 00 r- in CD in in
• • « • • # • • • • • cn • • • • Q Q Q
00 cn CD r- m CD in in r-4 CN z r-4 in TP CN Z Z Z
r-4 r~4 CN CN CN CN CO CN CN r-4 V
Eh
U to o in O in O in m o O O o O O O O o o o
CNh) D * r4 r-4 CN CN CO • CO «3* in CD 00 o TP o 00 TP CNCQ
5
0 CO r-4 CN CO TP in
cn
No
 
Sa
mp
le
 
ND
 
- 
No
t 
D
e
t
e
c
t
a
b
l
e
TA
BL
E 
4.
24
 
: 
CO
NC
EN
TR
AT
IO
NS
 
OF
 
d-
NO
RF
EN
FL
UR
AM
IN
E 
IN 
PL
AS
MA
 
FO
LL
OW
IN
G 
AN
203
g
Si
m
v
CM
i—I
m
o m
r—I
V  V v  y
co
I—I .V
vo
V
vo
m
o LO à\m
CM
CM
r—I
V
co
m
2
No
 
Sa
mp
le
 
ND
 
- 
No
t 
De
te
ct
ab
le
 
NM
 
- 
No
t 
M
e
a
s
u
r
e
d
TA
BL
E 
4.
25
 
: 
CO
NC
EN
TR
AT
IO
NS
 
OF
 
d
—F
EN
FL
UR
AM
IN
E 
IN 
PL
AS
MA
 
FO
LL
OW
IN
G 
AN
 
OR
AL
 
DO
SE
204
§
H
I
$2
H
§
5
i
i
v
i—i
V
O  CM
O 
i—I
r—I
00
VO
LO
LO
V  V
V
n
io
CM
V
cn
a
No
 
Sa
mp
le
 
ND
 
- 
No
t 
D
et
ec
ta
bl
e 
NM
 
- 
No
t 
M
e
a
s
u
r
e
d
TA
BL
E 
4.
26
 
: 
C
O
N
C
E
N
T
R
A
T
I
O
N
S
 
OF
 
d
-
N
O
R
F
E
N
F
L
U
R
A
M
I
N
E
 
IN
 
PL
AS
MA
 
FO
LL
OW
IN
G 
AN
 
OR
AL
 
D
O
S
E
205
§
H
ss
%
H
g
S
II
CM 
r—I
O  
i—I
<J\
00
vo
m
ro
CM
Q  Q  Q  
Z Z Z
Q
Z
0
W
ro
XI
Q)
0 vo
u
u-i
C
0u-i
$-i
OC
en
c
Q
2
Q
2
Q
2
H  Lf) 00
co
H
00
O
CM VO
m
cn
2
Q
2
Q
2
o
CM
en oo 
r~ vo
r-
cm m
CM
o
Q  Q  •
2 2 oo o
r—I
m
vo
VO CM O
co vo
r—i rH
C0
o
r4
<J\
CM C0 
i-4 i-4
vo en cm cm
i—I r4
CO co 
VO TP i-4
H
H  O  
en cm
i-4
CM
O
O
CM
i-4
r»
o
Q  Q  Q  Q  Q  £
2 2 2 2 2 2 CM CO 
i— 1 r—I
Q  Q  Q  Q  
2 2 2 2
en Tf 
en co
m o
co
en
m
i-4
O
CO
en en 
co
en LD
TT C0 CM
i— I r-4 r-4
C0 'd1
co
i-4  r-4
VO
«d1
00
LO
i-4
O
00
LO
C'­
en o 
r4
H  VO VO 
00 OO 00
00
C"
r-4
VO
vo
o
r-
co
CM
en
oo
r-
cm en vo io cm
0 0  r-4
r 4  p4
d^* LO LO
r- co oo
r-4 r4
LO
O O 
r-4 r—I
CO
VO
O
<d*
1-4 0 0  r-4
C'­
en
vo
o
CM
r-
vo
cm o
1-4 CM
LO LO f'*
r-4 rH r-4
LO
C0 CM LO CM CM «d1
i-4 r-4 i“4 r4 r-4 r4
00 00 
r-4 r-4
t"- VO r- CM LO CM
o
r-4
CO
O
r-4
VO
VO
•d1
CM
O
r-4
r-4 VO 00 H  LO
CO
CM C- 
r-4
00  LO 
LO C0
LO O  
CM CM
VO
VO
C0
en
CM co
r-4
t-4
<d«
r»
io
CM CO CM
vo en 
vo oo
d^1
en io
r- cm
v
o
■d*
r-4
O
O
LO LO LO 
CM CM CM
LO LO 
r-4 r-4 O
r-4
LO CM O
r-4 r-4 r-4
CM
co co en oo
O  vo CM o
CM r-4 r-4 r-4
VO CM VO O
en o  en œ
o
r-
co vo
CM CM
r-4
00
o
r-4
vo vo
• s
vo SS 
r-4
o
vo
en
co
LO
00
I
o  c o  c o
Eh
U m
H u
h) D
m 0
D y
en
LO
o
LO LO
H  H  CM CM C0
LO
r-
I  g
r-
en
Q
2
Q
2
en
en Q 
2  2  cm
r-
o
oo
oo en 
o  vo
en
CM
Q
2
I
LO
• Q  Q
CM £  £  
V
LO
• Q  Q
CN 12 £
V
cm
LO co
d1 vo
r-4  r-4
r 4  r-4
Q
2
vo
00
L O O  O O O O O O
C O d L O V O C O O d O C O d C M  
r-4 CM CO d1 LO r-
cn
2
No
 
Sa
mp
le
 
ND
 
- 
No
t 
D
et
ec
ta
bl
e 
NM
 
- 
No
t 
M
e
a
s
u
r
e
d
TA
BL
E 
4.
27
 
: 
C
O
N
C
E
N
T
R
A
T
I
O
N
S
 
OF
 
d
-
F
E
N
F
L
U
R
A
M
I
N
E
 
IN 
PL
AS
MA
 
FO
LL
OW
IN
G 
AN
 
OR
AL
 
D
O
S
E
OF
 
d
-
F
E
N
F
L
U
R
A
M
I
N
E
 
H
Y
D
R
O
C
H
L
O
R
I
D
E
 
IN
 
C
A
P
S
U
L
E
S
206
in o N1 CN CN ro ro in in in ro 00 O cnCN W spH o cn r- 2 CN o CD N* 00 in rH N1 cn pH N* 2pH rH ro ro ro CN CN CN CN CN pH pH
r-~ 00 in cn CN CN 00 pH CD Tf CN 00 rH opH srH ro o CN 00 CN O in pH CN 00 CD O cn CD in 2rH rH CN CN CN CN CN CN pH pH rH
in ro ro cn 00 N1 ro 00 CD in pH CD 00 CD N1O Q • • • • • • • • • . • ,iH 2 CN pH ro o cn pH CN 00 in in 00 N1 ro CN CNV pH pH CN CN CN CN pH pH rH
o <J\ in 00 CD CN 00 CN o cn r"
CT\ w • • • cn • • • • • CO « • • • Q2 in CN in 2 rH N1 N1 pH CD 2 CD CN CN 2CN CN ro CN CN CN i—I pHpH
r— ro a\ in 00 cn cn ro CD 00 00 o O r- 'd1
00 E Q n • • • • • • • - • •2 2 ID in r-~ co o cn ro CD CD o cn ro r~ N1 ro(U pH CN ro ro N1 ro ro ro ro ro pH pHw
rd
JQ o ID ro o cn cn cn in in in ro in O
[■'» Q • • • • • • • • • • • • « Q Q QQ) 2 <j\ CN r- 00 ro 00 CD in o in cn CD in z z 2<U i—i ro ro CN ro CN CN CN CN CN pHU4-1
in r- ro rH N1 O N1 pH in in CN in m
lO • • • • • • • • • • • • • e . Q pC CN pH N1 00 r~ CN cn 00 ro 1—1 in ro CN 2 20 V rH pH CN CN CN CN rH rH pH pH pH V44
cn in in ro VD ID CD pH r* r-* O r- cn in
in c • • • • • • • • • • • • « • Q Q QCN CN a\ N1 in ro ro o n- CN CN 2 2 2V V rH pH pH pH pH pH pH V
m ID in in m r- O O H in cn CDQ • • • • • • • • • • • • £ Q Q Q2 in o r- ro in 00 cn pH o o ro 2 y 2 2
rH pH pH CN pH pH pH pH rH pH
CN ID in cn 00 CN CD pH pH CN in CD in
ro Q Q Q Q2 2 ID KD cn o O r- N 1 CN pH cn N 1 CN CN 2 2i— 1 pH CN CN pH iH pH rH V
N 1 00 00 r* CN 00 00 TP N 1 r» CD N 1 o in in
CN Q2 ro rH in N* o cn 00 r>> m CD r~ m CN CNpH pH CN CN pH pH pH pH pH rH V V
in O o N* pH pH in r- CD <n 00 00 m
pH P • • • 2 • • • • • • • e • • Q Q2 CN ro 2 pH cn in pH r- ro cn ro CN 2 2V rH pH CN ro CN CN rH V
E4
UH COu in o in O in O in O o o o O o o O o o
m o o rH pH CN CN ro ro N1 in CD 00 O N1 o 00 N* CND y pH CN ro N1 inw
No
 
Sa
mp
le
 
ND
 
- 
No
t 
D
et
ec
ta
bl
e 
NM
 
- 
No
t 
M
e
a
s
u
r
e
d
TA
BL
E 
4.
28
 
: 
C
O
N
C
E
N
T
R
A
T
I
O
N
S
 
OF
 
d
-
N
O
R
F
E
N
F
L
U
R
A
M
I
N
E
 
IN 
PL
AS
MA
 
FO
LL
OW
IN
G 
AN
 
OR
AL
 
D
O
S
E
OF
 
d
-
F
E
N
F
L
U
R
A
M
I
N
E
 
H
Y
D
R
O
C
H
L
O
R
I
D
E
 
IN
 
C
A
P
S
U
L
E
S
207
in o 00 O o in 00 CN rH r- cn ro in
CN cn Q Q Q
i—1 CN vo 00 to ro CN CN 00 O CN o ro 00 vo to to toV rH rH rH i—1 i—1 rH rH
r- rH CN O ro in ro VO CN o ro cn 00
rH Q Q • s • • • » • • • •
rH s to ro to CN rH r> cn r~ o o CN rH <d< o 00 00
i—1 rH rH rH rH rH rH rH
•sr ro 00 n» CN VO in CN 00 CN in inO Q Q Q Q Q • • • « • • •
i—1 to to to to to <J\ cn rH rH ro o r- in rH vo
rH rH rH CN rH i—i rH
00 ro ro in cn 00 CN 'd*
C\ cn Q • • cn • • • • • • to • Q P Q Q
f—( to to 00 to o in cn o O o to o to to to to
i rH rH i—1 rH rH
rH
E CTi 00 ro r- 00 o «d1 cn ro 00 00 rH CN vo CN
00
U] in m 00 CN m CN vo «d1 O ro ro in cn 00 in rH 00
fd rH rH rH rH rH CN CN CN rH rH r—1 rH rH
JÛ
<y r- CN VO a\ VO CN cn vo cn in rH CN VO in CN
Q Q • • • • '• • * e « • • « .
to to rH m in vo m vo rH vo r- 00 in rH O 00
UH rH i—i i—i 1—1 rH H rH CN rH •—i r—1 rH rH rH
£2 ro r- CT\ O <d< in o <n 00 VO VO CN 00 00
VD (U
H_| CN vo in in in ro 'd1 'd1 vo o cn VO in Tf
U rH rH rH rH rH rH rH rH rH rH
0
G '3* rH VO O in in VO in in 'd1 VO vo ro ro 00
m rn * s
?  ro to 00 O rH 'd1 ro O ro r- o o r~- in inrH rH I—1 rH rH rH rH rH i—1 rH rH
O CN 00 CO ro <n ro 00 ro ro VO rH
g Q • • • • • • • • • • • • Q Q Pto to O CN ro ro ro CO rH CN ro m cn to to tor—1 rH rH i—I rH rH -H i— 1 ■—1
ro CN VO a\ cn cn O o O in in
ro g • • • • • • • • • • • • Q Q Q Qto in rH CN CN CN ro 'd1 ro r- to to to torH rH rH rH rH rH rH rH
ro o CTi "d1 VO VO 'd1 VO CN CN 00 VO in in 00 cn ro
CN o CN o rH VO CN in CN ro r* 'd1 VO CN CN r~ o o«—1 rH rH rH rH i—1 rH rH rH rH rH rH i—1 rH rH rH rH
00 ro ro CN ro O rH ro rH in VO O 00 O in cn r-
rH o ro ro r- OÏ rH m ro in in o r- vo •d1 CNrH rH rH rH rH rH rH
E-t
CJ
tti
œ
i_i in o in o in o in O O O O O O o o o O
CQ o o rH rH CN CN ro ro td1 in VO 00 O o 00 'd1 CN
D to rH CN ro in
cn
No
 
Sa
mp
le
 
ND
 
- 
No
t 
De
te
ct
ab
le
 
NM
 
- 
No
t 
M
e
a
s
u
r
e
d
208 
CHAPTER 5
THE METABOLISM AND KINETICS OF 780SE IN MAN
The results described in this chapter were obtained from two 
separate studies. In the first study, four healthy 
volunteers were given [^C]-780SE orally (Table 5.1). The 
fate of the radioactive label was followed quantitatively 
through to its eventual occurrence in urine. The
radioactive metabolites in urine were extracted, separated, 
isolated and identified. This first study highlighted the 
difficulty of extracting and quantitating the radioactive 
metabolites in plasma, therefore another study was carried 
out, using just one subject (Table 5.1), the main purpose of 
which was to study plasma metabolites.
5.1 Study Designs
5.1.1 Study in four healthy volunteers - Study 1 
14
Some [ C]-780SE hydrochloride (18mg at
8.96tiCi.mg 1) was dissolved in ethanol (4ml). 
Doses of non-radioactive 780SE hydrochloride 
(115mg) were weighed into four volumetric flasks 
(50ml). An aliquot (1ml) of the radioactive 
solution was added to each flask and a further 
volume of ethanol (4ml) added until all the dose 
had dissolved. The volumes were made up with 
distilled water and an aliquot (0.5ml) removed 
to exactly determine the radioactive dose.
Four healthy human volunteers (2 male and 2 
female), having no history of cardiac, renal or 
hepatic dysfunction, each received, orally, one 
of the prepared doses (Table 5.1). The subjects 
fasted for 12 hours before dosing and did not 
eat until 4 hours after. No other medication, 
or alcohol, were permitted from 24 hours before 
dosing and until the end of the study.
209
TABLE 5.1 : [14C]-780SE IN MAN 
DETAILS OF VOLUNTEERS AND DOSES
SUBJECT SEX AGE
(years)
JW M 51
JA M 41
AF F 45
EM F 46
BC+ M 35
WEIGHT DOSE
(kg) mg* nC
72 109 40.50
79 109 40.12
86 109 32.89
55 109 32.00
61 111 30.65
* - Dose expressed as mg of free base. 
+ - Study 2
210
Blood samples (20ml) were taken by venepuncture 
from the ante-cubital fossa at 0, 0.5, 1, 2, 3, 
4, 5, 6, 7,8, 10, 12, 14, 24, 36, 48 and 72
hours, separated into plasma and red cells and 
stored at -20°C until analysis. The bladder was 
emptied just before dosing and a sample of urine 
retained as a control. After dosing, total 
urine was collected up to 0.5, 1, 2.5,
3, 4, 5, 6, 7, 8, 10, 12, 14, 16, 24, 36, 48, 72, 
96 and 120 hours. As well as a control sample, 
total faeces were collected as close as possible 
to 24, 48 and 72 hours. Urine and faeces were 
stored at -20°C until analysis.
5.1.2 Study in male volunteer - Study 2
The dose for the second study was prepared by 
weighing 780SE hydrochloride (118.5mg) into a 
gelatine capsule and spiking this with 
["^C]-780SE ( 30p.Ci) dissolved in ethanol
(70^1). The capsule was not capped for 15 
minutes to allow the ethanol to evaporate.
A healthy male human volunteer, with no history 
of cardiac, renal or hepatic dysfunction was 
given the dose with water (50ml) . The subject 
fasted from 12 hours before the dose until 4 
hours after. No other medication, or alcohol, 
was allowed from 24 hours before the dose and 
for the duration of the study.
Blood samples (20ml) were taken from the 
ante-cubital fossa at 0, 0.25, 0.50, 0.75, 1, 2, 
3, 4, 5, 6, 8, 12, 24, 32, 48 and 72 hours.
Each blood sample was immediately separated into 
plasma and red cells. After removal of aliquots 
(3 x 100|il) for liquid scintillation counting, 
the remaining plasma was immediately extracted 
with Amberlite XAD-2.
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TABLE 5.2 : DETAILS OF DOSING AND SUBJECTS PARTAKING IN A 
HUMAN VOLUNTEER STUDY (STUDY 3) TO DETERMINE THE 
BIOAVAILABILITY OF 150mg 780SE HYDROCHLORIDE SUGAR COATED
TABLETS
Parameter Age Sex Body Dose 1 Dose 2
Weight
(kg)
Subject
RT 26 M 77 Solution Tablet2
AW 24 M 70 Tablet Solution
AH 21 M 65 Solution Tablet
BM 43 M 80 Tablet Solution
AT 30 M 73 Solution Tablet
PL 28 M 75 Tablet Solution
1. The solution was made up by dissolving 780SE hydrochloride 
(150mg) in distilled water (50ml).
2. 780SE hydrochloride (150mg) sugar coated tablets
212
The bladder was emptied just before dosing and a 
sample of urine retained as a control. After 
dosing, total urine was collected up to 0.25, 
0.50, 0.75, 1, 2, 3, 4, 5, 6, 8, 12, 24, 32, 48
and 72 hours and stored at -20°C until analysis.
5.1.3 The measurement of norfenfluramine in the plasma 
of six volunteers following oral 780SE (150mg) - 
Study 3
The pharmacological importance of
norfenfluramine made quantitation in plasma 
imperative. Results are shown from a study that 
included six healthy volunteers where the plasma 
levels of norfenfluramine were measured using 
the sensitive gas chromatographic method
(Methods 2.6.1). This study was designed to 
evaluate the bioavailability of 150mg 780SE
hydrochloride sugar-coated tablets. It was an 
open crossover design study in which each of the 
six subjects received 150mg of 780SE in tablet 
form or in solution on two separate occasions, 
with a one-week wash out period. The subject 
details and dose order are shown in Table 5.2. 
Blood samples (15-20ml) were taken by 
venepuncture and transferred into
lithium-heparinised tubes at predose, 0.5, 1, 2, 
3, 4, 6, 8, 11, 14, 25, 29, 34 and 49 hours
after administration of the dose. After 
centrifugation, plasma was separated and
analysed for norfenfluramine. The results from 
the dose given in solution are considered here 
as they bear more relationship to the 
radioactive doses which were also given in 
solution.
213
The results obtained from Study 2 were 
considered separately because of the difference 
in dosing formulations. The fate of the 
radioactive label is described under the four 
processes of absorption, distribution, 
metabolism and elimination, however, the 
isolation and identification of metabolites is 
described in a separate section within this 
chapter.
5.2 The Absorption of Radioactivity
5.2.1 Study 1
Absorption of radioactivity was rapid as shown 
by the mean plasma radioactivity time curve 
(Figure 5.1). All subjects displayed this rapid 
absorption with peak radioactivity
concentrations occurring in plasma between 1 and 
2 hours after the dose was taken. One subject 
(EM) displayed a delayed absorption relative to 
the other subjects with a peak concentration of 
radioactivity in plasma occurring 2 hours after
dosing (Table 5.3) which was about an hour later
than for the other subjects. The high urinary 
recovery (mean of 93.6% of dose) of
radioactivity in all subjects (Table 5.17) 
indicated that the radioactive dose was
completely absorbed. This observation is
supported by the low (<1% of dose) faecal 
recoveries (Table 5.15). The mean half-life of 
absorption was 0.21 + 0.19 hours (Table 5.4).
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TABLE 5.3 : CONCENTRATIONS OF RADIOACTIVITY IN PLASMA OF
HUMAN VOLUNTEERS (STUDY 1) FOLLOWING AN ORAL DOSE OF
[14C]-780SE (109mg) IN SOLUTION
Subject JW JA AF EM Mean + S.D.
Sex M M F F
Time after *\ig equivalents .ml"1
dose (h)
0.5 0.09 0.46 0.48 - 0.34 + 0 . 2 2
1 2.79 2.65 2.54 0.67 2.16 + 1.00
2 2.36 2.15 1.95 2.38 2 . 2 1 + 0 . 2 0
3 1-66 1.59 1.55 2.29 1.77 + 0.35
4 1.16 1.09 1.17 1.82 1 . 3 1 + 0 . 3 4
5 0.85 0.84 - - 0.85 + 0.01
6 0.92 0.64 0.67 0.92 0 . 7 9 + 0 . 1 5
7 0.53 - - - 0.53
8 0.49 0.52 0.53 0.48 0.51 + 0.02
10 0.36 0.38 0.33 0.32 0.35 + 0.03
12 0.33 0.22 0.36 0.29 0.30 + 0.06
14 0.27 0.26 0.30 0.23 0.27 + 0.03
24 0.21 0.23 0.16 0.14 0 . 1 9 + 0 . 0 4
36 0.17 0.17 0.12 0.08 0.14 + 0.04
48 0.14 0.16 0.11 0.10 0.13 + 0.03
72 - 0.03 0.07 0.05 + 0.03
* 7BOSE free base
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5.2.2 Study 2
This subject displayed a slower absorption than 
was seen with the other subjects (Figure 5.2) 
with a peak concentration of radioactivity in 
plasma of 1.17|ig equivalents .ml*"1 occurring at 3 
hours after dosing (Table 5.5). However, 
absorption of radioactivity was still rapid with 
a half-life of 0.78h (Table 5.6) . A total of 
94% of the dose was recovered by 72 hours (Table 
5.19) which was similar to the mean recovery for 
the other four subjects at that time (93.6%). 
Thus, although faeces were not collected in this 
study, total absorption of the dose was 
indicated.
5.3 The Distribution of Radioactivity
5.3.1 Study 1
Inspection of the plasma radioactivity-time 
curves (Figures 5.3, 5.4, 5.5 and 5.6) shows
that, after an initial rapid rise in 
concentrations of radioactivity for the first 
hour or two after dosing, all subjects displayed 
an initial rapid elimination phase. 
Concentrations of radioactivity declined 
exponentially up until 10 to 14 hours after 
dosing. At this time, plasma levels fluctuated 
rather than following a smooth exponential 
decline, indeed, two subjects, JA and AF, had a 
slight rise in radioactivity concentration at 12 
and 14 hours respectively (Figures 5.4 and 5.5). 
By 24 hours the levels of radioactivity 
displayed a much slower exponential decline with 
a mean half-life of 34.01 + 11.02 hours up until 
the last sample time at 72 hours.
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TABLE 5.5 : CONCENTRATIONS OF RADIOACTIVITY IN PLASMA OF A
MALE VOLUNTEER (STUDY 2) FOLLOWING AN ORAL DOSE OF
[14C]-780SE (lllmg) IN A GELATINE CAPSULE
Concn. in plasma 
*tig equivalents.ml-1
0.25 0.06
0.50 0.07
0.75 0.30
1 0.43
0.71 
1.17 
1.00 
0.76 
0.69 
0.83 
0.76
24 0.44
32 0.35
48 0.27
2
3
4
5
6 
8 
12
Time after dose 
(h)
* 780SE free base
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TABLE 5.6 : PHARMACOKINETIC PARAMETERS DERIVED FROM TOTAL 
RADIOACTIVITY DATA IN THE PLASMA OF A MALE VOLUNTEER (STUDY 2) 
DOSED ORALLY WITH [14C]-780SE (lllmg)
PARAMETER
C (o) 0.890
X
z 0.030
ka 0.888
11 a (h) 0.782
tie (h) 23.452
tlag (h) 0.1
1AUC (jig equiv.ml-1.h) 33.52
2Cmax (tig equiv.ml"1) 1.17
^"max (h) 3
1 - AUC was calculated by the trapezoidal rule.
2 - cmax was the maximum measured concentration.
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Radioactivity entered the red blood cells (Table
5.7). At any one time, there were considerable 
intersubject variations in red blood cell 
concentrations compared to the variations seen 
between plasma concentrations (Table 5.3). This 
observation was reflected in the intersubject 
variation seen with the red blood cell to plasma 
ratios of concentration of radioactivity (Table
5.8). The peak radioactive concentration in red
blood cells occurred between 1 and 3 hours after
dosing (Figures 5.3 to 5.6) and had a mean value
 1
of 0.81 + 0.41[ig equivalents.g red blood
cells. It is of interest to note that the peak
concentrations in the female subjects (mean
_ 1
1.14|ig equivalents.g ) were considerably
greater than those of the males (mean 0.48[ig 
equivalents.g )^ but this difference was not 
apparent at 8 hours after dosing and thereafter. 
There was also considerable intrasubject
variation in red blood cell radioactivity 
concentrations, in that the values did not 
follow a smooth exponential decline, as with 
plasma concentrations, but rather fluctuated. 
This observation was also reflected in the red 
blood cell to plasma ratios of radioactivity 
concentrations; the mean values of these ratios, 
however, displayed an early low value up to 14 
hours after dosing and thereafter a tendency to 
rise, approaching a value of one. One subject 
(JW) displayed a very high red blood cell to 
plasma ratio at 0.5 hour (1.77) compared with 
the other subjects, thus giving a high bias to 
the mean value (0.87 + 0.79); also another
subject (EM) had a relatively low value (0.29) 
at 72 hours thus giving a low bias to the mean 
(0.66 + 0.32).
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TABLE 5.7 : CONCENTRATIONS* OF RADIOACTIVITY IN RED BLOOD
CELLS OF HUMAN VOLUNTEERS (STUDY 1) FOLLOWING AN ORAL DOSE
14OF [ C]-780SE (109mg) IN SOLUTION
Subject JW JA AF EM Mean + S.D.
Sex M M F F
Time after *{ig equivalents.ml”1
dose (h)
0 .5  0 .16  0.23 0.16 0.18 + 0.04
1 0 .28  0.60 1.02 0.35 0 . 5 6 + 0 . 3 3
2 0.23 0.49 0.58 1.25 0.64 + 0.43
3 0 .35  0.39 0.85 1.10 0.67 + 0.36
4 0.18 0 .37  0.54 0.83 0.48 + 0.28
5 0.30 0 .26  -  -  0 . 2 9 + 0 . 0 1
6 0.17 0.25 0.48 0.38 0.32 + 0.14
8 0.14 0 .26  0.13 0.22 0.19 + 0.06
10 0 .15  0.28 0.07 0.08 0 . 1 5 + 0 . 1 0
12 0 .22  0.24 -  0 .16 0.16 + 0.10
14 0 .16  0.28 0.09 0.08 0 . 1 5 + 0 . 0 9
24 0.13 0.25 -  0 .13 0.17 + 0 .07
36 0.14 0.09 -  0 .15 0.13 + 0.03
48 0 .12  0.17 -  -  0 .15 + 0.04
72 0 .12  0 .15  -  0 .02 0.09 + 0.07
* 780SE free base .
+ Peak levels (used to calculate mean)
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TABLE 5.8 : THE DISTRIBUTION OF RADIOACTIVITY BETWEEN RED
BLOOD CELLS AND PLASMA IN HUMAN VOLUNTEERS (STUDY 1) FOLLOWING
14
ORAL ADMINISTRATION OF [ C]-780SE (109mg) IN SOLUTION
SUBJECT JW JA AF EM MEAN + S.D.
SEX M M F F
Time after Red blood cell/plasma ratio
dose (h)
0 .5  1.77 0.50 0.33 -  0 . 8 7 + 0 . 7 9
1 0 .10  0 .92  0.40 0.19 0.40 + 0 .37
2 0.10 0.23 0.30 0.53 0.29 + 0 .18
3 0 .21  0 .25  0 .55  0.48 0 . 3 7 + 0 . 1 7
4 0.16 0.34 0.46 0.46 0.36 + 0.14
5 0 .35  0 .31  -  -  0 . 3 3 + 0 . 0 3
6 0.18 0.39 0 .72  0.41 0.43 + 0 .22
8 0.29 0.50 0.25 0.46 0.38 + 0 .12
10 0.42 0.74 0 .21  0.25 0 .41  + 0 . 2 4
12 0.67 1 .09  -  0 .55 0.59 + 0 .44
14 0.59 1 .08  0.30 0.35 0.58 + 0 .36
24 0 .62  1.09 -  0 .93 0.88 + 0.24
36 0.82 0.53 -  1 .88  1 .08  + 0 .71
48 0.86 1.06 -  -  0 .96 + 0.14
72 0.80 0.88 - 0.29 0.66 + 0.32
228
The mean areas under the plasma 
concentration-time curves for radioactivity,
calculated by the sum of exponentials, and by 
the trapezoidal rule (Methods 2.7), were 23.33 + 
3.25 and 23.82 + 3.86^g equivalents.h.ml”1
respectively (Table 5.4).
5.3.2 Study 2
The plasma radioactivity-time curve (Figure 5.2) 
shows that after the peak radioactive level 
there was an exponential decrease, until 6 hours 
after dosing. At 8 hours, however, the 
concentration in plasma rose to 0.83[ig
equivalents.ml 1 falling to 0.44|ig equivalents, 
ml at 24 hours after which time there was a 
monoexponential decrease in concentration of 
half-life 23.45 hours reaching a level of 0.27pg 
equivalents.ml 1 at 48 hours which was the 
latest sample time (Tables 5.5 and 5.6). The
data was analysed as having a monoexponential 
decline as there was insufficient data to 
adequately define the initial, more rapid phase.
The area under the plasma concentration-time 
curve estimate was 33.52^g equiv.h.ml”1.
5.4 The Fate of the Radioactive Label
5.4.1 Study 1
Most of the radioactive dose had been recovered
in urine by 24 hours after dosing (87.2 + 3.7%),
so extraction, TLC and metabolite quantitation 
was carried out on 1-24 hour pooled urines.
Also the male subjects' urines were pooled and 
so were the female subjects' urines. An aliquot
of each of these urine samples was hydrolysed
229
using $-glucuronidase (Methods 2.5) so that
conjugated materials could be investigated. 
Hydrolysed and unhydrolysed samples were
extracted with Amberlite XAD-2 and the extracts 
chromatographed by TLC (Methods 2.5). 
Radioactive components were localised by
autoradiography.
After enzyme hydrolysis, the major metabolites 
were isolated, purified and identified by direct 
insertion, electron impact mass spectrometry.
230
TABLE 5.9 : MEAN PERCENTAGE ABUNDANCE OF METABOLITES IN
UNHYDROLYSED AND HYDROLYSED POOLED URINES (0-24 HOURS) FROM
MALE AND FEMALE VOLUNTEERS (STUDY 1) FOLLOWING AN ORAL DOSE
14OF [ C]-780SB IN SOLUTION
Sex - M M F F
Treatment - - - hydrolysed - hydrolysed
Metabolite Rf Mean % of total chromatogram
Nl 0.29 22.4 2.5 15.6 0.0
N3 S422 free base 0.62 8.7 3.6 8.7 1.8
N4 S1475 0.67 64.2 66.6 68.2 73.5
N6 S422 salt 0.77 1.0 19.8 2. 4 15.1
N7 m-TFM hippuric 
acid 0.82 1.1 1.6 1.7 2.4
N8 Norfenfluramine 0.87 1.5 1.5 1.0 2.4
N9 1-(m-TFMP)-1-OH 
propan-2-one 0.93 1.1 4.4 2.4 4.8
231
No radioactivity was found to co-chromatograph 
with 780SE in any sample. There were no 
qualitative differences in separated radioactive 
components between the male and female samples 
(Figure 5.7) and only minor quantitative 
differences (Table 5.9). However, there were 
some considerable quantitative differences 
between hydrolysed and unhydrolysed samples 
(Table 5.9). In all urines, 7 radioactive 
components were seen in various quantities. 
These have been labelled Nl, N3, N4, N6, N7, N8 
and N9 in order of increasing Rf value which 
then enables direct correlation with the animal 
metabolic data in the following chapter.
5.4.1.1 Identification of urinary metabolites after 
enzyme hydrolysis
Metabolites N3, N4, N6, N8 and N9 have all
been identified by mass spectrometry. 
Metabolite N7 has been tentatively identified 
as m-trifluoromethylhippuric acid based on 
chromatographic data only.
Metabolites N3 and N6
Metabolite N3 was shown to have an identical 
electron impact ionisation spectrum to that of
1-(m-trifluoromethylphenyl)-N-(2-hydroxyethyl)-
2-aminopropane (N-2-hydroxyethyl-norfenflur­
amine ; 2422) with major diagnostic ions of m/e 
247 (M+ ) , 246, 232, 228, 216, 187, 159, 109,
88 and 70 which can be accounted for by the 
fragmentation sequences shown in figure 5.8. 
Metabolite N6 gave the same spectrum and was 
subsequently found to be a stable salt of 
N-2-hydroxynorfenfluramine. A component 
chromatographing with an Rf value equal to 
metabolite 6 was found on thin-layer 
chromatographic analysis of blank urine to
232
FIGURE 5.7  : AUTORADIOGRAPHIC LOCATION OF RADIOACTIVE  
AREAS FOLLOWING CHROMATOGRAPHY OF HYDROLYSED AND  
UNHYDROLYSED, 0 - 2 4  HOUR POOLED URINES OF 
VOLUNTEERS DOSED ORALLY WITH [14C]-780SE
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FIGURE 5.10: ELECTRON IMPACT IONISATION AND CHEMICAL  
DESORPTION SPECTRA OF METABOLITE N8 
(NORFENFLURAMINE)
i) Electron Impact Ionisation
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which radiolabelled N-2-hydroxyethyl-
nor fenfluramine had been added.
Metabolite N4
Metabolite N4 was found to give an identical 
electron impact ionisation spectrum to that of 
1-(m-trifluoromethylphenyl)-N-carboxymethyl-2- 
aminopropane (N-carboxymethy1-norfenfluramine; 
S1475) with major diagnostic ions of m/e 261 
(M+), 246, 242, 216, 200, 187, 159, 102 and 56 
which were explained by the fragmentation 
sequences shown in figure 5.9.
Metabolite N 8
This metabolite was shown to be 
m-trifluoromethylphenyl-2-aminopropane (norfen 
fluramine) both by its gas chromatographic 
properties and by its electron impact 
ionisation spectrum which gave diagnostic ions 
at m/e 203 (M+) , 188, 184, 159, 109 and 44
which were accounted for by the fragmentation 
pattern shown in figure 5.10.
Metabolite N9
The electron impact ionisation spectrum of 
metabolite N9 gave diagnostic ions of m/e 218 
(M+) , 201, 176, 156, 146, 127, 107, 77 and 45 
(Figure 5.11), sufficient information to 
propose the structure 1- (m-trifluoromethyl­
phenyl) -l-hydroxypropan-2-one .
5.4.1.2 Quantitation of urinary metabolites
The most abundant metabolite in unhydrolysed 
urine was N-carboxymethyl-norfenfluramine
which accounted for 68.2% of the radioactivity 
in the females' urine and 64.2% in the males' 
urine. Metabolite Nl was the only other to 
account for more than 10% of the radioactivity
238
being 15.6% in females and 22.4% in males.
N-2-hydroxynorfenfluramine was also relatively 
major at 8.7% in both males' and females'
urines. The remaining activity was accounted 
for by metabolites N6, N7, N 8 and N9 which
range in abundance from 1 .0-2 .4% in females
and 1.0-1.5% in males. Norfenfluramine was 
less abundant in the females (1 .0%) than in 
the males (1.5%) but the other three minor 
metabolites were more abundant in the females 
(Table 5.9).
In extracts of hydrolysed urines only two
components were at levels greater than 10%
abundance. These were N-carboxymethyl- 
nor fenfluramine (73.5% in females, 66.6% in
males) and N-2-hydroxyethylnorfenfluramine
salt (15.1% in females, 19.8% in males).
Metabolite Nl was decreased markedly by 
hydrolysis (2.5% in males, 0.0% in females)
and N-2-hydroxyethylnorfenfluramine also
decreased (3.6% in males, 1.8% in females). 
Hydrolysis resulted in an increase in the 
abundance of 1- (m-trifluoromethylphenyl)-1- 
hydroxypropan-2-one to 4.4% in males and 4.8% 
in females, increases of 3.3% and 2.4% 
respectively. The other minor metabolites, in 
hydrolysed urine, m-trifluoromethylhippuric 
acid and norfenfluramine were relatively more 
abundant in females (2.4% each) than males 
(1.6% and 1.5% respectively) and these 
metabolites were also more abundant in the 
hydrolysed urines, especially in females.
5.4.2 Study 2
5.4.2.1 Urinary metabolites
Whereas in Study 1, urines (0-24 hour) were 
pooled before extraction, in this study the
239
individual urine samples were extracted and 
chromatographed separately, thus a time course 
of urinary metabolic content was obtained for 
both unhydrolysed and hydrolysed urines. 
Although the chromatograms were not 
quantitated, there were clear differences. In 
unhydrolysed urines N-2-hydroxyethyl-
norfenfluramine salt had a greater relative 
abundance in 1 hour urine than at other times 
whereas metabolite Nl and N-2-hydroxyethyl- 
norfenfluramine (free base) were present at 
this time but in relatively lower amounts. 
Norfenfluramine had a greater relative 
abundance from 32 hours onwards. Most 
hydrolysed urines displayed the same pattern 
with metabolite Nl almost disappearing and 
N-2-hydroxyethylnorfenfluramine and 1- (m-tri 
fluoromethylphenyl)-l-hydroxypropan-2-one 
increasing ; N-2-hydroxyethylnorfenfluramine 
was at its greatest relative abundance at 2 
hours and was present thereafter, whereas 
1- (m-trifluoromethylphenyl)-l-hydroxypropan-2- 
one did not appear until 5 hours after dosing. 
The major metabolite in all chromatograms was 
N-carboxymethylnorfenfluramine. It is
interesting to note that m-trifluoromethyl­
hippuric acid was not apparent in this 
subject's urine samples, however, metabolite 
N5 (which was not seen in Study 1) was present 
in relatively small quantities. There was no 
780SE in any sample.
5.4.2.2 Plasma metabolites
The recoveries of radioactivity, following 
Amberlite XAD-2 extraction of plasma and 
metabolites and methanol elution, were 
variable, ranging from 41 to 100%. These 
extracts were chromatographed by TLC (see 
Methods 2.5) in solvent system 3.
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In addition aliquots (5ml) of the early plasma 
samples, up to and including the 1 hour
sample, were immediately extracted, without pH 
adjustment, by shaking for 5 minutes with 
diethyl ether (5ml) in a stoppered 
round-bottomed tube (20ml). After separation 
of the phases by centrifugation, the solvent 
layers, were reduced to a small volume
(50-100^1) under a stream of nitrogen. The 
reduced extracts were then chromatographed in 
solvent system 3 (Methods 2.5) together with 
standard ["^C]-780SE which had been taken
through the same extraction procedure.
However, there was no evidence of the presence
14 '
of [ C]-780SE in any plasma extract.
The chromatograms of the Amberlite XAD-2
extracts were quantitated by scraping and 
scintillation counting of the segmented plate 
(Methods 2.5). The low level of radioactivity 
in the extracts together with the low relative 
abundance of metabolite N8 (norfenfluramine) 
made it impossible to quantitate that
metabolite by the method described. However, 
norfenfluramine was measured in Study 3 the
results of which are shown in Table 5.12.
Between 66.6% and 90.7% of the radioactivity 
in the plasma samples from Study 2, was 
accounted for by the metabolites Nl, N3, N4,
N6 and N9 (Table 5.10). The remaining
radioactivity was distributed over each
chromatogram giving a background level which,
although very low in terms of total 
radioactivity, was significant in terms of the 
amount of radioactivity in the chromatogram. 
However, the only well defined areas of
radioactivity were chromatographically
attributable to the metabolites mentioned.
241
TABLE 5.10 : THE RELATIVE ABUNDANCE OF METABOLITES IN THE
PLASMA OF A HUMAN VOLUNTEER (STUDY 2) FOLLOWING AN ORAL DOSE 
14
OF [ C]-780SE (lllmg) IN A GELATINE CAPSULE
Metabolite No. Nl N3 N4 N6 N9 Total
Time after % of chromatogram
dose (h)
0.5 0.0 3.6 10.5 5.9 62.2 82.2
0.75 2.7 2.6 32.1 3.9 49.4 90.7
1 1.4 2.0 13.3 11.7 58.2 86.6
2 13.7 6.4 12.8 3.8 31.3 68.0
3 6.1 6.5 41.5 2.1 30.5 86.7
4 6.9 3.8 41.3 1.9 32.4 86.3
6 4.0 2.3 35.1 2.3 41.4 85.1
12 8.7 3.9 25.9 1.9 41.9 82.3
24 7.0 3.8 22.6 3.8 40.0 77.2
32 6.9 2.1 14.4 5.2 42.0 70.6
48 5.2 5.8 12.0 5.8 37.8 66.6
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One of the major metabolites was 
1- (m~trifluoromethylphenyl)-l-hydroxypropan-2-one 
(metabolite N9) indeed, up to 2 hours and 
beyond 6 hours after dosing it was the most 
abundant accounting for between 37.8% and 
62.2% of the radioactivity in plasma at those 
times (Figure 5.12). Concentrations of this 
metabolite rose quickly to 0.251pg 
equivalents.ml ^ at 1 hour after dosing, then 
the levels remained quite constant up to 12 
hours with a peak level of 0.341pg 
equivalents.ml-^ occurring at 3 hours (Table 
5.11). Thereafter plasma concentrations 
declined slowly (Figure 5.11) with a half-life 
of approximately 24 hours reaching O.lOlpg 
equivalents .ml"-1 at 48 hours.
N-carboxymethylnorfenfluramine (metabolite N4) 
was the other major radioactive component. 
Concentrations rose steadily to a peak level 
of 0.463pq equivalents.ml~ at 3 hours after 
dosing (Table 5.11); at this time, this 
metabolite was the most abundant being 41.5% 
of the radioactivity in plasma (Table 5.10).
At 6 hours the concentration had dropped to 
0.243pg equivalents.ml" and thereafter 
decreased with a half-life of approximately 15 
hours reaching 0.032|ig equivalents.ml"1 at 48 
hours when its relative abundance in plasma 
had dropped to 12.0%. Metabolites Nl, 
N-2-hydroxyethyl norfenfluramine (metabolites 
N3 and N 6) had much lower concentrations. 
Metabolite Nl peaked at 2 hours reaching 
0.097ng equivalents.ml"1 . Its relative
abundance at this time was also at a maximum 
of 13.7% whereas after 2 hours it fluctuated 
between 4% and 8.7%. After this peak there 
was an initial rapid decline in concentration 
followed by another peak of 0.067|ig
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equivalents.ml ^ at 12 hours. Thereafter
concentrations of metabolite Nl declined
steadily with a half-life of about 15 hours.
N-2-hydroxyethylnorfenfluramine free base
(metabolite N3) was also minor, its relative
abundance ranging between 2% and 6.5% of the
total radioactivity in plasma. The peak
concentration, of 0.073|ig equivalents .ml~^,
occurred at 3 hours after dosing and
thereafter fluctuated between <0.01 and
0.038iig equivalents .ml""1 . At 1 hour after
dosing, the salt of the same metabolite (N6)
achieved a peak concentration of O.OSO^g 
-1equivalents.ml , a maximum relative abundance 
of 11.7%.
Thereafter levels dropped to below 0.02[ig 
equivalents.ml 1 at 4 hours and stayed at that 
level until 48 hours.
The method of plate scraping and scintillation 
counting of suspensions of silica allowed a 
limit of sensitivity of O.Oljig
equivalents.ml 1. Thus some results are shown 
as being above background but less than O.Oljig 
equivalents.ml 1. Although the areas on the 
chromatograms corresponding to norfenfluramine 
were scraped and counted, the results 
indicated that the concentrations did not rise 
sufficiently above O.Olpg equivalents.ml 1 to 
enable accurate quantitation of this 
pharmacologically important metabolite by this 
method. The observation was supported by the 
cold analytical data (Table 5.12) where mean 
peak plasma concentrations of 10.9 + 2.7ng of 
norfenfluramine.ml-1 occurred at 2 hours after 
dosing ; this is equivalent to 0.019p,g 780SE
free base.ml 1. Thereafter levels fell at
246
first quickly to 6.6 + 0.9ng.ini”1 (O.Ollgg
equivalents .ml”1) at 8 hours and then more 
slowly with a half-life of approximately 20 
hours. Table 5.13 brings the radioactive and 
non-radioactive data together in a comparable 
form and shows clearly the low abundance of 
norfenfluramine (metabolite N 8), for instance, 
at 2 hours the peak concentration of 0.009% 
dose.1 1 was reached, whereas the total 
radioactivity in plasma was at a level of 
0.644% dose. 1 1 , that is an abundance of only 
1.4%.
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TABLE 5.12 : CONCENTRATIONS OF NORFENFLURAMINE (METABOLITE
N8) IN THE PLASMA OF HUMAN VOLUNTEERS (STUDY 3) FOLLOWING
ORAL ADMINISTRATION OF 780SE (136mg) IN SOLUTION
SUBJECT RT AW AH BM AT PL MEANS + S.D.
Time after *Plasma concentration (ng.ml”1) 
dose (h)
0.5 1.1 1.9 5.1 1.9 2.0 2.9 2.5 + 1.4
1 3.2 10.8 9.7 4.0 5.3 9.6 7.1 + 3.3
2 9.0 16.0 11.4 9.1 9.8 10.0 10.9 + 2.7
3 9.3 15.0 8.1 9.7 11.3 10.4 10.6 + 2.4
4 10.6 12.3 8.0 10.8 10.8 10.6 10.5 + 1.4
6 10.6 9.5 7.5 7.8 9.7 6.2 8.6 + 1.7
8 7.5 6.6 6.8 6.4 7.4 4.9 6.6 + 0.9
11 7.0 5.6 6.4 6.1 6.8 4.1 6.0 + 1.1
14 6.3 4.8 6.0 5.9 5.9 3.9 5.5 + 0.9
25 4.2 1.9 3.9 4.5 3.6 3.3 3.5 + 1.0
29 3.6 1.8 3.5 4.2 3.1 3.1 3.2 + 0.8
34 3.1 1.5 2.9 2.7 2.4 2.8 2.6 + 0.6
49 1.7 0.7 1.1 1.5 1.4 1.6 1.3 + 0.4
* - Norfenfluramine free base
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5.5 The Excretion of Radioactivity
5.5.1 Study 1
The total recovery of radioactivity in urine and 
faeces ranged from 87.1% of the administered 
dose (JW) to 100.9% (AF) over the 5 day 
collection period (Table 5.14). The majority of 
the dose was recovered in urine, indeed, the 
faecal recoveries accounted for less than 1% of 
the dose in all subjects (Table 5.15). Urinary 
elimination of radioactivity was initially 
rapid. At 4 hours after dosing, three subjects 
had excreted more than 50% of the dose; the 
other subject showed a slower elimination and 
had excreted only 28.2% of the dose at 4 hours, 
but by 7 hours the recovery in urine had risen 
to 59.3% (Table 5.17). By 24 hours, greater 
than 90% of the final total urinary recovery was 
achieved in three subjects. Subject AF had 
excreted 88.0% of the dose at this time but 
whereas the other three subjects eliminated only 
a further 3-6% of the dose, AF continued to 
excrete radioactivity until 100.5% had been 
recovered at 120 hours. Mean data indicates a
maximum excretion rate of 0.276 + 0.158% of
""I —
dose.min occurring at 1.5 hours after dosing
(Table 5.18). In fact only the two male subjects
displayed their highest excretion rates at this
time, showing values of 0.339 and 0.432% of
dose.min-1 for JW and JA respectively (Table
5.18). Subject EM had a peak of urinary
excretion of 0.320% of dose, min”1 at 2.5 hours
but subject AF had a maximum rate at 4.5 hours,
although the value was very similar (0.325% of
dose.min 1). The initial relatively low urinary
recovery of radioactivity from subject AF was
reflected in the low urinary excretion rate
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TABLE 5.14 : THE CUMULATIVE TOTAL EXCRETION OF RADIOACTIVITY 
IN THE URINE AND FAECES OF HUMAN VOLUNTEERS (STUDY 1) 
FOLLOWING AN ORAL DOSE OF [14C]-780SE (109mg) IN SOLUTION
SUBJECT
Sex
JW JA AF EM
M M F F
Mean + S.D
Time period 
after dose (h)
Cumulative % of dose
0 - 24 83.1 92.0 88.2 86.1 87.4 + 3,7
0 - 
0 - 
0 -
48
72
96
86.2 95.6 95.5 89.3 9 1 . 6 + 4 . 7
87.1 96.9 99.0 90.2 93.3 + 5.6
87.1 97.1 100.2 90.4 9 3 . 7 + 6 . 0
0 -  120 87.1 97.4 100.9 90.6 9 4 . 0 + 6 . 3
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TABLE 5.15 : THE EXCRETION OF RADIOACTIVITY IN THE FAECES 
OF HUMAN VOLUNTEERS (STUDY 1) FOLLOWING AN ORAL DOSE OF 
[14C]-780SE (109mg) IN SOLUTION
Subject
Sex
Time period 
after dose (h)
0 - 24
24 - 48
48 - 72
JW JA AF
M M F
% of dose
0.2 0.2 0.2
0.2 0.1 0.1
0.0 0.1 0.1
EM Mean + S.D. 
F
0.0 0.2 + 0.1
0.5 0.2 + 0 . 2
0.1 0.1 + 0.0
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TABLE 5.16 : THE EXCRETION OF RADIOACTIVITY INTO THE URINE OF
HUMAN VOLUNTEERS (STUDY 1) FOLLOWING AN ORAL DOSE OF [14C]-780SE
(109mg) IN SOLUTION
Subject JW JA AF EM Mean + S.D.
Sex M M F F
Time period % of dose
after dose (h)
0 — 0.5
i—1
o
0.1 0.2
i—1
o
0.3 + 0.4
0.5 - 1 6.4 9.7 0.7 1.4 4.6 + 4.3
1 - 2 20.4 25.9 3.7 16.4 16.6 + 9.5
2 - 3 18.5 13.4 14.8 19.2 16.5 + 2.8
3 - 4 11.9 12.6 8.9 14.5 12.0 + 2.4
4 - 5 4.6 8.5 19.5 11.9 11.1 + 6.3
5 - 6 4.6 - 1.2 6.0 3.9 + 2.5
6 - 7 3.5 8.1+ 10.5 4.3 6.1 + 3.8
7 - 8 3.9 2.4 4.7 3.0 3.5 + 1.0
8 - 10 2.1 3.2 5.5 3.8 3.6 + 1.4
10 - 12 1.6 1.3 5.6 0.7 2.3 + 2.2
12 - 14 1.9 2.9 2.3 1.0 2.0 + 0.8
14 - 16 0.8 - - 3.9 1.3 2.0 + 1.7
16 - 24 2.7 3.2+ 6.7 2.5 4.0 + 2.4
24 - 36 1.9 1.7 3.0 1.3 2.0 + 0.7
36 - 48 0.9 1.9 4.2 1.3 2.1 + 1.5
48 - 72 1.0 1.1 3.4 0.8 1.6 + 1.2
72 - 96 - 0.3 1.3 0.3 0.6 + 0.6
96 - 120 - 0.3 0.7 0.1 0.4 + 0.3
+ - Value includes extra time period and thus is omitted from 
mean + s.d. calculation
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TABLE 5.17 : THE CUMULATIVE EXCRETION OF RADIOACTIVITY INTO
THE URINE OF HUMAN VOLUNTEERS (STUDY 1) FOLLOWING AN ORAL
14
DOSE OF [ C]—78OSE (109mg) IN SOLUTION
Subject JW JA AF EM Mean + S.D.
Sex M M F F
Time after 
dose (h) Cumulative % of dose
0.5 0.1 0.8 0.2 0.1 0.3 + 0.4
1 6.5 10.5 0.9 1.5 4.9 + 4.5
2 26.8 36.4 4.6 17.9 21.4 + 13.6
3 45.4 49.8 19.3 37.0 37.9 + 1 3 . 5
4 57.3 62.4 28.2 51.6 49.9 + 15.1
5 61.9 70.9 47.6 63.5 61.0 + 9.7
6 66.5 - 48.8 69.5 61.6 + 11.2
7 70.0 78.9 59.3 73.8 70.5 + 8.3
8 73.9 81.3 64.0 76.8 74.0 + 7.3
10 75.9 84.5 69.5 80.6 77.6 + 6.5
12 77.5 85.7 75.1 81.3 79.9 + 4.6
14 79.4 88.6 77.4 82.3 81.9 + 4.9
16 80.2 - 81.3 83.6 81.7 + 1.7
24 82.9 91.8 88.0 86.1 87.2 + 3.7
36 84.8 93.5 91.0 87.4 89.2 + 3.9
48 85.7 95.4 95.2 88.7 91.3 + 4.8
72 86.7 96.5 98.6 89.5 92.8 + 5.7
96 86.7 96.8 99.9 89.8 93.3 + 6.1
120 86.7 97.1 100.5 89.9 93.6 + 6.4
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values up to 1.5 hours and, thereafter, up to
7.5 hours the elimination rate fluctuated 
considerably in relation to the smooth excretion 
rate profiles in other subjects (Table 5.18).
There were no gross differences in the recovery 
of radioactivity in urine and faeces.
5.5.2 Study 2
There was no faecal collection in this study.
Radioactivity was quickly excretion in the urine
although not as quickly as seen in Study 1. At
8 hours after dosing 49.0% of the dose had been
recovered and this figure rose to 81.0% at 24
hours (Table 5.19). Urine collection continued
up to 72 hours by which time 94.0% of the dose
was accounted for. The elimination rate profile
followed a smooth curve with no marked
fluctuations and a maximum rate of 0.157% of 
_1
dose.min at 3.5 hours after dosing.
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TABLE 5.18 : RATES OF EXCRETION OF RADIOACTIVITY INTO THE
URINE OF HUMAN VOLUNTEERS (STUDY 1) FOLLOWING THE ORAL
ADMINISTRATION OF [14C]-780SE (109mg) IN SOLUTION
Subject JW JA AF EM Mean + S.D.
Sex M M F F
Time after 
dose (h) % of dose.min
0.25 0.002 0.027 0.007 0.002 0.010 + 0 . 0 1 2
0.75 0.214 0.324 0.023 0.048 0.152 + 0.142
1.5 0.339 0.432 0.061 0.273 0.276 + 0.158
2.5 0.309 0.223 0.246 0.320 0.275 + 0.047
3.5 0.199 0.210 0.148 0.242 0.200 + 0 . 0 3 9
4.5 0.077 0.140 0.325 0.199 0.185 + 0.106
5.5 0.076 - 0.020 0.100 0.065 + 0.041
6.5 0.059 - 0.175 0.072 0.102 + 0.064
7.5 0.064 0.040 0.078 0.050 0.058 + 0.017
9 0.017 0.027 0.046 0.032 0.031 + 0.012
11 0.013 0.011 0.047 0.006 0.019 + 0.019
13 0.016 0.024 0.019 0.008 0.017 + 0.007
15 0.006 - 0.032 0.011 0.016 + 0.014
20 0.006 - 0.014 0.005 0.008 + 0.005
30 0.003 0.002 0.004 0.002 0.003 + 0.001
42 0.001 0.003 0.006 0.002 0.003 + 0.002
60 0.001 0.001 0.002 0.001 0.001 + 0.001
84 - <0.001 0.001 <0.001 <0.001
108 - <0.001 <0.001 <0.001 <0.001
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TABLE 5.19 : THE EXCRETION OF RADIOACTIVITY IN THE URINE OF A
MALE VOLUNTEER (STUDY 2) FOLLOWING AN ORAL DOSE OF
[14C]“780SE (lllmg) IN A GELATINE CAPSULE
Time period % of dose Cumulative Mid-point Elimination
after dose excreted % of dose of rate % dose
(h) collection /min
period (h)
0 - 0.25 0.0 0.0 0.13 0.0
0.25 - 0.50 0.0 0.0 0.38 0.003
0.50 - 0.75 0.3 0.4 0.63 0.013
0.75 - 1 1.0 1.4 0.88 0.040
1 - 2 5.9 7.2 1.5 0.098
2 - 3 8.7 15.9 2.5 0.144
3 - 4 9.4 25.3 3.5 0.157
4 — 5 7.9 33.2 4.5 0.131
5 - 6 5.5 38.6 5.5 0.091
6 — 8 10.4 49.0 7 0.086
8 - 1 2 12.8 61.8 10 0.053
12 - 24 19.3 81.0 18 0.027
24 - 32 7.6 88.6 28 0.016
32 - 48 4.0 92.7 40 0.004
48 - 72 1.4 94.0 60 0.001
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CHAPTER 6
THE METABOLISM AND KINETICS OF F14C1-BENFLüOREX (780SE)
IN RAT, DOG, BABOON AND RHESUS MONKEY
During the development of benfluorex (m-trifluoromethyl 
phenyl-N-(2-benzoyloxyethyl)-2-aminopropane) as a novel 
antihyperlipidaemic agent, it was necessary to conduct long 
term toxicity tests. In order that the results from these 
studies should bear as much relevance to man as possible, a 
number of species were given oral doses of [14C]-benfluorex 
(780SE) and the absorption, distribution, metabolism and 
excretion of the doses determined to define which species 
bore the closest resemblence to man with regard to these 
parameters. This chapter describes and compares the data 
from the different species and then relates these data to 
man.
The preparation and administration of doses has been 
described in the chapter on methods (section 2.3). Table
6.1 gives details of the animals and the doses used.
TABLE 6.1 : DETAILS OF ANIMALS AND MEAN DOSES
Species Strain Number 1 Body wt. 
(kg)
Dose 2 
(mg)
Radioactive 
Dose 
(liCi.kg )
Rat Wistar 4 0.33 1.63 43.5
Dog Beagle 4 11.25 56.25 3.6
Monkey Baboon 2 3.85 19.25 7.1
Monkey Rhesus 4 3.00 15.00 15.0
1. Equal numbers of each sex were used.
2. All doses were at Smg.kg" ^ body weight.
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6.1 The Absorption of Radioactivity from the
Gastro-intestinal Tract
The concentrations of radioactivity in plasma for all 
species are shown in Table 6.2. As all animals were 
given a dose of 5mg.kg the plasma levels have been 
expressed as tig equivalents of 780SE.ml-1 which allows 
some comparison between species, although it must be 
emphasised that total radioactivity was measured which 
is composed of all the metabolites, which may vary 
between species.
6.1.1 Absorption in rat
The relatively low recovery of radioactivity in 
faeces (15.1% of dose) indicated extensive 
absorption of the dose (Table 6.7).
At 0.5 hours after dosing, mean plasma levels of 
0.13 + 0.03|ig equiv.ml ^ were reached and
thereafter rose quite steadily to a peak of 0.30 
+ 0.OS^g equiv.ml ^ at 10 hours (Figure 6.1) . 
The absorption profile was unusual in that, 
after the first 0.5 hours following dosing, the 
rate of absorption was relatively low with a 
half-life based on mean data of 0.86 hours 
(Table 6.3).
6.1.2 Absorption in dog
The high recovery of radioactivity in urine 
(80.7% of dose) relative to faeces (Table 6 .8) 
again indicated good absorption.
Radioactivity was seen in plasma (0.56 + 0.23p.g 
equiv.ml )^ at 0.5 hours after dosing (Table
6.2) with fitted data showing a lag time of 0.4 
hours (Table 6.3). Concentrations continued to
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rise to a mean measured peak of 3.60 + 0.23[ig 
equivalents.ml-1 at 2 hours after dosing. The 
half-life of absorption was 0.46 hours based on 
mean data.
6.1.3 Absorption in baboon
Faecal recoveries of radioactivity were very low 
(<1% of dose ; Table 6.7) thus absorption was 
complete. Radioactivity entered plasma quickly 
with a mean level of 2.06 + 1.54p.g equiv.ml ^ at 
first 0.5 hour after dosing. The lag time was 
0.4 hours (Table 6.3). The mean measured peak 
plasma level of 4.54 + 3.02pg equiv.ml"1 was
seen at 1 hour after dosing (Table 6.2). The 
half-life of absorption based on mean data was
rapid (0.22 hours).
6.1.4 Absorption in rhesus monkey
The pharmacokinetic analysis of mean data (Table 
6.3) shows a lag time of 0.5 hours followed by a 
rapid rise in mean plasma concentrations of 
radioactivity to 1.83 + l.O2^g equiv.ml"1 at 0.5 
hour and a mean measured peak of 5.28 + 1.91^g 
equiv.ml at 1 hour after dosing. The
half-life of absorption was 0.09 hours. 
Absorption was complete as indicated by the very 
low faecal recoveries (<2% of dose; Table 6.7).
6.2 The Distribution of Radioactivity in Plasma
The concentrations of radioactivity in plasma were
measured up to 72 hours after dosing in all species.
The mean results are presented here (Table 6.2) and a 
basic pharmacokinetic analysis (Methods, section 2.7) 
was performed on the mean to describe the data (Table
6.3) . Red blood cells were not analysed for radioactive 
content in these studies.
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6.2.1 Distribution in rat
After the relatively late peak plasma 
concentration, the mean concentration of 
radioactivity declines with a half-life of 44.9 
hours to 0.21 + 0.04pg equiv.ml*™1 at 24 hours 
after dosing. The plasma radioactivity profile 
(Figure 6.1) shows that plasma levels did not 
change a great deal over the sampling period 
resulting in a "flat" profile. The area under 
the plasma concentration-time curve extrapolated 
to infinite time, based on mean data, was 19.87 
Hg equiv.h.ml-1.
6.2.2 Distribution in dog
Following peak concentrations, the mean plasma 
concentrations declined monophasically with a
half-life of 5.9 hours. The last mean measured
concentration was 0.28 + 0.06pg equiv.ml""1 at 24 
hours after dosing. The area under the plasma
concentrâtion-time curve to infinite time was 
36.06ng equiv.h.ml” .
6.2.3 Distribution in baboon
The mean data was fitted to a curve having three 
exponentials, with a biexponential decline 
following the peak plasma concentrations. The 
early, more rapid decline phase gave a 
pronounced peak on the plasma profile (Figure 
6.1). At 12 hours after dosing, mean plasma 
concentrations had dropped to 0.25 + 0.08p,g
equiv.ml-1 after which a decline with a 
half-life of 29.4 hours was seen with the last 
measured concentration of 0.06 + 0.02jxg
equiv.h.ml-1 at 72 hours. The area under the 
plasma time curve extraploated to infinite time 
was 22.14[ig equiv.h.ml-1.
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TABLE 6.3 : BASIC PHARMACOKINETIC ESTIMATES ON THE MEANED 
PLASMA RADIOACTIVITY VERSUS TIME DATA OBTAINED FROM RATS, 
DOGS, RHESUS MONKEYS AND BABOONS DOSED WITH [14C]-780SE
(Smg.kg-1)
ANIMAL Rat Dog Baboon Monkey
Parameter
C x 0.31 4.84 0.28 0.33
X1 0.015 0.118 0.024 0.043
Cz - - 10.13 15.03
^2 - - 0.62 1.08
0.80 1.52 3.11 8.04
tie (h) 44.9 5.9 29.4 16.1
t|a (h) 0.86 0.46 0.22 0.09
tiag (h) 0 0.4 0.4 0.5
-1
*AUC (ng equiv.h.ml ) 19.87 36.06 22.14 14.71
Cmax (^9 equiv.ml”1) 0.30 3.60 4.54 5.28
tmax (h) 10
*AUC calculated by sum of exponentials.
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6.2.4 Distribution in rhesus monkey
The mean plasma radioactivity-time profile bore 
a closer resemblance to that of the baboon than 
the other species (Figure 6.1). After the peak, 
there was a sharp decline followed by a terminal 
phase (half-life 16.1 hours) to a mean last 
measured value of 0.05 + 0.02*ig equiv.ml”1 at 48 
hours after dosing. Based on mean data, the 
area under the plasma concentration—time curve 
extrapolated to infinite time was 14.71 \iq 
equiv.h.ml”1 .
6.3 The Fate of the Radioactive Label
The metabolic profiles were investigated in 0-24 hour 
pooled urines, from both male and female animals of 
each species, before and after enzyme hydrolysis. By 
24 hours, the majority of urinary excretion of 
radioactivity had occurred (Table 6.6) thus, as with 
the human study (Chapter 5) only 0—24 hour urine was 
used for metabolic profiling. The quantification of 
the metabolites is shown in Tables 6.4 and 6.5. The 
identification of metabolites in man has been discussed 
previously (Chapter 5.4) and the metabolite numbers in 
animals correspond chromatographically with those in 
man. Thus metabolites N3 (and N 6) , N4,.N7, N 8 and N9 
have been assigned the identities 1- (m-trifluoro- 
methylphenyl)-N-(2-hydroxyethyl)-2-aminopropane (2422, 
free base and salt), 1- (m-trifluoromethylphenyl)
-N-carboxymethyl-2-aminopropane (21475), m-trifluoro 
methylhippuric acid, norfenfluramine and 1- (m-trifluo­
romethylphenyl) -1- hydroxypropan-2-one respectively.
6.3.1 Metabolites in rats
Eight radioactive components were separated. 
There were no qualitative and very small
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quantitative differences between male and female 
urinary metabolic profiles both before and after 
hydrolysis. The major metabolite before and 
after hydrolysis was m-trifluoromethylhippuric 
acid which accounted for 27.3% and 24.4% in 
males and females respectively before hydrolysis 
and a slight increase to 32.3% and 26.9% after 
hydrolysis. S1475 accounted for 19.1% and 20.0% 
of urinary radioactivity before hydrolysis and
17.9% and 19.8% after in males and females
respectively. Other major metabolites before 
hydrolysis were the hydroxypropan-2-one (15.0% 
and 11.3% respectively), norfenfluramine (15.2% 
and 15.6% respectively) and 2422 free base
(12.0% and 10.8% respectively). Also present, 
in both hydrolysed and unhydrolysed urine, were 
Metabolites Ni, N5 and 2422 salt, but each at a 
level of less than 10% with little variation on 
hydrolysis. Metabolite N2 was not present. On 
hydrolysis only two major quantitative changes 
were seen. Firstly the hydroxypropan-2-one was
increased to 24.7% and 23.2% respectively. 
These increases were offset quantitatively by 
the disappearance of metabolite N3 thus it would 
appear that this metabolite was not 2422 free 
base but a conjugate of the hydroxypropan-2-one 
since the abundance of the other metabolites did 
not change appreciably on hydrolysis. There was 
also chromatographic evidence that m-trifluoro- 
methylbenzoic acid was present in the metabolite 
N9 position, thus metabolite N3 may also have 
been a conjugate of the benzoic acid.
6.3.2 Metabolites in dog
Nine radioactive components were separated out. 
21475 was the major component in the urine of 
male animals both before (28.3% and after
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(30.6%) hydrolysis. Female animals had lower 
amounts (13.5% before and 14.2% after 
hydrolysis). Metabolite Nl was appreciably 
depleted on hydrolysis, from 13.1% to 1 .6% in 
males and 15.9% to 4.6% in females. Metabolite 
N3 accounted for 18.2% and 24.4% of unhydrolysed 
urinary radioactivity in males and females 
respectively and slightly less (13.8% and 22.7% 
respectively) after hydrolysis suggesting that 
Metabolite N3 might in fact have been a mixture 
of 422 free base and conjugated material 
particularly in male animals. Metabolite N7 
(m-trifluoromethylhippuric acid) increased on 
hydrolysis from 10.5% to 14.3% in males and 9.0% 
to 15.2% in females as did the 
hydroxypropan-2-one (8.5% to 12.6% and 6.6% to 
11.7% respectively). Norfenfluramine, however, 
did not change on hydrolysis with 12.1% and 
13.0% in males and females respectively before 
hydrolysis and 10.6% and 11.7% after. 2422 salt 
increased on hydrolysis from 1.9% in males and 
females to 13.3% and 6.1% respectively.
Metabolite N5 was more abundant in females (9.6% 
and 10.6% before and after hydrolysis) than in 
males (2.5% and 2.9% before and after
hydrolysis). Metabolite N2 was only present 
(2.3%) in unhydrolysed urine of females.
6.3.3 Metabolites in baboon
Nine radioactive components were separated from 
the urinary extracts of which five each 
accounted for more than 10% of the 
radioactivity. The major metabolite (21475) 
accounted for 31.3% and 22.6% in males and 
females respectively before hydrolysis and 31.9% 
and 28.1% respectively after hydrolysis.
Metabolite Nl was decreased on hydrolysis in
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both males' urine (24.9% to <1.0%) and females' 
(17.9% to <1.0%). 2422 salt increased on
hydrolysis of males' urine (8.5% to 35.6%) and 
also with females' urine (28.8% to 43.4%) . 
Metabolite 8 accounted for 13.0% and 15.1% of 
the activity of unhydrolysed urines of males and 
females respectively and decreased appreciably 
on hydrolysis (7.2% and 6.5% respectively). The 
hydroxypropan-2-one (13.1% and 11.2% in males 
and females) also decreased after hyrolys is 
(9.6% and 7.2% respectively). Metabolites N2, 
N5 2422 free base and m-tr if luoromethylhippur ic 
acid were all minor each accounting for less 
than 5% of urinary radioactivity with no 
particular differences between sexes or between 
unhydrolysed and hydrolysed profiles.
6.3.4 Metabolites in rhesus monkey
Seven radioactive components were seen in
unhydrolysed urine with minor qualitative and 
quantitative differences between the sexes. 
Norfenfluramine and m-trifluoromethylhippuric 
acid are present in the males' urine (1 .3% and 
3.9% respectively) but not in the females'
whereas metabolites N5 and 2422 salt were 
present in females (1.4% and 5.7% respectively) 
but not in males. The major metabolite (Nl)
accounted for 66.4% and 59.4% in males and 
females respectively. 21475 was also important 
(16.7% and 19.5%). The males' urine contained
more of metabolite N2 (4.8%) than the females' 
(1.7%) f whereas there was less of 2422 free base 
(3.7% and 9.2% respectively). The hydroxy- 
propan-2-one accounted for 1.8% in males and 
1 .2% in females.
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Hydrolysis resulted in nine separate components 
and a decrease in Metabolite 1 to <1.0% in males 
and females. S1475 changed very slightly (16.4% 
and 24.2% in males and females) but S422 salt 
increased considerably on hydrolysis from <1 .0% 
and 5.7% respectively to 66.0% and 55.0% 
respectively. Metabolites N2, N5, m-trifluoro
methylhippuric acid, the hydroxypropan-2-one and 
norfenfluramine were all present but each 
accounted for less than 5% of the radioactivity. 
The hydroxypropan-2-one was slightly increased 
on hydrolysis from 1.8% and 1 .2% in males and 
females respectively to 3.8% in both sexes.
The Excretion of Radioactivity into Urine and Faeces
The recovery of radioactive dose in the urine and 
faeces of each species was determined. The urinary
recoveries are summarised in table 6.6 and the 
faecal data in table 6.7 with cumulative excretion data 
in table 6.8 and overall recoveries in table 6.9.
6*4.1 The excretion of radioactivity in the rat
A mean total of 90.8% of the radioactive dose
was recovered in the urine and faeces within 96
hours of dosing. Of that total, 75.6% was in
urine and 15.1% in faeces. The majority of the 
radioactivity was excreted in the first 24 hours 
after dosing with 55.4 + 4.7% in urine and 8.3 + 
0.7% in faeces. A total of 21.8% of the dose 
was recovered over the 24 to 48 hour period, the 
majority of this was in urine (16.0 + 2 .8%) with
5.8 + 0.9% in faeces. By 72 hours 74.5% had 
been recovered in urine and 14.9% in faeces 
leaving less than 2% of the dose to be excreted 
over the 72 to 96 hour period.
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6.4.2 The excretion of radioactivity in dog
The mean total recovery was 96.1% of the dose, 
with 80.7% in urine and 15.4% in faeces. The
dose was predominantly excreted over the first 
24 hours and mostly in urine (75.5 + 7.7%).
Faecal excretion over the first 24 hours 
accounted for 14.2 + 5.2% of the dose and only 
an extra 1.2% was recovered up to 96 hours. By 
48 hours, 79.5% had been recovered in urine 
alone and only a further 1.1 + 0 .2% and 0.2 +
0.1% was found at 72 and 96 hours respectively.
6.4.3 The excretion of radioactivity in baboon
The mean total recovery of dose was 87.6%. 
Faecal excretion was minor with a total mean 
recovery of 0.6% over the 96 hour collection 
period and no indication of delayed excretion.
Thus the important route of elimination was
renal and, in urine, most of the dose (75.6 + 
2.0%) was found after 24 hours. By 48 hours a 
further 7.4 + 3.7% was recovered in urine
resulting in an mean total cumulative recovery 
at this time of 83.5%. A further 3.0 + 1.0% by 
72 hours and 1.0 + 0.4% by 96 hours, together 
with a mean faecal recovery of 0 .1% over the 
48-96 hour period, accounts for the overall
total.
6.4.4 The excretion of radioactivity in the rhesus 
monkey
The mean overall recovery was less than that of
the other species (76.4%). Like the baboon,
very little radioactivity was found in faeces of 
which the majority was recovered over the first 
24 hours (0.7 + 0.3%). Most of the dose was
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TABLE 6.8 : THE MEAN CUMULATIVE EXCRETION OF RADIOACTIVITY 
INTO THE URINE AND FAECES OF RAT, DOG, BABOON AND RHESUS 
MONKEY FOLLOWING ORAL ADMINISTRATION OF [14C]-780SE (Smg.kg-1)
Urinary Excretion
SPECIES Rat Dog Baboon Monkey
Period (h) % of dose (mean)
0 - 2 4 55.4 75.5 75.6 64.8
0 — 48 71.5 79.5 83.0 70.1
0 - 7 2 74.5 80.5 85.9 74.0
0 - 96 75.6 80.7 87.0 75.4
Faecal Excretion
SPECIES Rat Dog Baboon Monkey
Time Period (h)
0 - 2 4
0 - 4 8
0 - 7 2  
0 —  96
8.3
14.1 
14.9
15.1
% of dose (mean)
14.2 0.3
15.2 0.5
15.3 0.6
15.4 0.6
0.7
0.9
1.0
1.1
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TABLE 6.9 : THE MEAN TOTAL CUMULATIVE EXCRETION OF 
RADIOACTIVITY INTO THE URINE AND FAECES OF RAT, DOG, BABOON 
AND RHESUS MONKEY FOLLOWING ORAL ADMINISTRATION OF 
[14C]-780SE (Smg.kg-1)
SPECIES Rat Dog Baboon Monkey
Time Period (h) 
0 - 2 4  
0 —  48 
0 - 72 
0 - 9 6
% of dose (mean)
63.7 
85.5 
89.4
90.8
89.8
94.7
95.8
96.1
75.9
83.5
85.5
87.6
65.5
71.0
75.0
76.4
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recovered in urine within 24 hours (64.8 +
12.0%). By 48 hours a further 5.3 + 1.5% in 
urine brought the mean overall total recovery to 
71.0%. Over the 48-72 hour period, 3.8 + 1.0% 
of the dose was seen in urine and 0 .1% in 
faeces. By 96 hours, a further 1.4 + 0.3% in 
urine and 0.1% in faeces brought the mean total 
recoveries to 75.4% and 1.1% respectively.
6.5 Discussion of Results and Comparison with Human Data
The purpose of these experiments has already been 
explained regarding the need to validate the choice of 
species for long term toxicity studies. This section 
discusses the results presented in this chapter with 
regard to the equivalent mean data obtained for man
(Chapter 5). The dose level in man (2.Smg.kg""1) was 
lower than that in other species (Smg.kg”1) but the 
small dose differences allow comparison between 
species.
6.5.1 The absorption of radioactivity
Absorption of radioactivity was extensive in all 
species as reflected in the low faecal
recoveries. However, species differences were 
seen in that man, baboon and rhesus monkey all
excreted <2% of the radioactive dose in faeces 
whereas rat and dog showed a considerably higher 
faecal recovery. All species showed 
radioactivity in plasma at 30 minutes after
dosing. The absorption of radioactivity was
fastest in the rhesus monkey and slowest in the 
rat with baboon amd man having similar 
absorption half-lives. The maximum plasma levels 
of radioactivity were reached at 10 hours after 
dosing in rats but between 1 and 2 hours in all 
other species. Slower absorption in rat
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probably resulted in the much lower peak levels 
than those seen in other species. Allowing for 
the dose differences and assuming linear 
kinetics, man and rhesus monkey showed similar 
peak levels which were higher than those for 
baboon and dog (Figure 6.1).
6.5.2 The distribution of radioactivity
After peak plasma concentrations of 
radioactivity, the rat and the dog showed a 
monoexponential decline with mean half-lives of 
44.9h and 5.9h respectively. Baboon, rhesus 
monkey and man all had biexponential decline 
curves with mean terminal half-lives of 29.4h, 
16.Ih and 34.Oh respectively. The plasma 
radioactivity versus time profile for rhesus 
monkey most closely resembled that of man 
(Figure 6.1). The mean areas under the plasma 
radioactivity versus time curves extrapolated to 
infinite time ranged from 14.71pg equiv.h.ml”1 
in rhesus monkey to 36.06^ig equiv.h.ml*"1 in dog 
with the baboon having the value closest to that 
of man. However, the data should be normalised 
for the dose level which raises the mean area 
under the curve for man to approximately 63|ig 
equiv.h.ml 1 which is considerably higher than 
the other species.
6.5.3 The radioactive urinary metabolites
The radioactive urinary metabolites separated 
and quantitated in man were m-trifluoromethyl- 
phenyl-N-carboxymethyl-2-aminopropane (66%), m- 
trifluoromethylhippuric acid (1%), m-trifluoro- 
methylphenyl-2-aminopropane (norfenfluramine 1%)
1- (m-trifluoromethylphenyl)-l-hydroxypropan-2-one
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free (2%) and conjugated (3%) and m-tr if luoro- 
methylphenyl-N-(2-hydroxyethyl)-2-aminopropane 
as its free base (3%) , salt (2%) and as a 
conjugate 19%). The metabolic profiles of rat, 
dog and baboon showed these plus two other 
unidentified metabolites (N2 and N5) . In 
addition, the quantitation showed the presence 
of at least one other conjugated metabolite and 
there was evidence of m-trifluoromethylbenzoic 
acid. The quantitative and qualitative 
comparison of urinary metabolites both before 
and after enzyme hydrolysis (Figures 6.2 and
6.3) show that the rhesus monkey bore the
closest resemblence to man in this aspect.
6.5.4 The excretion of radioactivity
In all species, the majority of the recovered 
dose was excreted into urine within the first 24 
hours after dosing. In the rat and the dog 
there was a significant elimination of
radioactivity in the faeces (approximately 15% 
of the dose) whereas in monkey, baboon and man 
the faecal recoveries were all less than 2% of 
the dose.
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CHAPTER 7 
CONCLUSIONS
This final chapter summarises the extent of studies on 
fenfluramine and 780SE so far f the results obtained and the 
significance of these findings in the understanding of the 
metabolism and kinetics of these compounds. The findings 
are discussed in relation to known data on structurally 
related compounds. The chapter is divided into the 
following sections:-
7.1 The extent of the studies described in this thesis
7.2 Summary of [^C]-fenfluramine metabolism and kinetics 
7.3. Summary of [^C]-benfluorex metabolism and kinetics
7.4 The absolute pharmacokinetics of d-fenfluramine
7.5 Enantiomeric differences in the metabolism and kinetics 
of fenfluramine
7.6 Routes of metabolism of fenfluramine in man
7.7 Routes of metabolism of 780SE in man
7.8 The effect of ring and nitrogen substitution on the
metabolism and kinetics of amphetamine analogues in man
7.9 Summing up
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7.1 The Extent of the Studies
7.1.1 Fenfluramine
Fenfluramine isomers and the racemate, 
radio-labelled in the carbon 1 position, were 
separately administered to male and female 
volunteers. The recovery of radioactive dose in 
urine and faeces was ascertained and the 
distribution of radioactivity in plasma and red 
blood cells was described. The major urinary 
metabolic products have been identified by 
co-chromatography and mass spectrometry. 
Fenfluramine and norfenfluramine were analysed 
in plasma by gas chromatography and the 
comparative kinetics of the isomers described. 
Absolute pharmacokinetics of the d-isomer were 
determined in a separate non-radioactive study 
in 12 volunteers.
7.1.2 780SE
Racemic 780SE, labelled with carbon 14 in the 1 
position, was administered orally to male and
female volunteers, rats, dogs, baboons and
rhesus monkeys. The recovery of radioactivity 
in urine and faeces was determined for all
species and the distribution of radioactive dose 
in plasma was determined. Metabolites were 
identified in the urine and plasma of humans and 
the plasma concentrations of metabolites 
described and compared at various times after
dosing.
14
7.2 Summary of [ C]-Fenfluramine Metabolism and Kinetics
Metabolic and kinetic data, obtained from studies in
human volunteers dosed with radiolabelled dl-, d- and
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1-fenfluramine, is summarised in this section and
reference is made to Tables 7.1, 7.2 and 7.3.
7.2.1 The absorption of radioactivity and parent drug 
from the gastro-intestinal tract
The radioactive doses were all well absorbed in 
both subjects as shown by the very high urinary 
recoveries (>90%). Maximum plasma concentrations 
of radioactivity were reached at 3 to 4 hours 
after dosing. However, in both subjects the 
half-life of absorption of radioactivity was 
faster for the 1-isomer than for the d form; 
there was insufficient data to ascertain the 
absorption half-life of the parent drug in each 
case. The maximum plasma levels of radioactivity
were higher for d-fenfluramine than for the
other, as was most clearly demonstrated by the % 
dose I-1 values shown in Table 7.1. This
phenomenon was not seen with actual fenfluramine 
concentrations, indeed for the male subject the 
d-fenfluramine peak concentration was
considerably lower than that of the 1-isomer. 
The lower relative peak levels of d-fenfluramine 
to total radioactivity may reflect a more 
extensive first pass metabolism of the d-isomer, 
the extent of absorption being the same.
7.2.2 The distribution of total radioactivity, 
fenfluramine and norfenfluramine
Total radioactivity distributed into red blood 
cells but comparison of the radioactive levels 
in red cells and plasma clearly showed that the 
ratio of red cell levels to plasma levels was 
consistently higher for 1-fenfluramine than for 
the d-isomer (Figures 7.1 and 7.2). This 
indicated a greater abundance of lipophilic
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radioactive material in blood and thus probably 
a difference in the metabolic profile in blood.
The areas under the total radioactivity versus 
time curves for the 1-isomer were slightly 
higher than those for d-fenfluramine in each 
subject and the sum of the areas for the isomers 
was very similar to the area for the racemate in 
each subject. The difference between the 
isomers, in areas under the plasma concentration 
time curve, was more marked with parent drug 
itself, with 1-fenfluramine showing the greatest 
values particularly in subject AT. Areas under 
the 1-norfenfluramine plasma-time curves were 
also higher than the respective d-fenfluramine 
values. The areas for the racemate were 
approximately the sums of those for the isomers.
The additive nature of the d- and 1-isomer 
kinetics in the data for the racemic compound 
was further exemplified by studying the decline 
of levels of radioactivity, and parent drug in 
plasma. For all doses, there was a biphasic 
elimination of radioactivity with the terminal 
half-lives for the 1-fenfluramine dose being 
considerably longer. Elimination of
dl-fenfluramine was biphasic with a terminal 
half-life which closely resembled that of
1-fenfluramine which, like d-fenfluramine, 
declined monoexponentially. The half-life of 
d-fenfluramine was much shorter. The plasma 
concentration versus time curves for 
dl-fenfluramine were a close approximation to 
the sum of those for the isomers. By comparing 
areas under the plasma concentration versus time 
curves it can be seen that there was a greater 
abundance of 1-fenfluramine and 1- 
norfenfluramine in plasma than the d-isomers for
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equivalent doses. This is in accord with the 
difference seen in red blood cell to plasma 
ratios of total, radioactivity.
7.2.3 The urinary metabolites of fenfluramine
Four major metabolites and the parent drug were 
positively identified and quantitated in urine 
up to 48 hours after dosing with either 
radioactive fenfluramine isomer (Figure 7.3). 
The de-ethylated metabolite, norfenfluramine, 
was the only compound identified which retained 
the amino group. The other metabolites were 
products of oxidative deamination,
1 - (m-trifluoromethylphenyl)propane-1f 2-diol and 
m-trifluoromethylbenzoic acid. The glycine 
conjugate of the benzoic acid, m-trifluoro­
methylhippur ic acid was also present. The diol 
was present entirely in conjugated form. 
Enzymic hydrolysis (48 hour incubation) was 
found to liberate only about 50% of the diol 
liberated by acid hydrolysis of the urine of 
dl-fenfluramine subjects, indicating either 
multiple species of conjugates or a stable 
conjugate (eg. ether glucuronide).
Although there are no qualitative differences 
between d- and 1-fenfluramine metabolism, there 
were marked quantitative differences. 
Fenfluramine was less abundant in the urine of 
the d-fenfluramine subjects (mean 6.4% up to 48 
hours) than with the 1-fenfluramine (mean 9 . 5 %)  
indicating a more extensive metabolism of the 
d-isomer. There was also less d-norfenfluramine 
(mean 3 . 9%)  than 1-fenfluramine ( 5 . 4 % ) .  The 
ratio of fenfluramine to norfenfluramine was 
less for the d-isomer than for the 1-isomer.
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FIGURE 7.3  : The U rin ary  Metabolites 
of Fenfluramine
NH— C H — CH
1 - 2  3
CH2— CH — CH3
Fenfluramine
& NH2ICH— CH — CH Norfenfluramine
CF
OH
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c h 2- c h - c h 3
m - 1 rif luoromethy Iphenylpropan - 2 - ol
OH OH
I I
CH— CH— CH
1 - (m - 1 rif luoromethylphenyl )propane -1.2 - diol
C— OH
m-trifluoromethylbenzoic acid
C — NH — CH2— C— OH
m- tnfluoromethylhippuric acid
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Conversely, the deaminated products of 
d-fenfluramine metabolism were more abundant 
than those of 1-fenfluramine. The diol was the 
major metabolite in each case. The urinary pH 
did not differ markedly between the subjects.
7.2.4 The elimination of total radioactivity, 
fenfluramine and norfenfluramine
Faecal elimination was low (<1% of the dose).
Total radioactivity was excreted into urine more
quickly after [^C]-d-fenfluramine than with the
1-isomer, up to 48 hours after dosing. After
seven days the mean total recoveries were only
marginally different (92% of dose after
d-fenfluramine; 90% after 1-fenfluramine). The
female subject showed higher total urinary
recoveries of fenfluramine and norfenfluramine
than the male. The non-radioactive data showed
higher total urinary recoveries of
1-fenfluramine and 1-norfenfluramine than with
the d-isomer, particularly in the female
subject. Although the final recoveries of
radioactivity were similar, the excretion rates
were higher for the d-fenfluramine doses earlier
in the collection period (up to 48 hours) . This
phenomenon, together with the non-radioactive
data, supports the observation of higher
recoveries of deaminated metabolites in 0-48
hour urine. The urinary excretion of l-(m-tri-
fluoromethylphenyl)propane-1,2-diol, following 
14
[ C]-dl-fenfluramine was monitored by gas 
chromatography. In the male subject, 34.7% of 
the dose was totally recovered as the diol and 
in the female this figure was 34.0%. After 48 
hours these recoveries were 20.7% and 22.4% 
respectively, rather higher than the respective 
radioactive recoveries at 48 hours (15.0 and
295
16.0% of dose). However, addition of the 
residual unextracted radioactivity (6.4% and 
6.4% of dose) gave more comparable results.
This indicates, perhaps, incomplete
deconjugation of the samples for radioactive 
analysis, the conjugated diol being 
unextractable using the procedure described.
1 4
7.3 Summary of [ C]-780SE Metabolism and Kinetics
Radioactive 780SE studies have been carried out in man, 
rhesus monkey, baboon, beagle dog and wistar rat. The 
results are summarised here under the general headings 
of absorption, distribution, metabolism and excretion.
7.3.1 The absorption of radioactivity from the
gastro-intestinal tract
The high urinary and low faecal recovery of 
radioactivity in man, baboon and rhesus monkey 
is indicative of the high extent of absorption 
of the dose in these species (Table 7.4). 
However, it does not relate to the availability 
of the parent drug itself and, indeed, plasma 
metabolic profile studies in man indicated that 
780SE is not available but acts as a pro-drug 
for norfenfluramine and N-hydroxyethyl- 
norfenfluramine which have been shown to be
pharmacologically active molecules (Turner et 
al., 1982) . Absorption was rapid in all 
species, except the rat, with peak plasma
concentrations occurring at 1-2 hours after 
dosing. In the rat, a mean peak concentration 
of 0.30^ ig equivalents .ml"1 was reached at 10 
hours after dosing. This peak concentration was 
lower than that seen in the other species. 
Correcting for the dose differences (normalised 
for body weight), assuming linear kinetics, the
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TABLE 7.4 : MEAN KINETIC PARAMETERS OF TOTAL RADIOACTIVITY 
AND URINARY METABOLITE QUANTITATIONS IN VARIOUS SPECIES 
FOLLOWING ORAL DOSES OF [14C]-780SE
SPECIES MAN RHESUS
MONKEY
BABOON BEAGLE
DOG
WISTAR
RAT
PARAMETER
Dose
UNITS
mg.kg”1 2 5 5 5 5
Cmax lig equiv. 
ml”1 2.21 5.28 4.54 3.60 0.30
Tmax 2 1 1 2 10
No of exponentials 2 2 2 1 1
tàa hr 0.21 0.09 0.22 0.46 0.86
H e hr 34.0 16.1 29.4 5.9 44.9
AUC Hg equiv. 
hr.ml"1 23.33 14.71 22.14 36.06 19.87
Urinary
excretion % dose 93.6 75.4 87.0 80.7 75.6
Faecal
excretion % dose 0.5 1.1 0.6 15.4 15.1
Urinary 
Met 1* % 20.2 61.9 44.3 28.0 2.8
Urinary 
Met 2* % 70.1 20.3 30.0 22.4 18.9
Urinary 
Met 3* % 2.0 1.9 6.9 11.2 18.9
Urinary 
Met 4* % 4.6 3.8 8.4 12.2 24.0
Urinary 
Met/Other % 3.1 12.1 10.4 16.2 35.4
♦Metabolite quantitations refer to enzyme hydrolysed urine 
Met Is 1-(m-trifluoromethylphenyl)-2-N-hydroxyethyl-2-aminopropane 
Met 2: 1 - (m-trifluoromethylphenyl)-N-carboxymethyl-2-aminopropane 
Met 3: Norfenfluramine
Met 4: 1 - (m-trifluoromethylphenyl)-l-hydroxypropan-2-one
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highest mean peak concentration of total
radioactivity was seen in man (approximately
-I6. 6|ig equivalents .ml ) with the rhesus monkey 
having the next highest value (5.28pg 
equivalents.ml” ).
7.3.2 The distribution of radioactivity
Correcting for dose differences, man showed the 
highest area under the plasma time curve. The 
terminal half-lives range from 5.9 hours in the 
dog to 44.9 hours in the rat with man and baboon 
comparing closely (34.6 and 29.4 hours) and the 
rhesus monkey having a lower value (16.7 hours).
7.3.3 The metabolism of [^C]-780SE
The radioactive urinary metabolites were 
compared qualitatively and quantitatively in all 
species with identities confirmed for most major 
metabolites (Figure 7.4). The metabolites in 
the plasma of a single male human volunteer have 
been measured at various times after dosing and 
plasma metabolite profiles have been plotted.
Some qualitative and quantitative differences 
were found between the species with regard to 
the radioactive metabolites found in their 
urine. The identified metabolites were 1-(m-tri 
fluoromethylphenyl)-l-hydroxypropan-2-one, m-tri 
fluoromethylphenyl-2-aminopropane (norfen­
fluramine) , 1- (m-trifluoromethylphenyl)-N-2-
hydroxyethyl-2-aminopropane and 1-(m-trifluoro­
methylphenyl) -N-methyIcarboxy-2-aminopropane.
The TLC solvent system used did not separate 
1-(m-trifluoromethylphenyl)-N-2-hydroxyethyl-2- 
aminopropane and conjugated 1 - (m-trifluoromethyl 
phenyl)-l-hydroxypropan-2-one and thus enzymic
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FIGURE 7.4  : The U rin ary  Metabolites 
of Benfluorex
NH— CH,—CH OH
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NH2
I
C H — CH— CH3
Norfenfluramine
OH O
I II
CH— C — CH
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p ropan-2-one
-f2-hydroxyefhy0-
-(carboxymethyl)-
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-29-9
hydrolysis resulted in quantitative changes 
which depended on the relative amounts of those 
two metabolites present. In some hydrolysed 
urine samples further chromatographic analysis 
of isolated 1-(m-trifluoromethylphenyl)-1- 
hydroxypropan-2-one using TLC solvent system 2 
(Table 2.5) resolved it into 2 components one of 
which co-chromatographed with trifluoro 
methylbenzoic acid. Although mass spectral data 
is not available, chromatographic data showed 
the trifluoromethylbenzoic acid to be present 
after hydrolysis of the rat and baboon urine.
The most abundant urinary metabolite varied 
depending on the species. In the rhesus monkey, 
the estérification product 1-(m-trifluoromethyl 
phenyl)-N-2-hydroxyethyl-2-aminopropane was most 
abundant and was eliminated mainly conjugated. 
In female baboons and dogs unconjugated
1-(m-trifluoromethylphenyl)-N-2-hydroxyethyl-2- 
aminopropane was the major elimination product 
with hydrolysis making little difference to its 
abundance, whereas hydrolysis products made no 
difference to the fact that the oxidation 
product 1-(m-trifluoromethylphenyl)-N-methyl
carboxy-2-aminopropane was predominant in the 
male animals of these species. In the rat, the 
major urinary elimination product remained 
unidentified. Apart from 1 - (m-trifluoromethyl 
phenyl)-N-2-hydroxyethyl-2-aminopropane the only 
other pharmacologically active molecule present 
was norfenfluramine (Turner et al., 1976) and 
the rat, dog and baboon showed a relatively high 
abundance of this metabolite in urine 
(10.6-20.9% with little sex or species 
variation) compared with the 0-2.2% seen in 
rhesus monkey.
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Compared to man, no one species exhibited a 
quantitatively comparable urinary metabolic 
profile. However, taking into account the 
pharmacologically active molecules (l-(m-tri 
fluoromethylphenyl)-N-2-hydroxyethyl-2-aminopropane 
and norfenfluramine) and the quantitatively 
important metabolites (>5%) comparisons can be 
drawn. The rat bore few resemblences to man 
having very little l-(m-trifluoromethylphenyl)- 
N-2-hydroxyethyl-2-aminopropane and a lot more 
norfenfluramine. Hydrolysis resulted in a 
depletion in metabolite N3 and an increase in 
metabolite N9 which was subsequently found to be 
composed of both 1 - (m-trifluoromethylphenyl)-1- 
hydroxypropan-2-one and trifluoromethylbenzoic 
acid and the quantities involved indicated that 
the lower Rf metabolite was in fact a conjugate 
of trifluoromethylbenzoic acid. The major 
metabolite in rat was not quantitatively 
important in man.
The dog exhibited a sex difference in the 
relative quantities of urinary metabolites but, 
even though the males showed the same major 
metabolite, 1 - (m-trifluoromethylphenyl)-N-
methylcarboxy-2-aminopropane, considerable
differences were seen with the amounts of 
norfenfluramine, the unidentified metabolite 
(N5) and 1 - (m-tr if luoromethylphenyl)-1--
hydroxypropan-2-one. Furthermore, in the male 
animals, 1 - (m-trifluoromethylphenyl)-1-hydroxy
propan-2-one increased on hydrolysis concomitant 
with a decrease in another metabolite (N3) 
suggesting the presence of
trifluoromethylbenzoic acid although this was 
not confirmed chromatographically.
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The baboon data was difficult to interpret 
because of poor chromatographic separation of 
some components and an apparent decrease, on 
hydrolysis, of norfenfluramine and 1 - (m-tri 
fluoromethylphenyl)-l-hydroxypropan-2-one. These 
observations warrant further investigation of 
the isolated components as it appeared that the 
metabolic profile was not as straight-forward in 
this species as in the others investigated.
The most abundant metabolite in the rhesus 
monkey urine was 1 - (m-trifluoromethylphenyl)-N-
2-hydroxyethyl-2-aminopropane which was
eliminated as a conjugate with 1-(m-trifluoro 
methylphenyl)-N-methylcarboxy-2-aminopropane 
also being quantitatively important.
Norfenfluramine was much less abundant than in 
the other animal species but compared closely 
with man. On hydrolysis the quantity of 1-(m- 
trifluoromethylphenyl)-l-hydroxypropan-2-one 
more than doubled but did not become very 
abundant (3.8%) again, unlike the other animal 
species but very similar to man. So, in 
conclusion, although there were quantitative 
differences the urinary metabolic profile in the 
rhesus monkey most resembles that in man.
7.3.4 The elimination of radioactivity
The elimination of radioactivity was 
predominantly renal in all the species studied. 
However, whereas in the primates less than 2% of 
the radioactive dose was recovered in faeces, in 
the rat and dog the recoveries were 15.1% and 
15.4% respectively. This higher figure could be 
a result of either a lower absorption of the 
dose or biliary elimination of metabolic
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products. In all species, most of the
radioactivity was eliminated into urine within 
the first 24 hours after dosing.
7.4 The Definitive Pharmacokinetics of d-Fenfluramine
A continuous intravenous infusion of approximately 20mg 
d-fenfluramine resulted in mean maximum plasma 
d-fenfluramine concentrations of 30.3 + 6.3ng.ml~1. At 
9.3 + 8.5 hours after the start of the infusion, peak 
d-norfenfluramine concentrations of 12.5 + 4.4ng.ml-1 
were reached. After cessation of the infusion the mean 
half-life of the terminal elimination phase of 
d-fenfluramine and d-norfenfluramine was 15.53 + 6.59 
hours and 31.13 + 15.81 hours respectively with 7 of
the 12 subjects showing a biphasic decline. The mean
plasma clearance of d-fenfluramine was calculated to be
745.2 + 232.lml.min and the volume of distribution 
based on area was 913.0 + 378.9 litres.
The plasma fenfluramine concentration versus time 
profile after oral dosing (30mg d-fenfluramine), of 
both a solution and capsule formulation, was not
significantly different from the intravenous profile 
indicating that the intravenous infusion successfully 
mimicked the oral doses both in terms of disposition 
and dose. Comparison of data for the capsule and 
solution showed that the capsule had a high relative 
availability and as the results for both formulations 
were very similar only the solution data is discussed 
here. Maximum plasma concentrations of d-fenfluramine 
and d-nor fenfluramine of 30.5 + 7.1ng.ini*’1 and 16.8 + 
3. Ong .ml 1 were reached after 3.04 + 1.45 and 7.58 + 
5.65 hours respectively. Comparing the areas under the 
plasma time curve for the oral and intravenous doses an 
absolute bioavailability of 82.93 + 16.67% was
calculated. The low faecal recovery (<1%) of
radioactivity following oral administration of a
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solution of [^C]-d-fenfluramine showed that the drug 
was initially absorbed thus the absolute 
bioavailability figure indicated that the drug was
subject to gut microfloral, gut wall or hepatic first 
pass metabolism. The metabolites of fenfluramine are 
products of various oxidative and conjugation reactions 
none of which have been associated with gut microbes or 
gastro-intestinal mucosal cells so hepatic first pass 
metabolism seems to be the more feasible explanation. 
The terminal half-lives of d-fenfluramine and
d-norfenflurmine were 19.69 + 10.51 and 47.26 + 16.47 
hours respectively.
The relatively high non-renal clearance of 
d-fenfluramine indicates that metabolism is an
important factor in the elimination of the drug. 
Non-radioactive analysis of human urine (Chapter 4) 
indicated that the recovery of d-fenfluramine in urine 
following oral dosing of [^C]-d-fenfluramine accounted 
for 6.0 and 10.6% of the administered dose in the male 
and female respectively which also reflects the 
importance of metabolism. The renal clearance of the 
drug was calculated (plasma clearance x fraction of 
dose eliminated) to be 45 and 79ml.min~^ in the male 
and female subjects respectively.
The primary metabolic product of fenfluramine is likely 
to be the de-ethylated product norfenfluramine based on 
metabolic studies of other N-alkylated phenylpropyl 
isoamines (Beckett and Brookes, 1967; Beckett and 
Brookes, 1970; Caldwell, 1976; Bring and Millburn, 
1979). Thus, as d-fenfluramine undergoes first pass 
metabolism, a peak concentration of norfenfluramine in 
plasma would be expected at or slightly before the time
of the fenfluramine peak concentration (Houston, 1982).
—\
However, the plasma data from both the radiaoctive and 
non-radioactive studies clearly shows norfenfluramine 
peaking several hours after fenfluramine.
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Unfortunately, the majority of the radioactivity 
present in plasma has remained unidentified because of 
a lack of sufficiently sensitive non-radioactive 
analytical techniques. However, 1-(m-trifluoromethyl­
phenyl) propane-1,2-diol was monitored in urine 
following oral doses of radiolabelled racemic 
fenfluramine (Chapter 3) and the results showed that 
maximum excretion rates of this metabolite occurred 
over 36 to 48 hours and 4 to 8 hours in the male and 
female subject respectively, which indicated that the 
peak plasma levels of this metabolite also occurred 
later than those of fenfluramine. Peak plasma 
concentrations of radioactivity occurred at 3-4 hours 
after radioactive doses of either d-, 1- or
dl-fenfluramine. Using mean [14C]-d-fenfluramine data 
from the both subjects (Chapter 4) plasma time curves 
can be constructed for total radioactivity, 
d-fenfluramine, d-norfenfluramine and unidentified 
metabolites (Figure 7.5). This plot would suggest that 
the unidentified fraction is the most likely candiate 
as the first pass product of d-fenfluramine. The 
urinary data on the diol indicated that this metabolite 
was not a major component of the unidentified fraction 
in plasma at the peak times. This data would suggest 
that there is another primary metabolic route of 
d-fenfluramine apart from the classical N-dealkylation 
pathway and that the diol is not a product of it.
7.5 Enantiomeric Differences in the Metabolism and Kinetics 
of Fenfluramine
Only d-fenfluramine has been administered to humans by 
the intravenous route. In the absence of intravenous 
data for 1-fenfluramine, the pharmacokinetic parameters 
of clearance and volume of distribution cannot be 
compared, so enantiomeric comparisons will be limited 
to radioactive and non-radioactive data.
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Following oral doses of [^Cj-d- and
[■^C]-1-fenfluramine, peak plasma levels of
radioactivity were reached at similar times although
the actual concentrations of radioactivity were lower
with [^^C]-1-fenfluramine than the d-isomer. A
difference in absorption rate is unlikely to explain
this difference in Cp as tm=v did not vary.max max
However, there is a higher relative concentration of
radioactivity in red blood cells after
[■^C]-1-fenfluramine indicating a higher amount of
lipid components in whole blood compared with
[■^C]-d-fenfluramine. There was very little difference
in the areas under the plasma radioactivity versus time
curves between the isomers. Although there were no
differences in the overall urinary recovery of
radioactive dose, the rate of elimination was faster
with [^C]-d-fenfluramine up to 30 hours after dosing.
In 0-48 hour pooled urine quantitative differences were
found in the relative abundances of the identified
metabolites between ["^C] -d- and [^C]-1-fenfluramine.
The d-isomer samples showed less parent drug and
norfenfluramine than those of the 1- isomer although
the ratio of the two remained the same. The abundance
of deaminated products (m-trifluoro methylated benzoic
and hippuric acids and 1- (m-trifluoromethylphenyl)
propane-1,2-diol) was greater with the d-isomer. The
d-isomer therefore appeared to undergo more extensive
metabolism and the presence of a greater proportion of
relatively polar metabolites in blood after 
14
[ C]-d-fenfluramine explains the differences in the 
relative red blood cell content of radioactivity and 
thus the differences in peak plasma concentrations.
Non-radioactive analytical data both from these studies 
and from other published work indicates an enantiomeric 
difference in the metabolism and kinetics of 
fenfluramine. Brookes (1968) and later Beckett and 
Brookes (1970) showed that, under conditions of
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controlled urinary pH, after separate administration of 
the isomers, greater urinary recoveries of 
1-fenfluramine than d-fenfluramine were found although 
recoveries of norfenfluramine were the same in each 
case. Because of the change in drug/metabolite ratios 
(d>dl>l) it appeared that stereoselectivity did occur 
however, as Jenner and Testa (1973) pointed out, the 
results could be explained by either stereoselective 
fenfluramine metabolism via another route (not 
dealkylation) or further stereoselective metabolism of 
norfenfluramine.
Jenner and Testa (1973) also described how they 
measured the urinary enantiomeric ratio of both 
fenfluramine and norfenfluramine at various times after 
oral administration of racemic fenfluramine to man. 
They were able to measure both isomers of each compound 
simultaneously using the method of Beckett and Testa 
(1972) . At various dose levels they found that the 
ratio of d- to 1-fenfluramine decreased with time 
showing a stereoselectivity in the dealkylation of 
fenfluramine. Also, after administration of racemic 
norfenfluramine, the enantiomeric ratio (d/1) of 
norfenfluramine dropped with time indicating a 
stereoselectivity in the deamination process. The 
urinary data presented in this thesis also suggests 
stereoselectivity in the metabolism of fenfluramine. 
Urine was collected without pH control and, as the 
urinary excretion of fenfluramine and norfenfluramine 
is markedly affected by urinary pH, care must be taken 
when interpreting the data. However, urinary pH was 
monitored over the first 24 hours after dosing and the 
intersubject variation in pH between the studies was 
not large enough to explain the differences seen 
between them. In order to compare the data, a plot was 
constructed (Figure 7.6) showing the enantiomeric 
ratios (d/1) of urinary excretion rates of fenfluramine 
and norfenfluramine at various times after separate
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oral doses of d- and 1-fenfluramine to the two
subjects. Despite some fluctuations there was a
definite trend towards a decrease in the ratio with 
time for fenfluramine whereas the enantiomeric ratio 
for norfenfluramine stayed more constant. The declining 
urinary enantiomeric ratio with time agrees with the 
data of Jenner and Testa (1973).
Analysis of fenfluramine and norfenfluramine in plasma 
showed some differences between the isomers. There 
were no pronounced differences between the isomers up 
to the time when peak plasma concentrations of 
fenfluramine were reached (4-6 hours after dosing) with 
one subject (male) showing a higher 1-fenfluramine peak 
concentration but the female subject showing little 
difference. Thereafter, fenfluramine concentrations
declined monoexponentially with the 1-isomer having a 
longer half-life. The areas under the plasma 
1-fenfluramine versus time curves, for each subject, 
were greater than the corresponding areas for the 
d-isomer. The difference was quite marked (mean of 95% 
higher for the 1-isomer in the two subjects) and even 
assuming total availability, ie. no first pass 
metabolism as seen with d-fenfluramine, it is apparent 
that the clearance of 1-fenfluramine, as reflected in 
the ratio of dose absorbed to area under curve, was 
less than d-fenfluramine. As d-fenfluramine is 
predominantly cleared by metabolism (section 7.4) it 
follows that a stereoselective difference exists in the 
overall metabolism of fenfluramine. Caccia et al. 
(1979) administered a single dose of racemic 
fenfluramine to healthy volunteers and measured, 
simultaneously, plasma concentrations of each isomer of 
both fenfluramine and norfenfluramine and found no 
difference between them in half-life and area under
the curve. After 10 days chronic dosing, the half-life 
of the d-isomer decreased and the area under the curve 
was approximately half that of the 1-isomer.
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These findings together with the differences shown 
between the isomers when administered separately,
suggest a possible enantiomeric interaction, indeed, 
such a phenomenon has been reported with amphetamine 
(Gal et al., 1976) and l-(2,5-dimethoxy-4-
methylphenyl)-2-aminopropane (McGraw et al., 1977). In 
9,000g supernatant fractions of rabbit liver the 
d-isomer of amphetamine or one of its metabolites
appeared to inhibit the metabolism of the 1-form
although the question of whether this phenomenon could 
account for the lower recovery of d-amphetamine in 
human urine remained unanswered. Similarly an
enantiomeric difference was found in the metabolism of 
racemic 1-(2,5-d ime thoxy-4-me thyIpheny1)-2-aminopropane 
by 10,000g rabbit liver homogenate supernatant with the 
d-isomer being metabolised faster. However, as with 
amphetamine, if each isomer was incubated separately, 
no difference in the rate of metabolism was found. 
Caccia1s results (1979) show a relatively long 
half-life for d-fenfluramine and thus suggest that the 
1-isomer affects the metabolism of the d-isomer after 
administration of the racemate as d-fenfluramine has 
subsequently been shown to have a shorter half-life 
after administration of the d-isomer alone (Caccia et 
al., 1982) . The data presented in this thesis shows
that the plasma concentrations of total fenfluramine, 
following a single oral dose of the racemate, declined 
biexponentially with the terminal half-life the same as 
that seen for the 1-isomer. Indeed, the
dl-fenfluramine plasma curve was very similar to the 
sum of the plasma curves for each of the isomers 
(Figure 7.7). This summation was also true for the 
areas under the curve (Tables 7.1, 7.2 and 7.3). These 
data indicate that the isomers are metabolised and 
eliminated independently at least at therapeutic dose 
levels. The enantiomeric interactions found in vitro 
may well be due to a high concentration of drugs 
causing saturation of the enzyme systems and 
competition between the isomers for enzyme sites.
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Apart from the greater abundance of deaminated 
metabolites with d-fenfluramine, quantitative analysis 
of the relative amounts of m-trifluoromethylbenzoic and 
hippuric acids and 1-(m-trifluoromethylphenyl)propane- 
1, 2-diol showed a difference between the isomers in 
urine samples up to 12 hours after dosing. With 
d-fenfluramine the relative quantities of diol and 
acids stayed constant but with 1-fenfluramine the diol 
to acid ratio increased.
7.6 Routes of Metabolism of Fenfluramine in Man
Since no qualitative differences have been found 
between the optical isomers of fenfluramine, the 
schemes described below apply to both enantiomers. The 
metabolic reactions involved in the biotransformation 
of fenfluramine are N-de-ethylation with subsequent 
deamination, aliphatic oxidation and conjugation of the 
oxidation products. There is also evidence of an 
alternative primary metabolic route involving direct 
oxidation or deamination of fenfluramine itself without 
prior N-de-ethylation. The proposed metabolic route is 
shown in Figure 7.8.
Jenner and Testa (1976) reported Beckett's suggestion 
that both fenfluramine and norfenfluramine underwent 
considerable deamination. Since d-fenfluramine 
undergoes first pass metabolism and the plasma profiles 
determined for norfenfluramine do not resemble those of 
a typical first pass product (Houston, 1982), this 
suggests an alternative primary metabolic reaction for 
the unchanged drug other than N-de-ethylation.
The in vivo metabolic products found in the urine of 
man are norfenfluramine, m-trifluoromethylbenzoic acid, 
m-trifluoromethylhippuric acid, 1-(m-trifluoromethyl 
phenyl)propane-1,2-diol(conjugated) and m-trifluoro 
methylphenylpropan-2-ol. The latter two metabolites
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FIGURE 7.8  : The Metabolism of 
Fenfluramine in Man
CE CE
NH.N H -C H — CH.
C H — CH— CH.
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CF-
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CH— CH — CH.
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OH OH
CH— CH— CH. C — OH
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have also been found by Midha et al. (1983). The 
formation of each metabolic product can be considered 
separately and the rationale behind the reactions 
discussed. It should be noted that only compounds 
containing the radiolabelled benzylic carbon have been 
identified.
Jenner and Testa (1976) quote Gorrod as stating that 
both deamination and N-dealkylation are really the same 
reaction viewed from either end. The oxidative 
reactions in both processes are the same. Both 
reactions are effectively an oxidative C-N cleavage and 
this term should be used where any doubt or confusion 
exists. However, in unambiguous cases, where the 
chemical moieties attached to the nitrogen can be 
clearly differentiated in terms of size, the terms 
deamination and N-dealkylation can be usefully applied 
to describe more clearly and concisely the reactions 
involved. Deamination describes the removal of an 
amino moiety from the bulk of the molecule, leaving an 
aldehyde or ketone. N-dealkylation describes the 
removal of an N-substituent from the bulk of the 
molecule, leaving an amine.
7.6.1 N-De-ethylation_______of_______fenfluramine  to
norfenfluramine
The N-de-ethylation reaction has been reported 
for ethylamphetamine (Beckett et al., 1970) and 
a mechanism elucidated in rabbit liver 
microsomes involving = -C-oxidation and 
N-oxidation (Beckett and Belanger, 1975; Beckett 
and Haya, 1978). Hucker et al. (1971) had 
already isolated an oxime of amphetamine from 
rabbit liver preparations and thus proposed that 
=-C-oxidation resulted in dealkylation and 
deamination probably through unstable 
carbinolamines. Beckett and Belanger (1975)
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demonstrated that N-oxidation could partially 
account for dealkylated and deaminated products.
Wright et al. (1977) found that deamination was 
more rapid for amphetamine than
N-hydroxyamphetamine and concluded that although 
the ketone can be formed from the
N-hydroxyamphetamine, the latter is not an
obligatory intermediate from amphetamine. Cho 
and Wright (1978) in a review of the pathways of 
metabolism of amphetamine and related compounds, 
have discussed the relative con tributions of
N-hydroxylation and C-hydroxylation in the 
formation of phenylacetone and present various 
findings (Parli and McMahon, 1971; Wright et 
al., 1977; Hucker et al., 1971) which suggested 
that N-hydroxylation is not as important as 
C-hydroxylation in the deamination or 
N-dealkylation process.v
With regard to fenfluramine it seems reasonable
to postulate that the formation of 
norfenfluramine is predominantly through a
carbinolamine intermediate (Figure 7.9) 
although, like other secondary amines derived
from amphetamine, N-oxidation has been shown to 
occur in vitro, resulting in a hydroxylamine and 
a nitrone (Beckett et al., 1973). These 
similarities would suggest a possible 
involvement of N-oxidation in the overall 
N-deethylation process.
7.6.2 The formation of 1-(m-trifluoromethylphenyl)
propan-2-ol
This metabolite is equivalent to the 
l-phenyl-propan-2-ol formed by reduction of 
phenylacetone, the deamination product of
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FIGURE 7 .9  : Possible Formation of Norfenfluram ine  
from Fenfluramine by C - and N-Oxidation
N H - C H - C H 3 
CH — CH — CH
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CH — CH— CH
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I
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amphetamine and its analogues. Thus 1 - (m-tri 
fluoromethylphenyl)-propan-2-ol is proposed to 
arise from the reduction of m-trifluoro 
methyIphenylacetone probably by the cytosolic 
carbonyl reductase enzymes described by Felsted 
and Bachur (1980). Beckett and Haya (1978) 
described mechanisms for the formation of 
phenylacetone from ethylamphetamine.
Deamination proceeded, predominantly through a 
carbinolamine intermediate which dissociated to 
form phenylacetone and ethylamine. In addition, 
phenylacetone is formed by oxidative deamination 
of amphetamine itself. N-oxidation probably 
plays a part in the deamination process just as 
for dealkylation. Figure 7.10 shows the likely 
metabolic routes leading to the formation of 
1-(m-trifluoromethylphenyl)propan-2-ol from both 
fenfluramine and norfenfluramine.
Both benzylamphetamine in vitro (Beckett and 
Gibson, 1978) and prenylamine in vivo (Remberg
et al., 1977) have been shown to undergo a
deamination reaction resulting in phenylacetone 
and a primary amine.
7.6.3 Formation of 1-(m-trifluoromethylphenyl)propane- 
1, 2-diol
A likely reaction leading to formation of this 
metabolite is oxidation of the benzylic carbon 
of 1-(m-trifluoromethylphenyl)propan-2-ol
(Figure 7.11). This reaction has been suggested 
in the metabolism of 3-methoxyamphetamine in 
dog, monkey and man (Midha et al., 1981). Midha 
et al. (1983) have also proposed the same route 
for fenfluramine metabolism. The urinary
excretion profiles of norfenfluramine and 
1 - (m-trifluoromethylphenyl) propane-1,2-diol are
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similar in their qualitative aspects with the 
ratio of their excretion rates being reasonably 
constant with time (Chapter 3). The excretion 
profile of fenfluramine, however is different 
favouring the formation of 1- (m-trifluoromethyl 
phenyl)propan-1,2-diol from norfenfluramine 
rather than fenfluramine. The diol is excreted 
as at least two conjugates. Approximately half 
of the total diol was liberated by incubation 
with 3-glucuronidase (sue helix pomatia) but the 
remainder required treatment with 2N 
hydrochloric acid at 90°C. Although Midha et 
al. (1983) used enzyme hydrolysis to liberate 1- 
(m-trifluoromethylphenyl)propane-1,2-diol, their 
study was not quantitative and thus the 
incomplete deconjugation would not have been 
apparent.
The diol 1,2-dihydroxy-l-pheny1-propane was an 
in vitro metabolic product of norephedrine 
(Beckett et al., 1974). Thus 1-(m-trifluoro 
methylphenyl)propane-1,2-diol could arise from 
oxidative deamination of 3-hydroxylated 
fenfluramine and norfenfluramine with subsequent 
carbonyl reduction of the resulting keto 
alcohol. As stated by Caldwell (1976) the 
evidence available suggests that
$-hydroxylation, by dopamine 3-hydroxylase, is 
restricted to primary amines. Although the same 
author stated that the large m-trifluoromethyl 
ring substituent in norfenfluramine appeared to 
block the reaction, that observation was based 
on the current knowledge of fenfluramine 
metabolism in vivo, which favoured extensive 
formation of m-trifluoromethylhippuric acid 
(Bruce and Maynard, 1968). During the present
work, a m-trifluoromethylnorephedrine metabolite 
has not been specifically looked for in urine or
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plasma and only the major metabolites, ie. >5%, 
have been isolated and positively identified. 
So despite the lack of positive experimental 
evidence the possible contribution of 
3-hydroxylation has not been ruled out and is 
discussed also in relation to the formation of 
m-trifluoromethylbenzoic acid (section 7.6.4).
The stereoselective difference in the ratios of 
diol to acid metabolites mentioned at the end of 
section 7.5 can be explained in terms of both 
the 3-hydroxylation and deamination with 
subsequent oxidation being evident. If the diol 
is formed by carbonyl reduction and subsequent 
benzylic hydroxylation of m-trifluoromethyl 
phenylacetone and the benzoic and hippuric acids 
(see also section 7.6.4), by both further 
metabolism of the diol and through
3-hydroxylation then a stereospecificity in the 
latter reaction, with the d-isomer being 
favoured (see Caldwell, 1976) could explain the 
phenomenon (Figure 7.11).
7.6.4 Formation of m-trifluoromethylbenzoic acid
Complete side chain degradation of amphetamine 
analogues to a benzoic acid derivative does not 
occur in all cases. No benzoic acid is found in 
vivo after administration of 3-methoxy 
amphetamine to various species (Midha et al., 
1981). However amphetamine itself is metabolised 
to benzoic acid in man (Caldwell, 1976) as are 
the ephedrines (Feller et al., 1977). Since the 
original report of Axelrod (1955) on the enzymic 
deamination of amphetamine to phenylacetone, the 
latter has been considered to be the precursor 
of benzoic acid, but by an unknown mechanism. 
However, in vivo (Smith et al., 1954) and in
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FIGURE 7.11 : The Formation o f I -  (m -  Trifluorom ethylphenyl) 
Propane -  1, 2 -  Diol
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vitro (Kammerer et al., 1977) studies have
indicated that phenylacetone forms only minor 
quantities of benzoic acid. Caldwell (1978) 
showed a correlation between the degree of 
N-hydroxylation displayed by various species and 
the excretion of benzoic acid. Lindeke et al.
(1978) thus proposed that benzoic acid could 
arise from an N-hydroxylation pathway through a 
8-hydroxynitroso- compound resulting in 
benzaldehyde which is enzymically oxidised to 
benzoic acid. This is of particular significance 
in the metabolism of fenfluramine and 780SE in 
man, since benzoic acid is a major metabolite in 
the former but is not found in the latter. If 
m-trifluoromethylphenylacetone were the
precursor of the benzoic acid, one would expect 
to see the benzoic acid metabolite from both 
fenfluramine and 780SE, as both molecules 
undergo eventual deamination (Figure 7.12). Thus 
^-hydroxylation seems a likely reaction for 
fenfluramine. As mentioned previously (section 
7.6.3) Caldwell (1976) stated that 
3-hydroxylation seems limited to primary amines 
as shown by norephedrine and p-hydroxy 
norephedrine being metabolites of metamphetamine 
but not the N-methylated analogues. Indeed the 
reaction proposed by Lindeke et al., (1978) was 
depicted as occurring on a primary amine. Thus, 
by these theories, 3-hydroxylation is limited to 
norfenfluramine which would result in 
m-trifluoromethylnorephedrine which has not been 
identified in urine. Caldwell (1976) reported 
that the recovery of norephedrine in urine after 
amphetamine administration was very low (<3% of 
the dose) . This can be explained by either
3-hydroxylation being a very minor pathway or 
the norephedrine undergoing further extensive 
N-oxidation and degradation with
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FIGURE 7.12 : The Formation o f m -  Trifluorom ethylbenzoic  
and m -  T rifluorom ethylh ippuric Acids
CF
C H —  CH— CH,
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OH NHNH— OH
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oxidation to benzoic acid. As the evidence is 
in favour of the 3-hydroxylation pathway it
seems likely, although there is no evidence for 
or against it, that norfenfluramine undergoes 
this reaction but the m-trifluoromethyl 
norephedrine, is then extensively metabolised to 
the benzoic acid which is then conjugated. The 
free acid was liberated by acidification and
ether extraction of the urine indicating the 
presence of a relatively labile conjugate, 
perhaps an ester-glucuronide. The remaining 
benzoic acid was excreted as m-trifluoro 
methylhippuric acid (Figure 7.12) a metabolite 
which was also found from amphetamine metabolism 
(Caldwell, 1976).
7.7 The Metabolic Pathways of 1- (m-trifluoro methylphenyl)- 
N-benzoyloxy-ethyl-2-amino-propane (780SE)
At least 90% of the urinary metabolites of 780SE are
different from those of fenfluramine, showing the
profound influence of N-ethyl modification. Whereas
deamination is a major reaction in the metabolism of
fenfluramine it is only minor for 780SE and the
deaminated metabolite is different. As with
fenfluramine, only metabolites retaining the 
14[ C]-benzylic carbon have been identified.
7.7.1 Formation of 2-hydroxyethylnorfenfluramine by
hydrolysis of 780SE
Unchanged drug has not been found in the plasma 
or urine of volunteers dosed orally with 
["^C]-780SE. This finding is in agreement with 
that of Beckett, Shenoy and Brookes (1972) and 
suggests that the drug is rapidly hydrolysed to 
N-2-hydroxyethyl-norfenfluramine during the
first pass, so that 780SE effectively acts as a
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pro-drug. There is no evidence to suggest that 
780SE undergoes any other reaction. The
metabolite is eliminated both unchanged and as a 
conjugate (Figure 7.13) which is readily cleaved 
by treatment with 8-glucuronidase (sue helix 
pomatia).
7.7.2 Formation of N-carboxymethyl-norfenfluramine
This metabolite has not been previously reported 
but is the major in vivo metabolic product in 
man (Figure 7.14). It is a product of side 
chain oxidation of the N-2-hydroxyethyl- moiety 
a reaction which is well documented for a number 
of different compounds and probably mediated by 
alcohol and aldehyde dehydrogenases. In man, 
this side chain oxidation takes preference over 
N-dealkylation or deamination but it is 
interesting to compare the yield of 
N-carboxymethylnorfenfluramine in the various 
species (Chapter 6). Since the rat and dog show 
less of this metabolite and more norfenfluramine 
(dealkylation products) plus another metabolite, 
which chromatographs with the same Rf value as 
tr ifluoromethylhippuric acid. The rat shows a 
preference for ring hydroxylation of amphetamine 
itself whereas deamination is favoured in man 
(Jenner and Testa, 1976). When ring 
hydroxylation is blocked with the 
m-trifluoromethyl group and an N-2-hydroxyethyl- 
group introduced there is a preference for 
deamination in the rat whereas this reaction is 
very minor in man.
7.7.3 The formation of norfenfluramine
Norfenfluramine is not an abundant urinary 
metabolite (<5%) and thus N-dealkylation seems a
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FIGURE 7.13 : The Hydrolysis of Benfluorex to 
N -  2 -  H ydroxyethylnorfenfluram ine
OF
o
O
II
NH— CH2— CH2— O — C
CH2— CH — CH3
CF
NH— CFL— CH OH
CH — CH— CH.
GLUCURONIDE
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FIGURE 7. 4 : Oxidation o f N -  2 -  Hydroxyethylnorfenfluram ine  
to N -  2 -  Çarboxym ethylnorfenfluram ine
o NH— CH2— CH2OH
CF.
o
c h - c h - c h 3
o 
II
NH— CH— C — OH
CH — CH— CH3
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less important pathway than with fenfluramine. 
Both N-2-hydroxyethylnorfenfluramine and N- 
carboxymethylnorfenfluramine could undergo
N-dealkylation to form norfenfluramine (Figure 
7.15). In an additional study, a small amount 
of norfenfluramine was detected in the urine of 
a human volunteer who was dosed orally with 
N-carboxymethylnorfenfluramine, so that
possibility exists.
7.7.4 The formation of 1-hydroxy-l-(m-trifluoromethyl 
phenyl)propan-2-one
It is interesting that this metabolite is found 
for 780SE but not for fenfluramine indicating 
that the N-alkyl substitutent has some influence 
over the pathways involved. Deamination of 
N-2-hydroxyethylnorfenfluramine, N-carboxy
methylnorfenfluramine or norfenfluramine itself 
would result in m-trifluoromethylphenylacetone 
which could be hydroxylated on the benzylic 
carbon (Figure 7.16). However, it remains
unclear why the keto alcohol is excreted without 
any evidence of the diol or benzoic acid 
especially considering the fact that the major 
component of plasma is the keto alcohol (Chapter 
5). In the metabolism of ephedrine, the keto 
enol is shown to result from deamination of 
ephedrine itself whereas norephedrine gives rise 
to benzoic acid. Reduction of the carbonyl 
group then forms the diol. It seems feasible 
that 3-hydrolyated 2-N-hydroxye thyl- or
2-carboxymethy1-norfenfluramine could deaminate 
to give the analogous keto alcohol although 
carbonyl reduction does not occur. The 
B-hydroxylation ( 3 to a nitrogen) has been shown 
to occur for N-2-[5-(m-chlorophenyl)-1,2,4- 
oxadiazol-3-yl]-ethyl-N-methyl acetamide, which
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is a very doubtful substrate for 
dopamine-3-hydroxylase (Jenner and Testa, 1976). 
If this reaction does occur then formation of 
1-(m-trifluoromethylphenyl)propane-1,2-diol is 
unlikely to be through m-trifluoromethyl 
norephedrine as indicated in section 7.6.3 since 
deamination of this would result in keto alcohol 
formation. Thus it seems more likely that 
further oxidation of the secondary alcohol 
results in the diol as indicated by Midha et al. 
(1983). The stereoselectivity in the deamination 
of fenfluramine (section 7.5) could be explained 
by the presence of stereoselective 
8-hydroxylation (possibly by dopamine-3 
-hydroxylase) of d-norfenfluramine going through 
to the benzoic acid metabolite, whereas straight 
forward deamination of the 1-fenfluramine is 
favoured (Figure 7.11).
7.8 The Relationship Between Ring and Nitrogen Substitution 
and the Metabolism and Kinetics of Amphetamine 
Analogues in Man
The previous sections have described the metabolic 
products of two structural analogues of amphetamine and 
have postulated metabolic routes. The first stage in 
the metabolism of 780SE is a complete pre-systemic 
de-esterification to liberate ■ N-2-hydroxyethyl 
1-(m-trifluoromethylphenyl)-2-aminopropane, a compound 
very similar in structure to fenfluramine, the only 
difference being the hydroxyl group on the N-ethyl side 
chain. Considering that the radioactive label is in 
the same position in both molecules and that only 
radiolabelled metabolites have been investigated, the 
difference in the N-ethyl side chain has a profound 
effect on the metabolic products eliminated into urine. 
The literature contains many examples of alterations in 
amphetamine metabolism with side-chain and ring
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FIGURE 7.16 : The Possible Role of (3- Oxidation in the  
Formation o f I -  (m -  Trifluorom ethylphenyl) -  
I -  Hydroxypropane -  2 -  One
ÇF CF
NH — CH-— CH-OH NH—C H —C — OH
CH2— CH — CH. CHo—CH—CK
CFCF
OH NH — CH2— CH2OH 
CH -  CH — CH,
OH NH—C H —C — OH
CH—CH—CH.
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substituents. In man, amphetamine itself (at 
therapeutic levels) is metabolised predominantly by 
deamination to phenylacetone, phenylacetone-sulphate, 
benzoic and hippuric acids (Caldwell, 1976). Some 25% 
of the dose is excreted unchanged and a small 
percentage undergoes ring hydroxylation to
4-hydroxyamphetamine. To study ring hydroxylation of 
the molecule itself, a species such as the rat is more 
useful as ring hydroxylation is the major metabolic 
route and thus changes are easier to quantitate. Ring 
substitution, however, can influence the metabolism of 
the rest of the molecule as exemplified by Nagamusatsu 
et al. (1978) where the major metabolic route of 
2,5-dimethoxy-4-methylamphetamine in rabbit and guinea 
pig, was oxidation of the 4-methyl group on the benzene 
ring rather than deamination which is the major route 
of metabolism of amphetamine itself. Similarly Kitchen 
et al. (1979) showed that in guinea pig and man (with 
some individual variations ie. one subject had a 
genetically determined drug oxidation defect) the major 
route of metabolism was O-demethylation with subsequent 
conjugation. Although man did show some deamination 
products, the guinea pig, which metabolises amphetamine 
itself entirely by deamination, showed only free and 
conjugated 4-hydroxyamphetamine. Hubbard et al. (1977) 
had already demonstrated O-demethylation as the major 
metabolic route in monkey and dog, two species which 
also show a preference for deamination in the 
metabolism of amphetamine. Tiflorex (1-(m-trifluoro 
methylthiophenyl)-2-ethylaminopropane was predominantly 
metabolised by sulphoxidation causing Andre et al. 
(1979) to conclude that S-oxidation predominates over 
ring hydroxylation when the phenyl ring is substituted 
with the m-trifluoromethylthio group. Introduction of 
the lipophilic m-trifluoromethyl- group into the ring 
(norfenfluramine) blocks ring hydroxylation in all 
species but, in man, increases the overall extent of 
metabolism (Beckett and Brookes, 1971). The route of
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metabolism, however, is by deamination rather than ring 
hydroxylation. Comparison of the metabolism of 
ethylamphetamine and fenfluramine also gives an 
indication of the effect of the trifluoromethyl moiety 
in the aromatic ring. Ring hydroxylation is blocked 
but, unlike norfenfluramine, fenfluramine is no more 
extensively deaminated than ethylamphetamine (Beckett 
and Brookes, 1970). Fenfluramine appeared to exhibit a 
less marked stereospecific metabolism than 
ethylamphetamine.
Introduction of a N-alkyl substituent into the 
amphetamine molecule has been shown to increase ring 
hydroxylation whilst decreasing deamination. Coutts 
and Dawson (1977) showed two in vivo phenolic 
metabolites of N-(n-propyl)-amphetamine in man whereas 
with amphetamine alone, ring hydroxylation is a very 
minor pathway. Coutts, Dawson and Jones (1978) went on 
to investigate the effect of N-alkyl chain length on 
oxidation of the aromatic ring in the rat and found 
that the amounts of 4-hydroxy-3-methoxy- products 
increased with respect to the 4-hydroxy- products with 
increasing chain length. A direct correlation has been 
described between partition coefficient and total 
metabolism in man for amphetamine and its N-methyl 
N-ethyl-, N-n-propyl- and N-n-butyl- derivatives 
(Beckett and Shenoy, 1973) however this correlation 
only held for the d-isomers. Jenner and Testa (1976) 
discuss a study which demonstrated a linear and direct 
relationship between the rates of N-dealkylation of 
those same amphetamine derivatives and the logarithm of 
their respective partition coefficients. However, 
N~isopropyl- and N-isobutylamphetamine were metabolised 
more slowly than their lipid solubility would indicate, 
showing the steric influence of the branched alkyl 
chain. The degree or rate of N-dealkylation cannot be 
simply correlated with the size of the N-substituent or 
the lipid solubility of the molecule. More recently,
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Gorrod and Patterson (1983), has indicated that the pKa 
of the nitrogen group in some 4-substituted-N- 
ethyl-N-methyl- anilines is some measure of the 
reactivity of that centre with regard to « - c -  and 
N-oxidation but, as before, the extent of metabolism is 
not governed solely by one factor.
The choice of species can also influence such 
correlations as exemplified by the metabolism of the 
N-diphenylpropyl derivative, prenylamine, which is 
extensively N-dealkylated in rat to give amphetamine 
but not so much in man, whereas considering the general 
relationship between N-substituent size and metabolism, 
a more extensive N-dealkylation in man would be 
expected. The introduction of a functional group into 
the N-alkyl chain also influences the metabolism of 
these compounds. N-Cyanoethyl-amphetamine is more 
extensively N-dealkylated than N-ethylamphetamine 
(Beckett, Shenoy and Salmon, 1972). The weakening 
influence of the strong electron-withdrawing effect of 
the -CN group on the in vivo cleavage of the C-N bond 
cannot be assessed as the dealkylation appears to be 
mainly enzymic.
The in vivo metabolic products of fenfluramine and 
780SE differed considerably. It seems most probable 
that 780SE was hydrolysed presystemically and thus the 
in vivo metabolic products were those of liberated 
N-hydroxyethylnorfenfluramine rather than 780SE. This 
enabled the effect of the hydroxyl group on the
metabolism of the fenfluramine molecule to be assessed. 
Comparison of figures 7.3 and 7.4 shows clearly the 
differences in the metabolism of the compounds.
Oxidation of the N-ethyl- group did not occur with 
fenfluramine but the presence of the 2-hydroxy- group
appeared to initiate such a reaction with complete 
oxidation to the N-carboxymethyl- moiety with 780SE. 
Deamination products of 780SE in man accounted for
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only 2-5% of urinary metabolites whereas 50-80% of 
fenfluramine metabolites had lost the amino-function.
The 1-hydroxy-l-(m-trifluoromethylphenyl)-propan-2-one 
was the only deaminated metabolite of 78OSE found in 
human urine, whereas this compound was not detected for 
fenfluramine. It is commonly thought that the 
l-hydroxypropan-2-one, propan-1,2-diol and benzoic acid 
metabolites arise from further oxidation of the 
respective primary deamination product, a 
phenylpropan-2-one, which in the case of fenfluramine 
and 780SE seems likely to be the common product 
m-trifluoromethylphenylpropan-2-one. With this common 
precursor, it would be expected to see some 
similarities in subsequent oxidation products which was 
not the case. This would suggest, therefore, that 
m"trifluoromethylphenyl propan—2—one was not the common 
deamination product.
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7.9 Summing up
Studies on the metabolism of fenfluramine have shown
that the trifluoromethyl ring substitution blocks ring 
hydroxylation of the amphetamine nucleus with 
deamination and N-dealkylation accounting for most of 
the metabolites found. Benfluorex, however, undergoes
only slight deamination and N-dealkylation in man 
indicating the profound influence of the N-alkyl 
substitution on the metabolic fate of the compound.
The stereoselectivity of fenfluramine metabolism and 
kinetics has been studied. Stereoselectivity has been 
defined as the extent to which an enzyme or other
macromolecule or macromolecular structure (antibody or 
receptor) exhibits affinity towards one molecule of a 
pair of stereo-isomers in comparison with, and in 
contrast to, the others (Rauws, 1983). Stereoisomers
often differ in bioactivity. Thus an active racemic 
agent often contains an active isomer (eutomer)
together with an inactive isomer (distomer) which may 
not contribute to the desired effect and undoubtably 
gives rise to a toxicological risk. Where 
stereoselectivity exists, it seems good sense to use 
the pure eutomer but, as discussed by Soudijn (1983),
there are instances where it is better to use the 
racemate. The rationale for using the pure eutomer 
involves consideration of the effect of the distomer. 
If the distomer contributes to side effects, 
counteracts the pharmacological action of the eutomer, 
or is metabolised to a product showing toxicity or
unfavourable pharmacology, then the pure eutomer should 
be used. However, racemates should be used when the 
racemate and eutomer are equipotent and equitoxic, when 
the racemate is more active than both intrinsically
equipotent isomers, where there is enzymatic inversion 
of the distomer, when the distomer counters the side
effects of the eutomer or indeed when the racemate is a
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useful drug and the cost of eutomer production is 
prohibitive.
Fenfluramine exhibits a considerable stereoselectivity. 
There is a stereoselective pharmacology, to the extent 
that d-fenfluramine is active in reducing appetite and 
food intake whereas the 1-isomer appears not to be 
(Silverstone et al., 1985) . As well as this, the
enantiomers of the active metabolite, norfenfluramine, 
show different activities (Mennini et al., 1985). 
Clinical studies have shown d-fenfluramine to be better 
tolerated than equipotent doses of dl-fenfluramine 
(Silverstone et al., 1985) suggesting that
1-fenfluramine contributes to the side-effects. The 
work presented in this thesis shows a stereoselectivity 
in metabolism and kinetics and the data of Caccia et 
al. (1979) showed that steady-state concentrations of 
1-fenfluramine are higher than those of d-fenfluramine. 
In addition, inter individual differences were seen in 
the extent of this stereoselectivity.
Consideration of all these facts leads one to envisage 
a clinical situation where obese patients showing a 
large stereoselective difference in the disposition of 
fenfluramine are taking the racemic compound. Although 
the plasma concentrations of fenfluramine may appear 
adequate, a stereospecific analysis shows the 
concentrations of the distomer to far exceed those of 
the eutomer. These hypothetical patients may then 
experience side-effects associated with 1-fenfluramine 
without the beneficial pharmacological effects of 
d-fenfluramine. Clearly, d-fenfluramine should be 
considered preferable to the racemate in the treatment 
of obesity.
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